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1 SUMMARY 
The AR-CALUX® in vitro method was submitted by the Dutch company BioDetectionSystems (BDS) to EURL 
ECVAM to be considered for a EURL ECVAM coordinated validation study. The method is applied to the detection of 
compounds with (anti)androgenic potential. The AR-CALUX® cells are osteosarcoma U2OS cells which are transfected 
with the cDNA of a human androgen receptor and a luciferase encoding reporter gene preceded by androgen receptor 
(AR) response elements (ARE), hence responding to chemicals with androgenic activity. The method allows the 
detection of chemicals with an agonist or/and an antagonist behaviour. 
The objectives of the study included assessing the reproducibility (within and between laboratories) and the relevance 
of the in vitro method, leading to the drafting of an OECD Test Guideline. EURL ECVAM is both sponsor and 
coordinator for this validation study. Three test facilities were selected from the European Union Network of Validation 
Laboratories for alternative methods (EU-NETVAL) to participate in this validation study: RISE, ENVIGO and 
CitoxLAB. The test method submitter BDS produced an additional data set for the assessment of the between lab 
reproducibility.  
Reproducibility was evaluated on a set of 20 coded test chemicals based on concordance of classifications. 
Classification was carried out by the 4 laboratories, applying faithfully the classifier which led to the conclusion of 
"Positive", "Negative" and "Inconclusive". The latter classification was given when the test chemical displayed activity 
for only one tested concentration above (agonist) or below (antagonist) threshold values as determined in the classifier. 
This occurred with an overall frequency of 0.9 % in the agonist assay, and, 7.4% in the antagonist assay. Analysis of the 
data generated by the 4 laboratories showed a within lab reproducibility (WLR) of 89%, 95%, 100% and 100% for the 
agonist assay, and, 75%, 80%, 85% and 90% for the antagonist assay. The overall between lab reproducibility (BLR) 
scored via concordance of classifications was 100% for the agonist assay and 87.5% for the antagonist assay.  
In order to arrive at a clear classification of "Positive" or "Negative" for a given test chemical, the classifier was 
reformulated and guidance included in the Standard Operating Procedure (SOP) for handling borderline situations of 
only the highest tested concentration displaying an activity passing the threshold values. An approximation of the 
results, when applying this new guidance in the SOP and the new classifier to the results of the validation study, is 
shown and discussed. This would lead to increased WLR (94.7% to 100%) and BLR (100%) for both agonist and 
antagonist testing. 
The variability within the measurements (% CV of log of EC50, PC10, IC50, PC80) was less than 2.5% and comparable to 
what is reported for the ER-CALUX® in vitro method validation and the AR STTA (cell line EcoScreen™) validation. 
A comparison was made of the classifications in the AR-CALUX® validation study for 46 tested chemicals with reliable 
published or publicly available ARTA classifications. For 23 tested chemicals a 94.6% concordance was found with the 
ICCVAM AR-Reference list (2017). Performance values were calculated versus this AR-Reference list. For the 
additional 23 tested chemicals, an overall comparison was performed with classifications from two Tox21 assays and 
the AR-pathway computational model. This revealed that for all chemicals tested with the AR-CALUX® method there 
is an identical classification with at least one other ARTA.  
Having reviewed the data, the VMG concluded that the AR-CALUX® method is a reliable test method. It is 
nevertheless opportune to provide a warning in the SOP for potential interferences. The response to the vehicle control 
should be assessed to ensure no interference from glass or plastic ware before running studies.  
The VMG is of the opinion that the AR-CALUX® method merits proposal to OECD for the development of a test 
guideline. 
 
Important note:  
This validation report is best read together with the statistical report. Whereas the structure of the validation report 
follows the modules of the modular approach to validation, the statistical report gives the overall analysis of all data 
obtained in the study. By clicking on a specific test chemical in the index of the statistical report, one is guided 
immediately to the corresponding data analysis and graphs of the dose responses obtained in the studies. 
Due to size constraints, the statistical report and the final version of the SOP (version 07) are not part of this report.  
They can be found as individual files at EURL ECVAM’s Tracking system for alternative methods towards regulatory 
acceptance (TSAR) ( https://tsar.jrc.ec.europa.eu/test-method/tm2010-07) 
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2 INTRODUCTION AND OBJECTIVES 
2.1 General introduction  
Endocrine disruptors (EDs) are a high priority topic on the agenda of several national and international governmental 
institutions given the observed and documented endocrine-related adverse effects on human and animal health (UNEP 
WHO, 2013). These substances impact development and reproduction by disturbing the functioning of the endocrine 
(hormone) system.  
National and international governments are in the process of establishing testing programmes and strategies to assess 
the safety of currently used chemicals with regard to their potential to interfere with the endocrine system. Several 
pieces of European legislation address EDs: chemicals Regulation 1907/2006 'REACH'; Regulation 1107/2009 on Plant 
Production Products (PPP); Regulation 1223/2009 on Cosmetic Products; Regulation 528/2012 on Biocidal Products 
(BP). The European Commission launched a work programme entitled "Community strategy for endocrine disruptors" 
(EC, 1999) addressing several actions, e.g. to establish criteria to identify EDs for further evaluation, to develop and 
validate test methods to assess EDs, to fund research for understanding the ED mechanisms and to adapt present EU 
legislation to take account of ED effects. Scientific criteria to identify an ED under the PPP and BP regulations were 
established and published in 2017 and 2018 (EC, 2017; EC, 2018) and a guidance document for the implementation of 
the criteria was published by the European Chemicals Agency (ECHA) and the European Food Safety Authority 
(EFSA) (EFSA, 2018). The United States Environmental Protection Agency (EPA) developed the Endocrine Disruptor 
Screening Program (EDSP) as one of the first national programmes. In Japan, the Japan Environment Agency initiated 
the Strategic Programs on Endocrine Disruptors (SPEED) to promote e.g. test method development, while in the 
republic of Korea, the relevant ministries developed mid and long term research plans mainly dealing with 
environmental monitoring (Hecker and Holler, 2011; WHO, 2014).  
The Organisation for Economic Co-operation and Development (OECD) recognised the potential impact of ED 
substances on human health and the environment. Since 1996, effort has been made in developing Test Guidelines (TG) 
and other tools to support member countries' needs for testing and assessment of chemicals for endocrine disruption. In 
terms of providing overview and guidance, a number of important documents have been drafted, e.g. Guidance 
document No. 150 on the assessment of chemicals for ED was developed in 2012 as a tool to support regulatory bodies 
by helping to interpret assay results and suggesting additional studies for reducing uncertainty. It was updated in 2018 
(OECD, 2018). GD 150 also contains the Conceptual Framework for screening and testing EDs (CF) which was 
adopted in 2002, and revised in 2011 and 2017. It lists OECD TGs and standardized test methods available, under 
development or proposed to be used to evaluate chemicals for ED. It is structured over different levels where level 2 
includes in vitro assays (data about selected endocrine mechanism) and levels 3, 4 and 5 include in vivo assays (data 
about selected endocrine mechanisms and/or adverse effects on endocrine-relevant endpoints).  
The OECD CF as well as the US EPA have adopted in vitro assays as regulatory test guidelines, in order to measure 
hormone receptor binding and transactivation, for the fast screening of putative EDs for prioritisation purposes and for 
identifying endocrine activity. Within the set of transactivation assays, the Androgen Receptor Transactivation Assays 
(ARTAs) incorporate androgen receptors (AR) that, once activated, initiate transcription.  
AR-CALUX® cell lines were identified within the EU funded project ReProTect (LSHB-CT-2004-503257) which 
aimed at optimizing an integrated set of tests as a basis for a reproductive/developmental battery, in order to provide 
detailed understanding of the main tissues or biological mechanisms which could be targeted and disrupted by toxicants 
across different stages of reproduction. The AR-CALUX® cell lines were considered as addressing a critical biological 
mechanism (androgen receptor interaction) and therefore a relevant test system for the development of a method for ED 
screening. The test developer of the AR-CALUX® method carried out a pre-validation (van der Burg et al, 2010) and 
the in vitro method was subsequently submitted to EURL ECVAM (Dec. 2011) for a validation process. EURL 
ECVAM reviewed the submission in 2012 with a favourable outcome for entering into a formal validation study.  
 
2.2 Goal and Objectives 
EURL ECVAM launched a validation study of the AR-CALUX® method in 2014 with the overall goal, provided the 
validation study would be successful, of proposing the test method to OECD to become a test guideline (TG). The 
European Commission submitted in 2012 a Standard Project Submission Form (SPSF) to OECD for the development of 
a Performance Based Test Guideline (PBTG) on ARTAs. This was accepted and inserted in the OECD 2013 work plan. 
Several ARTAs would be considered to be annexed to the PBTG: 
 the AR-STTA of Japan, using the AR-EcoScreen™ Chinese hamster ovary cell line (validation finalised and TG 
458 adopted)  
 the ARTA of Korea, using the 22Rv1/MMTV GR- Human prostate cancer cell line (validation finalised, report 
under review)  
 the ARTA of the Netherlands, AR-CALUX®, subject of this validation report 
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The objectives of this validation study were as follows: 
 to evaluate the transferability and reliability (reproducibility within and between laboratories)  
 to evaluate the relevance of the test method by comparison of the classifications by this test method to reported 
classifications of the ICCVAM AR-reference list and of other ARTAs.  
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3 MANAGEMENT OF THE VALIDATION STUDY  
The organisation and conduct of the study was performed in compliance with the principles laid down in the OECD 
guidance document on test method validation GD 34 (OECD, 2005). 
3.1 Sponsor 
EURL ECVAM was the sponsor and coordinator of the validation study.  
 
 
 
 
 
 
 
 
 
The EU-NETVAL laboratories had the possibility to ask for support to their respective governments under Directive 
2010/63/EU on "The protection of animals used for scientific purposes". EURL ECVAM provided the test system, test 
chemicals and training. 
 
The overall study coordination was conducted by EURL ECVAM. This included the organisation of all necessary VMG 
meetings and teleconferences, SOP technical and experimental assessment, acting as contact point for the participating 
laboratories for day to day work and troubleshooting, contact point for the method developer, the maintenance of the data 
sharing platform (CIRCABC) for all data and document storage and retrieval, all data handling and analysis, as well as 
producing the draft statistical report and the draft validation report.  
 
3.2 Validation Management Group (VMG) 
The VMG was established by EURL ECVAM and consisted of three external experts in the field, the validation study 
coordinator and the biostatistician from EURL ECVAM. VMG's role was to provide oversight on the validation study. 
Its responsibilities, defined in a Terms of Reference (ToR), included the following: 
 To review and approve the validation project plan in all its components (objectives, validation study design, 
organisation, statistical analysis methods, list of chemicals to be tested, the SOP to be implemented); 
 To monitor progress through setting key milestones and reviewing the results of the test facilities and to provide 
assistance in troubleshooting when need be; 
 To manage deviations to the validation study; 
 To interpret the validation results and formulation of conclusions; 
 To assist, review and approve the validation report;  
 To assist in the drafting of the EURL ECVAM recommendation and the TG for ARTAs.  
 
Table 02: Composition of the AR-CALUX® VMG 
Name Role and expertise Affiliation 
EURL ECVAM members 
Anne Milcamps  Coordinator  
EURL ECVAM, Ispra, Italy 
Email: anne.milcamps@ec.europa.eu 
Roman Liska  Data analysis  
EURL ECVAM, Ispra, Italy 
Email: roman.liska@ec.europa.eu 
External members 
Warren Casey 
Director NICEATM  
Expertise in toxicology, EDs, validation  
NIEHS/NICEATM, Research Triangle Park, 
North Carolina, USA 
Email: warren.casey@nih.gov 
Matthew Dent 
Safety Science Leader  
Expertise in general/reproductive 
toxicology, risk assessment 
Unilever, Colworth Science Park, Bedford, 
UK 
Email: matthew.dent@unilever.com 
Jenny Odum 
Independent consultant toxicologist 
Expertise in toxicology, EDs, validation 
Stockport, UK 
Email: jenny.odum@regulatoryscience.com 
Table 01: Sponsor Address 
Maurice Whelan 
Email: Maurice. Whelan@ec.europa.eu 
 
The EU Reference Laboratory for Alternatives to 
Animal Testing (EURL ECVAM) 
European Commission Joint Research Centre 
Directorate F3  
Via E. Fermi, 2749 
I-21027 Ispra, Italy 
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3.3 Participating Test Facilities  
Three laboratories were identified from EU-NETVAL, EURL ECVAM's network of expert laboratories that was 
established in January 2014. The network is comprised of 37 laboratories from the EU member countries as well as 
EURL ECVAM's own laboratory. Its tasks and responsibilities are formulated within a ToR with primary focus on 
participation in validation studies. In the beginning of 2014, an invitation was launched to the EU-NETVAL members 
for participation in the AR-CALUX® validation study. This Call for expression of interest included a description of the 
different tasks to be undertaken when participating to the validation study. Essential requirements had to be met in order 
for a laboratory to participate. Several test facilities met the requirements and were ranked on the basis of a 
communicated selection procedure. The 3 highest ranked facilities were approved by the EU Member States via the 
National Contact Points. For details of the Call see Annex 13.7.11. Commitment of the laboratories was ensured 
through a Collaboration Agreement / Licence Agreement (+) (January 2015 / July 2018(+)). 
Table 03: The participating laboratories 
1 RISE* EU-NETVAL member / GLP laboratory                                Sweden 
 
Address: RISE Research Institutes of Sweden, Brinellgatan 4, SE-501 15 Boras 
Laboratory manager: Benny Lyven 
Study director: Emma Pedersen/Kristina Fant 
Study personnel: Jenny Johansson, 
Therese Andersson, Lovisa Bodin 
 
Email: benny.lyven@ri.se 
Email: emma.pedersen@ri.se;  
kristina.fant@ri.se 
2 CitoxLAB* EU-NETVAL member / GLP laboratory                             France 
 
Address: CitoxLAB, BP 563, 27005 Evreux Cedex 
Laboratory manager: Olivier Foulon 
Study director: Mylene Valin/ Kelly Chevalier/ 
Cedric Gerbeix 
Study personnel: Rachel Lercier,  
Megane Auvray, Pascal Bogdanowicz, Baptiste 
Coulon, Marion Godefroy 
 
Email:Mylene.Valin@fr.CitoxLAB.com; 
Cedric.Gerbeix@fr.CitoxLAB.com; 
Kelly.Chevallier@fr.CitoxLAB.com 
3 ENVIGO* EU-NETVAL member / GLP laboratory                              UK 
 
Address: ENVIGO, Woolley Road, Alconbury, Huntingdon, Cambridgeshire 
Laboratory manager: L. Akhurst, J. Carter 
Study director: Joanne Hubbard 
Study personnel: Joanne Kelsall 
Email: leslie.akhurst@ENVIGO.com, 
john.carter@ENVIGO.com 
Email: joanne.hubbard@ENVIGO.com 
4 BDS Test method developer (non EU-NETVAL member) (+)                      Netherlands 
 Address: BioDetection Systems BV (BDS), Science Park 406, 1098 XH Amsterdam 
Laboratory manager: Harrie Besselink 
Study director: Harrie Besselink 
Study personnel: Matthijs Naderman 
 
Email: Harrie.Besselink@bds.nl 
*Note: During the course of the validation study, the participating laboratories changed name: SP became RISE,  
Huntingdon became ENVIGO. In 2019, ENVIGO became Covance, CitoxLAB became Charles River Labs. 
 
The laboratory BDS (test method developer) was included in June 2018 as a participating laboratory. The facility 
CitoxLAB observed frequently high RLUs, first during Study 1 (Transfer phase) which were thought to be resolved, but 
continued during Study 2 (BLR). The test method developer visited the laboratory (2018) to assist in discovering the 
source of the high RLUs but a concrete indication was not found and the technical issues remained (Report on the 
technical issues can be found in Annex 13.7.9). These issues did not occur in the other laboratories and could be 
considered as specific to one laboratory only (see section 6.5). Given the uncertainty of achieving a full and valid third 
set of data to determine BLR, the VMG agreed to ask the laboratory BDS (test method developer) to deliver the third 
required set of data to evaluate BLR. CitoxLAB continued investigating the technical issues and succeeded in producing 
a full set of acceptable data within the deadline. For the following modules, data sets of both laboratories BDS and 
CitoxLAB are included. 
The 3 EU-NETVAL laboratories were GLP facilities and were asked to perform GLP compliant studies for the testing 
of the coded test chemicals. BDS is an ISO17025 accredited laboratory and performed the study following the GLP 
principles. This would entail qualified personnel and facilities, study planning, data to be recorded in the provided Data 
Analysis Files (DAFs), reporting of deviations and amendments during the study and quality control to confirm raw 
data are accurately reflected in the report. 
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3.4 Structure of the Validation Study & Validation Project Plan 
The validation study was organised according to EURL ECVAM's Modular Approach to validation (Hartung et al, 
2004), to generate information relevant to the modules 1 to 6 (Module 1: Test definition; Module 2: WLR; Module 3: 
Transferability; Module 4: BLR; Module 5: Predictive capacity (PC); Module 6: Applicability domain). 
 
Table 04: Overview of studies, purpose of the study, modules and laboratories 
Studies Assessment of Modules Test chemicals Participating Laboratories 
Training  3  RISE, ENVIGO, CitoxLAB 
Study 1 Transfer  3 6 non coded RISE, ENVIGO, CitoxLAB 
Study 2A 
Study 2B 
WLR and BLR and PC 2, 4, 5 
10 coded 
10 coded 
RISE, ENVIGO, CitoxLAB, BDS 
Study 3 WLR and PC 2 and 5 26 coded RISE 
 
Prior to the start of the validation study, a Validation Project Plan was drafted by EURL ECVAM, reviewed and 
approved by the VMG. This document was updated whenever a modification to the validation study was necessary. 
Detailed information of the management of the study, responsibilities and tasks of the participating laboratories and of 
EURL ECVAM, overall set-up of the study and the organisation into 3 studies covering Modules 2 to 5, are provided in 
this Validation Project Plan (see Annex 13.2). 
 
3.5 Test Chemicals and Test System 
3.5.1 Selection procedure for the test chemicals 
Compilation of data for a set of chemicals  
A list of 83 chemicals, and their reported classification as positive or negative androgen as well as positive or negative 
anti-androgen, was compiled on the basis of the following data sources.  
Literature  
 ICCVAM recommendations for ARTAs (2003): list of 78 chemicals recommended for validation of in vitro 
ARTA agonist and antagonist assays that use mammalian cell reporter gene systems  
 Publication on AR-CALUX® (B. van der burg, et al, 2010): AR-CALUX® cells tested with 11 chemicals for 
agonism, 9 chemicals for antagonism  
 Publication on PALM (A. Freyberger et al, 2012): human prostate cancer cells (PC-3) transformed with the 
cDNA for a human androgen receptor, tested with 6 chemicals for agonism, 6 chemicals for antagonism  
 Publication on AR-STTA (N. Araki et al, 2005): Chinese hamster ovary cells (EcoScreen™), transformed with 
the cDNA for a human androgen receptor, tested with 40 chemicals  
 
Tox21 ARTA assay data  
 Tox21 AR-BLA assay (no cytotoxicity data): human embryonic kidney cells (HEK293T) transformed with the 
cDNA for a human androgen receptor  
 Tox21 AR-luc assay (no cytotoxicity data): human breast carcinoma cells (MDA-kb2)  
 
QSAR  
The Pass AR agonist model (http://www.pharmaexpert.ru/passonline/) was applied. This model relies on structural 
similarity towards a reference sample of AR agonists and non-agonists. Positive classification is achieved when the 
probability of being an agonist is higher than the probability of being inactive. 
  
Expert consultation (VMG-NA, ICATM)  
The list was provided to all members of the VMG-NA in 2013, for review and input. The list was also shared with 
ICATM. A few additional chemicals were suggested.  
 
In addition, the chemicals were tested in-house via high throughput screening for a first evaluation (no cytotoxicity 
data).  
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Selection of a subset for testing in the AR-CALUX® validation study  
A subset of 45 chemicals was selected, aiming at a balanced set of agonist, antagonist and negative chemicals (~15 from 
each class). Detailed information of the selection procedure can be found in the report of J. Burton (2014) (Annex 13.3) 
The criteria listed below were considered:  
 Dose responses and classifications.  
 Availability and price.  
 Solubility as stock solution and as working solution (in cell medium).  
 Potency.  
 Known properties of the chemical.  
 Structural diversity.  
 Glucocorticoid receptor crosstalk.  
 
A selection was carried out as follows:  
 Few of the chemicals had restrictions for access while others were quite expensive leading to the elimination of 
15 potential candidates.  
 Solubility of each chemical was tested in-house and based on insolubility observations at the lowest 
concentration admitted for the validation study (a priori determined). A few candidate chemicals were 
eliminated.  
 Diversity in terms of potency, chemical properties, structural space, glucocorticoid crosstalk were addressed.  
 Values for the potency of the chemicals were retrieved from publications and/or databases. Chemicals were 
selected with the aim of representing low, medium and high potency values. 
 The structural space was investigated based on structural similarity and cluster analysis (Avalon structural 
fingerprint, Tanimoto similarity). Substances were selected on the basis of maximum structural diversity as far 
as possible.  
 AR-CALUX® cells are reported to have a highly specific selective response to low levels of different natural 
and synthetic androgens, and an insignificant response to other nuclear hormone receptor ligands such as 
estrogens, progestins, and glucocorticoids. The inclusion of one chemical with glucocorticoid binding 
properties was therefore considered in order to challenge the test system (Corticosterone).  
 
The requests from the OECD's VMG-NA at the meeting of December 2014 were taken into consideration. Amongst the 
chemicals with antagonistic response, an inclusion of false competitive antagonists was suggested.   
Overlap with the test chemicals of the Japanese ARTA and the Korean ARTA, both test methods under validation at the 
time of assembling the chemicals' list for the AR-CALUX®, was evaluated. During the course of both validation 
studies, the identity of the chemicals tested in these 2 ARTAs became available. Those that were not present yet in the 
list of 45 were added (see Annex 13.3). In 2017, a new ICCVAM list of AR-reference chemicals became available 
(Kleinstreuer et al, 2017). Given that the EURL ECVAM list of chemicals to be tested had only a small number of 
chemicals with reported agonist activity, it was discussed with the VMG to add 5 chemicals with agonist behaviour 
from the ICCVAM list. The two lists have 30 chemicals in common (overlap of 60%).  
The VMG decided on the following:  
 the reference chemicals DHT and Flutamide would not be used as coded test chemicals but the PC and NC 
chemicals could be used given that they had been used, in their capacity as controls, only at fixed 
concentrations.  
 the 6 chemicals used in the transfer phase would not be used again as coded test chemicals given that the 
laboratories had gained already experience with these chemicals. The exception was SoAz, included as coded 
chemical for the reproducibility phase because 1) this is the only chemical soluble in water 2) challenges were 
experienced by some laboratories during the transfer phase.  
 the chemical Disulfiram was proposed by the VMG as a putative control for the specificity control test i.e. a 
false competitive antagonist. This chemical had been tested in the Tox21 project with the assay Tox21 AR-luc. 
It was reported to have antagonist activity at concentrations that were not cytotoxic. 
 one chemical tested in the reproducibility phase, Spironolactone, was once more included in the predictive 
capacity phase to test repeatability.  
 
The complete list of the chemicals used in the AR-CALUX® validation is shown in Annex 13.3 and comprises in total 
53 chemicals of which 46 were used as coded test chemicals.  
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3.5.2 Procurement and coding of the test chemicals 
EURL ECVAM was responsible for the acquisition of all chemicals (including reference and control chemicals) and the 
preparation, labelling and storage at EURL ECVAM's chemical repository. 46 test chemicals were coded (for studies 2 
and 3) and distributed to the 4 laboratories. In the event of an accident in the laboratory with these test chemicals, an 
emergency procedure was foreseen to obtain adequate information on the specific chemical. The laboratories had been 
instructed to treat all coded test chemicals as potential endocrine disrupters. A detailed description of the chemical 
coding and distribution procedure is provided in Annex 13.4. 
The list with all the codes was provided to the statistician when all data had been received and analysed.  
 
3.5.3 Test system   
The test system consists of the AR-CALUX® cell line developed by the Dutch company BDS.  EURL ECVAM 
prepared a cell bank of this test system for distribution to the test facilities. Prior to distribution, EURL ECVAM had the 
cell line tested for purity: 1) the absence of Hepatitis B and C, and HIV 1; 2) the absence of mycoplasma; 3) 
authenticity: the absence of cross contamination by other cell lines (STR profiling).  Each laboratory received at the 
onset of the validation study 6 vials of frozen cells and more vials were supplied when so needed. For each study, a 
fresh vial of cells was used.  
During the validation study, all laboratories had been asked to send aliquots of the last passage of the cell cultures to 
EURL ECVAM for a final verification of authenticity (see Annex 13.7.10). In summary, during the period of the 
validation study, the AR-CALUX® cell lines kept their identity and remained free of mycoplasma in all 4 laboratories.  
 
3.6 Experimental Study Design  
The VMG had reviewed and agreed on the following experimental set-up, per laboratory and across the laboratories. 
Each laboratory had received a set of coded test chemicals, for which maximal solubility had to be determined starting 
from a concentration not higher than 50 mg/ml. A test chemical had to be tested with both the agonist assay and 
antagonist assay. The testing regime for each test chemical consisted of one (or more if needed) pre-screen experiments 
(with dilution factor 10) combined with a cytotoxicity test (LDH test) to 1) determine if the test chemical displayed a 
significant positive response according to the instructions in the SOP, 2) determine if and which concentrations were 
cytotoxic, 3) conclude on the proper dose range, both non-cytotoxic and soluble, for a test chemical showing a 
significant response (full or partial dose response). In order to achieve 3 valid runs (3 biologically independent 
replicates), the pre-screen test would be followed by either 
 More pre-screen tests in case the test chemical did not display a positive response, leading to a total number of 
3 valid runs of which two would have a cytotoxicity test. Visual checking of cytotoxicity was mandatory for all 
runs. 
 Comprehensive tests (with a closer dose spacing) in order to obtain better resolution for calculating the 
parameters) in case the test chemical did display a positive response, leading to a total number of 3 valid runs, 
of which the first valid run would have a cytotoxicity test. In total, a test chemical with a positive response 
would have been tested twice with the cytotoxicity test (once in the pre-screen and once in the comprehensive 
test). Visual checking of cytotoxicity was mandatory for all runs. 
 
The determination of a response being significantly positive was imbedded in the first series of Data Analysis Files 
(DAFs) and relied on an ANOVA Test. A classifier was not included in the first SOP versions used by the laboratories 
given that it was under development. With the introduction of the classifier in the final version of the SOP (V06), the 
criteria were also included in the updated DAFs leading to the removal of the ANOVA test.   
The laboratories were informed that if it was practically difficult to meet the acceptance criteria (e.g. for a problematic 
test chemical), leading to invalidity of experiments, it would suffice to perform a maximum of six biological replicates 
irrespective of their validity.  
For each pre-screen test and each comprehensive test, 8 concentrations per test chemical were tested. Each 
concentration was tested 3 times as defined by the plate layout for both agonist and antagonist testing (3 technical 
replicates). 
In case of an agonist response, the testing proceeded as described above. In case of an antagonist response (full or 
partial dose response) each comprehensive test had to be accompanied by a specificity control (see section 4.7).  
The 4 laboratories were asked to test 20 coded test chemicals for the assessment of reproducibility (WLR and BLR). 
The laboratory RISE was asked to test an additional 26 coded test chemicals for the assessment of predictive capacity 
on a total number of 46 test chemicals. The VMG considered this number sufficiently large to allow such assessment.  
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3.7 Data Collection and Analysis  
3.7.1 Data collection 
EURL ECVAM provided validated Data Analysis Forms (DAFs) to the participating laboratories for them to collect 
and analyse their data. These forms had embedded (and locked) calculations for the determination of the requested 
parameters (e.g. acceptance criteria, specificity control criterion, concentration points above or below the thresholds set 
for classifications). The test facilities received these forms with a data set to verify the correct functioning of the forms 
at the test facilities premises. In addition, the software Graphpad Prism was recommended for generating dose 
responses. During the Training phase of the validation study, the laboratories had received these forms in order to 
familiarise themselves with their use. 
The following DAFs were used throughout the study: 
 Form DAT02-ASY06 for the agonist assay (pre-screen and comprehensive testing) 
 Form DAT04-ASY06 for the antagonist assay (pre-screen) 
 Form DAT05-ASY06 for the antagonist assay (comprehensive testing and specificity control) 
 Form DAT06-ASY06 for cytotoxicity data recording  
The forms were modified and updated during the course of the validation study (see section 4.8 and Table 10).  
EURL ECVAM retrieved all quality controlled data (completed DAFs, (Draft) final reports) of all test facilities via 
CIRCABC. Upon receipt of the DAFs from each laboratory, EURL ECVAM verified that 1) all data of valid and 
invalid runs (reported in DAFs and final reports) were submitted 2) the parameters calculated in the DAFs corresponded 
to those reported in the final reports. 
The overall statistical analysis of the data reported in the DAFs was performed by EURL ECVAM statistician with the 
statistical software Matlab. The data analysis was performed according to the SOP, i.e. the evaluation of all acceptance 
criteria, the re-scalement of raw data into relative induction, the visualisation of concentration responses, estimation of 
parameters such as EC50, PC10, IC50, PC80, R2 etc. In addition, for the initial part of the study where the classifier was 
not yet available, classification was applied on the reported data. These outcomes (dose responses, the measured values 
for the criteria, and final conclusions) for each test chemical were compared to the final conclusions and outcomes 
provided in the reports from the 4 participating laboratories. 
 
3.7.2 Acceptance of data sets 
Each laboratory was required to report all obtained data, being either valid or invalid. "Valid" data sets are defined as data 
that are in accordance with the acceptance criteria of the AR-CALUX® method. "Invalid" data sets are defined as the data 
from failed experiments (not meeting the acceptance criteria). The data were submitted to EURL ECVAM via DAFs on a 
regular basis. The laboratories were requested to report the measures that had been taken to overcome any failure to meet 
the acceptance criteria. Solubility data were submitted either as separate reports or as part of the Final report.  
 
3.7.3 Data analysis  
A statistical evaluation of all studies was performed on the basis of the following criteria:  
 The number of valid/invalid runs (acceptance criteria met or not) and the reasons for invalidity 
 Similarity of the obtained patterns (dose responses)  
 EC50/IC50 estimates of reference and test chemicals (where possible) and its variability 
For the Transfer phase, the data generated by the laboratories had been compared to data generated during EURL 
ECVAM's GLP study ST57 (Annex 13.7.7) 
The data that fulfilled the Acceptance Criteria (data from valid runs) were used for further data analysis. The 
determination of reproducibility within laboratories (WLR) and between laboratories (BLR) was based on concordance 
of classifications. A classifier to determine agonist and antagonist behaviour was developed by EURL ECVAM, in 
collaboration with the test method submitter, and included a criterion for the specificity control to be applied in the 
antagonist assay. This classifier was introduced in the SOP V06 (used for studies 2 and 3). 
Once all data had been obtained from all 4 laboratories and analysed by the statistician for the assessment of WLR and 
BLR, the test chemicals were decoded. A final review of the data was performed by the VMG. 
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3.8 Time line for the studies 
 
Time line for the studies (experimental part) 
 RISE ENVIGO CitoxLAB BDS 
Transfer phase 
(Study 1) 
(6 chemicals) 
1/09/2015 – 5/12/2015 
(6 chemicals) 
03/11/2015 – 25/05/2016 
(6 chemicals) 
22/07/2015 – 12/04/2016 
(6 chemicals) 
 
08/11/2016 – 13/07/2017 
(additional tests) 
NA 
     
Reproducibility 
phase 
(Study 2) 
 
25/10/2016 – 14/12/2016 
(10 chemicals) 
17/01/2017 – 27/04/2017 
(10 chemicals) 
 
16/05/2017 – 22/02/2018 
(10 chemicals) 
03/07/2018 – 07/11/2018 
(20 chemicals)(*) 
15/07/2018 – 28/11/2018 
(20 chemicals) 
     
Additional 36 
chemicals  
(Study 3) 
16/05/2017 – 23/02/2018 NA NA NA 
Note: The indicated time slots may not reflect the actual time spent to the validation study given that all participating  
laboratories provided services to their clients. (*) investigative tests took place during Study 2 (10/10/2017 – 16/05/2018).  
NA = not applicable 
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4 TEST DEFINITION (MODULE 1) 
4.1 Description of the in vitro Method 
The AR-CALUX® cell based assay provides information on the endocrine activity of chemicals, and more specifically 
the (anti-)androgenic activity, when the AR-CALUX® cells are exposed to substances. This in vitro method is a 
transactivation assay where the reporter gene luc (encoding luciferase) is activated by the androgen receptor but only 
when bound to a ligand, i.e. a chemical with androgen receptor affinity. This receptor-ligand complex enters the nucleus 
where it will bind to specific recognition sequences in the promoter region of a target gene (so called androgen 
responsive elements or ARE). Hence, the target gene will be transcribed. When the target gene expresses the reporter 
(luciferase), in vitro hormonal activity of chemicals can be quantified as well as the agonistic or antagonistic mode of 
action. Such assays are called Androgen Receptor Transactivation Assays (ARTA).  
The AR-CALUX® cell line was created via transfection of the human osteosarcoma cell line U2-OS (ATCC HTB 96) 
with 2 constructs: pSG5-neo-hAR carrying the cDNA of a human androgen receptor under a constitutive promoter, and, 
a luciferase reporter gene which is preceded by a triple tandem of AREs in front of a TATA box (3x ARE Luc).  
This cell line had been reported to stably express the human androgen receptor, to be highly selective in its response to 
low levels of different androgens (due to the multimerized ARE and a minimal promoter – TATA box only), and to 
have an insignificant response to other nuclear hormone receptor ligands such as estrogens and glucocorticoids (due to 
the cells not expressing other steroid receptors that can activate transcription via the same ARE as the androgen 
receptor) (Sonnenveld et al, 2004).  
The cell line has low metabolic activity as was shown via RNA sequencing where major classes of metabolic genes 
were targeted and found to have no or low expression (personal communication). By combining the test method with a 
S9 fraction, the impact of metabolism on test chemical activity can be studied (van Vught-Lussenburg et al, 2018).  
The assay has been used for high throughput screening (van der Burg et al, 2015) 
The name "CALUX" has been registered at a national trade mark office. This trade mark, owned by Abraham Brouwer 
and BDS, is for "Conducting chemical, biochemical and biological analyses; preparing cell lines, tissue cultures, culture 
media and supplements therefore and products thereof". The cell lines, the protocol, training and technical support are 
available through a license agreement. The parental cell line U2OS was obtained from ATCC and approval for 
commercialisation was given in 2002.  
 
4.2 Purpose and Regulatory context of the in vitro Method 
The AR-CALUX® method is intended to be used for screening purposes because of an easy and time efficient 
application. Both the OECD Conceptual Framework and the US EPA have recommended transactivation assays as an 
important tool for fast screening of chemicals with possible endocrine disrupting properties. OECDs Conceptual 
Framework has identified several type of methods classified over levels, e.g. level 2 involves in vitro assays providing 
mechanistic data.  Validated ERTAs are included at this level, but there is still a lack of validated ARTAs. The 
proposed AR-CALUX® method, once validated, could be inserted at this level 2.  
 
4.3 Principle of the in vitro Method  
The test method is described by the test method submitter to measure the ability of a chemical to activate AR dependent 
transcription (i.e. act as an agonist) and to suppress AR dependent transcription (i.e. act as an antagonist). Hence, the 
test method is composed of an agonist and an antagonist assay. 
Both assays include a pre-screen for determining the appropriate dose range, followed by comprehensive testing. To 
determine the agonist or antagonist nature of a test chemical, it will be tested in the following manner: 
1) A dilution series of the chemical is prepared in solvent (e.g. DMSO) and applied to the cells in assay medium. When 
the luminescent signal increases in a concentration dependent way in comparison to the solvent control, the chemical 
has an agonist response. 
2) A dilution series of the chemical is prepared in solvent (e.g. DMSO) and applied to the cells in assay medium 
supplemented with the EC50 concentration of Dihydroxytestosterone (DHT). When the luminescent signal decreases in 
a concentration dependent way in comparison to the solvent control, the chemical has an antagonist response unless 
there is a non-specific response. In order to rule out a false antagonist response, the chemical is tested with an EC50 and 
100X EC50 concentration of DHT within the same plate. 
 
In order to label a test chemical as an agonist or antagonist, a classification scheme is applied.  
 
 
 
18 
 
 
4.4 Reference Chemicals and Control Chemicals  
The agonist and antagonist assays each have a reference chemical for which the dose response is measured, and EC50 \ 
IC50 values, the induction factor and the Z factor (see Tables 05 and 06) calculated. It is also the chemical to which the 
response of a test chemical is compared (normalisation).  
The positive control and negative control consist of the addition of a chemical to the test medium (including DMSO) for 
which respectively a response or no response is expected. Both assays have a vehicle control VC which is the assay 
medium including DMSO (0.1%) while the antagonist testing includes also a solvent control SC which is the vehicle 
control plus EC50 of DHT. 
 
Table 05: Proposed reference and control chemicals for the agonist assay 
 Name CAS No. 
Reference Dihydroxytestosterone (DHT) 521-18-6 
Positive control Methyl testosterone 58-18-4 
Negative control Corticosterone 50-22-6 
 
 
Table 06: Proposed reference and control chemicals for the antagonist assay 
 Name CAS No. 
Reference  Flutamide 13311-84-7 
Positive control  Linuron 330-55-2 
Negative control Levonorgestrel 797-63-7 
 
 
4.5 Acceptance Criteria 
Criteria for the reference chemical, positive and negative control were established by both the test method submitter and 
EURL ECVAM during the assessment of the SOP. An experiment is considered valid and will be accepted when all of 
these acceptance criteria are met (Tables 07 and 08).  
 
Table 07: Acceptance criteria in the agonist assay Table 08: Acceptance criteria in the antagonist assay 
No. Acceptance criterium Value No. Acceptance criterium Value 
 Reference chemical DHT  Reference chemical Flutamide 
1 Curve fitting Sigmoidal 1 Curve fitting Sigmoidal 
2 EC50 range  1.0 E-10-1.0 E-9 M 2 IC50 range  1.1 E-7-1.1 E-6 M 
3 CV of estimated log(EC50) < 1.5% 3 CV of estimated log(IC50) < 3% 
4 Induction factor  > 20 4 Inhibition factor  > 10 
5 Z-factor > 0.5 5 Z-factor > 0.5 
 Positive control  Positive control 
6 RI Methyl testosterone > 30% 6 RI Linuron < 60% 
 Negative control  Negative control 
7 RI Corticosterone < 10% 7 RI Levonorgestrel > 85% 
    Reference chemical Flutamide specificity control 
   8(*) 
R2 between the RI of Yc and 
Sc for Flutamide 
≤ 0.7 
   RI = Relative Induction 
   (*) To be applied for assessment of the specificity response (Sc) of Flutamide, Yc being the standard response. 
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4.6 Classifier 
EURL ECVAM and the test method developer worked together to assemble a classifier for both agonist and antagonist 
assay. When the specificity control criterion was developed (see section 4.7), the VMG decided to include this criterion 
into the classifier. The classifier, as introduced in SOP V06, is shown below.  
Agonism: For each run, a test item is considered  
A.  Positive when the relative induction (Yc) of the test item is equal or exceeds 10% (REF RPC10) for two or 
more consecutive concentrations. 
B.  Negative when the relative induction (Yc) of the test item does not exceed 10% (REF RPC10) for any 
concentration. 
C.  Inconclusive in all other cases. 
Antagonism: For each run, a test item is considered  
A. Positive when the following two conditions are met: 
 the relative induction (Yc) of the test item is less or equal to 80% (REF RPC80) for two or more consecutive 
concentrations and  
 the correlation coefficient (R2) is less or equal to 0.9 between the relative induction of the test item (Yc) and the 
relative induction of its specificity control (Sc).   
B. Negative  
Either  
 when the relative induction (Yc) of the test item is greater than 80% (REF RPC80) at all concentrations; 
or 
 when the relative induction (Yc) of the test item is less or equal to 80% (REF RPC80) for at least 2 consecutive 
concentrations and the correlation coefficient (R2) is greater than 0.9 between the relative induction of the test 
item (Yc) and the relative induction of its specificity control (Sc).  
C. Inconclusive in all other cases. 
During the review of all obtained data at the end of the validation study, the SOP and the classifier were modified by the 
VMG. This included guidance in the SOP regarding the observation of one concentration passing the thresholds of 10% 
(for agonism) and 80% (for antagonism), and, a modified classifier (see section 10 Discussion). 
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4.7 Development of a Specificity Control for the Antagonist Assay 
An antagonist assay is performed by spiking the assay medium with a specific concentration of a known ligand. Usually 
this concentration will be the EC50 of the ligand. The antagonist assay leads typically to dose responses with a sigmoid 
shape (see figure 02, response Yc) which is normally caused due to increasing competition at the receptor binding site 
between the agonist ligand (at fixed concentration) and the antagonist test chemical (with increasing concentration). 
Such response however can also be caused by other effects of which cytotoxicity is the most occurring cause.  
Interferences along the pathway of receptor-ligand binding, dimerization, binding to the UREs, transcription, translation 
up to protein stability have also been reported.  
A control to identify (true) competitive antagonists (i.e. competition for the same binding site on the AR) and false 
positive antagonists (e.g. due to cytotoxicity) was introduced. It consists of testing the chemical with two different 
concentrations of stimulating ligand (DHT 3x10-10 M for a standard response (=EC50), and, 3x10-8 M for the specificity 
response (=100X EC50)), leading to two different dose responses and subsequently a potency shift (see figure 02). 
4.7.1 Concentration for spiking 
The 100X EC50 concentration was defined on the basis of the complete dose response for DHT when administered to 
the cells (see figure 01). A concentration was chosen that was as high as possible in order to have full saturation of the 
receptor binding places but not leading to cytotoxicity. 
     
4.7.2 Criterion R2 
A criterion was sought to quantify the shift of the two dose responses, based on the assumption that the decrease of the 
test chemicals response which is not due to competitive antagonism is proportionally the same as the decrease of the 
specificity control response at all (non-cytotoxic) concentration. The VMG agreed on the criterion R2 : the square of the 
correlation coefficient between the Relative Induction (RI) of the test chemical at concentration c (Yc) and the Relative 
Induction of its specificity control at concentration c (Sc).  
    
Figure 02: Dose responses generated by Flutamide and Actinomycin D. The curve in blue is the standard response (Yc), the curve in 
red is the specificity response (Sc). 
The threshold value for R2, to distinguish (true) competitive antagonist from false positive antagonist, was based on 
historical data obtained from several data sets generated at EURL ECVAM and BDS (see Annex 13.7.8). The following 
values were applied in the validation study: 
 Competitive antagonist: R2 ≤ 0.9.  
 False positive antagonist: R2 > 0.9  
This measurement was included as a criterion in the experimental design. To verify the proper functioning of the 
specificity control, an acceptance criterion for Flutamide was introduced when tested with the specificity control. The 
threshold value was determined from historical data (see Annex 13.7.8.). This criterion was added in the list of 
Acceptance Criteria leading to the decision of a valid run (see section 4.5): R2 between Yc and Sc for Flutamide ≤ 0.7.  
Figure 01: 
Dose response of DHT 
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4.8 Protocol of the Test Method 
In the test submission of the test method developer BDS to EURL ECVAM, 6 SOPS had been provided that included 
instructions for both ER and AR-CALUX®. BDS in discussion with EURL ECVAM modified the SOPs, assembling 
them to one SOP, removing references to ER-CALUX®, adding additional acceptance criteria. EURL ECVAM drafted 
SOP V01 for experimental testing in the laboratory, leading to versions 02 and 03. Modified versions of the SOP have 
been generated throughout the validation study based on observations and feedback from the 3 laboratories. The different 
SOP versions have been used as follows: 
 Version 03 for the Training 
 Version 04 for the Transfer phase (6 test chemicals) 
 Version 05 for the Reproducibility phase (10 test chemicals by RISE and ENVIGO) 
 Version 06 for the Reproducibility phase (10 test chemicals by ENVIGO, 20 test chemicals by CitoxLAB and 
BDS), and, for the Predictive capacity phase (26 test chemicals by RISE)   
Version 06 included the classifier as well as a criterion for the specificity control. Version 07 was prepared and released 
by the VMG at the end of the validation study. It included a warning for the usage of glass ware and plastic ware, to be 
carefully verified for contaminants prior to initiating experiments.  
The major modifications to the SOP included the following: 
 Completion and modification of acceptance criteria for both agonist and antagonist assay 
 Development and inclusion of a specificity control for the antagonist assay, including a quantitative criterion 
R2 for the reference chemical Flutamide and for test chemicals 
 Adding a classifier (with inclusion of the criterion for the specificity control) 
In summary, for 20 coded test chemicals, to be evaluated for WLR and BLR, two SOPs were handled that differed only 
by having the classifier included in the last version V06. The additional 26 coded test chemicals evaluated by RISE were 
all tested with the SOP version V06 (with classifier). The use of these two different versions is due to the laboratories 
initiating and finishing the studies at different times. Once the SOP version V06 was ready, it was provided to those 
laboratories that still needed to start with part (ENVIGO) or whole (CitoxLAB and BDS) of the study 2 (20 coded test 
chemicals). 
A summary overview of the modifications made to the set of SOPs is given in Table 09.   
Data analysis files (DAFs), for recording and analysing data, had been received from the test method developer and were 
updated during the course of the validation study in line with the updates in the SOP versions. A summary overview of 
the changes introduced to those DAFs is shown in Table 10. The major changes included:  
 replacement of the ANOVA test with the classifier 
 inclusion of the specificity control criterion 
 modifiable dilution factor instead of a fixed dilution of 3.33 in the comprehensive test 
 inclusion of VC level of 5% for monitoring too high RLUs 
DAT 06 for recoding data of cytotoxicity testing remained unchanged. 
The most recent forms were provided to the laboratories RISE, CitoxLAB and BDS during the validation study in order 
to make use of a flexible dilution factor. ENVIGO did not use this form because it had finished the experimental part. 
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Table 09: Overview of major changes introduced in the SOP versions used in the validation studies: ASY06 versions 3, 4, 5 and 6 and 7 
Version 03 (09/02/2015) - used for the Training 
Changes from SOP BDS versions 
General  Merged 6 BDS SOPs into one EURL ECVAM SOP-ASY06.
 Highest concentration of a chemical to be tested shall be 50 mg/ml instead of 100 mM. This was changed because molecular weight of test
chemicals will be unknown.
 Inclusion of a specificity control for antagonist assay (experimental part only, no criterion)
 Inclusion of pictures for confluency and cytotoxicity visual checking
 Removal of BDS solubility section
 No classifier
Technical aspects  Change to a fixed sub-culturing seeding density of AR-CALUX® cells instead of splitting 1:5 or 1:7
 Inclusion of option to use also commercially available solutions for luciferase expression, lysis buffer, trypsin, geneticin and charcoal stripped FCS
 Change in sample preparation: 24 hours after seeding 100 l assay medium is not removed from the wells. 100 l of test chemical with double
concentration is added to the wells.
 Maximum DMSO concentration reduced from 1% to 0.1% on basis of EURL ECVAM in-house experiments.
 Increase of linuron concentration (PC Antagonist) from 1 x 10-6 M to 1 x 10-5 M to ensure sufficient antagonistic (positive) response. Higher
linuron concentrations are not recommended because signs of insolubility were observed at 15 g/ml in assay medium.
 Increase of concentration of Levonorgestrel (NC Antagonism) from 1 x 10-7 M to 1 x 10-6 M (giving the maximum agonist response).
 Increase of concentration of 17-Methyltestosterone (PC Agonist) from 1 x 10-9 M to 1 x 10-7 M (giving the highest agonist response).
 Instruction for cytotoxicity determination via both LDH leakage and visual inspection.
 Inclusion of a cytotoxicity control: Triton X to be used in column 1 of the plates.
 Established the concentration of DHT to be used for Antagonism specificity control at 100 x EC50 DHT concentration.
 Induction factors are calculated per plate to confirm validity.
Plate layout  Plate layout changed for Agonist and Antagonist assay. Cytotoxicity positive control added; C4 concentration of FLU and DHT replaced by their
C8 concentration to be able to calculate the IF. The plate layout of the Antagonist assay had an additional change to one test chemical per plate
only to accommodate the inclusion of the specificity control within the same plate.
Acceptance 
Criteria 
 Removal of the tolerated variability of triplicate samples: % SD of triplicate wells for reference chemical C1 to C8, test chemical samples, PC, NC,
CO and SC
 Induction factors (IF) are calculated for each plate using SC and highest concentration C8 of the reference chemical, to confirm validity of each
separate plate, instead of comparing C4 and C8 samples with those on plate 1
 Inclusion of CV of estimated log(EC50) and estimated log(IC50)for the reference chemicals DHT and Flutamide
 Inclusion of the Z-factor to encompass tolerated variability of all samples
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Data analysis 
 Included the calculations of the existing parameters
 Added the calculations for the additional parameters Z-factor and induction factors (IF) per plate
 Data analysis section revised and calculations moved to the Annex
 Inclusion of an ANOVA test to distinguish significant differences from the solvent control (VC in Agonist testing or SC in Antagonist testing) and
simplify the selection of proper concentrations for Agonist and Antagonist comprehensive testing after the pre-screen
Version 04 (16/06/2015) – used for the Transfer phase (6 chemicals) and for EURL ECVAM study ST57 (comparison date for transfer) 
Changes from v03: 
General 
 Re-organisation of the SOP to better separate Agonist and Antagonist data analysis from concentration selection and acceptance criteria.
 No classifier
Technical aspects 
 Addition of procedure for manual preparation of trypsin-EDTA solution starting from powder
 Addition of schemes for dilution of reference and control chemical stock solutions
 Inclusion of extra control step to microscopically confirm successful lysis of the cells for luminescence sample preparation.
Plate layout 
 Solvent control of the reference chemical C0 is renamed to SC as it is identical to the SC of the test chemical
 Included plate layout for the Antagonism specificity control.
AC Not changed 
Data analysis Not changed 
Version 05 (24/10/2016) – used for the reproducibility phase (10 chemicals for RISE, 10 chemicals for ENVIGO) 
Changes from V04: 
General 
 Inclusion of reference to the SOP for solubility testing: SOP-ASY15
 No classifier
Technical aspects 
 Monitoring instruction included for VC: to monitor closely the RI for unexplainable increase
 Monitoring instruction included for SC: to monitor closely that RI of C1 samples is approximately at SC level in order to be able to calculate the
parameters
 Laboratories own historical DHT EC50 value to be used in the Antagonist tests instead of the default EC50 value
Plate layout Not changed 
AC Not changed 
Data analysis Correction of formulas for PC50 and PC10 
Version 06 (30/03/2017) – used for the reproducibility phase / predictive capacity (10 chemicals ENVIGO, 37 chemicals RISE, 20 chemicals CitoxLAB and BDS ) 
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Changes from V05: 
General Inclusion of the classifier for Agonism and Antagonism and visual explanation of the specificity control. 
Technical aspects Not changed 
Plate layout Not changed 
AC Inclusion of the R
2 criterion (criterion 8) for Flutamide that shows the proper functioning of the specificity control in the Antagonist assay. 
Data analysis 
 Removal of the calculation of ANOVA test that distinguished SC from C1 concentration and replaced it by the threshold values 10% for agonism
and 80% for antagonism.
 Inclusion of the calculation of R2
 Introduction of parameter Sc for specificity response and Yc for normal response in the calculations for Antagonist responses. Calculating these
parameters and using the ratio between Sc and Yc it can be determined if a test chemical is a true competitive Antagonist or not.
Version 07 – FINAL SOP for dissemination (available at TSAR) 
 Warning for verification of assay performance with the usage of material and reagents such as glass ware, plastic ware and solvents. Include the
material and reagents that worked well as examples
 Classifier modified
 Change the test chemical concentration from mg to mM
 Guidance for testing with dilution factor 2 when only the highest tested concentration is found to pass the threshold values for classifications
 Flexibility for the use of fresh or frozen stock solutions of the two reference chemicals
 Flexibility for the use of plastic 24 well plates or glass tubes for preparing working solutions
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Table 10: Overview of major changes introduced to the DAFs 
DAT02 
Agonist PRE and COM 
DAT04 
Antagonist PRE 
DAT05 
Antagonist COM and specificity 
control 
Forms used for  
Draft V04 Draft V03 Draft V03  
 Revised BDS DAF conform SOP V03  Revised BDS DAF conform SOP V03  Revised BDS DAF conform SOP V03 
 
Training 
V04 (validated) V03 (validated) V03 (validated)  
No change No change No change Study 1: 6 chemicals (Transfer phase) 
Study 2A: 10 coded chemicals RISE and 
ENVIGO 
V05 (validated) V04 (validated) V04 (validated)  
 ANOVA replaced by classification 
threshold 10%  
 
 ANOVA replaced by classification 
threshold 80%  
 
 
 ANOVA replaced by classification 
threshold 80%  
 Inclusion R2 calculation for reference 
ítem Flutamide 
 Inclusion R2 for calculation for test 
chemical 
 Inclusion graph plotting dose 
responses Sc versus Yc 
Study 2B: 10 coded chemicals ENVIGO 
Study 2: 20 coded chemicals CitoxLAB and 
BDS  
Study 3: 36 coded chemicals 
RISE 
 
V06 V05 V05  
 Dilution factor made flexible 
 
 
 Formulas changed for calculation of 
average RLU and RI, to ensure that non-
numerical values are ignored for 
calculation of parameters and 
visualisation of graphs 
 Dilution factor remained to be 10X                  
 Inclusion IF calculation for the VC in 
antagonist assay 
 Formulas changed for calculation of 
average RLU and RI, to ensure that 
non-numerical values are ignored for 
calculation of parameters and 
visualisation of graphs 
 Dilution factor made flexible 
 Inclusion IF calculation for the VC in 
antagonist assay 
 Formulas changed for calculation of 
average RLU and RI, to ensure that 
non-numerical values are ignored for 
calculation of parameters and 
visualisation of graphs 
For some coded chemicals 
RISE,  
CitoxLAB, 
BDS 
in Study 2 and 3 
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4.9 Known Technical Limitations and Drawbacks of the Test Method 
The test method developer reported no specific limitations of the test method except for the general limitations of 
transcription assays: direct extrapolation to the in vivo complex network of signalling and regulation should not be 
made; information is gained on the parent molecule while in vivo other molecules may be generated due to the cells' 
metabolism.  
4.10 Conclusion of the VMG 
The need of the test method in the context of current OECD regulatory requirements is evident. The proposed use of the 
test method as a screening method for EDs is relevant. 
The AR-CALUX® SOP was considered sufficiently developed for the purposes of this study. The acceptance criteria 
and their values were considered as adequate.  
The introduction of a test to verify the true positive nature of an antagonist response (this is the specificity control) was 
considered of added value (see further section 10 Discussion). 
During the course of the validation study some minor modifications were made to the SOP. At the end of the validation 
study, recommendations were made by the VMG for further modifications to the SOP e.g. additional instructions for the 
choice of the dilution factor and modifications of the classifier (see Table 9 and section 10 Discussion). These changes 
will be introduced in the final version of the SOP. 
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5 TRANSFER (MODULE 2 / STUDY 1)  
Reference documents: 
 Statistical report (Annex 13.1) 
 SOP version V03 and V04 (Annex 13.7.3) 
 Agenda and Planning of the training (Annex 13.7.1) 
 EURL ECVAM report GLP compliant study on 6 test chemicals SR-ST57 (Annex 13.7.7) 
 JRC technical report on " Technical meeting on the Implementation of the AR-CALUX® in vitro method" 
(Annex 13.7.4) 
 JRC technical report "Transfer Evaluation report" (Annex 13.7.5) 
 Study plans and study reports of the participating laboratories (Annex 13.7.2) 
 
 
5.1 General Aspects 
The first phase of the validation study consisted of the Transfer phase where the laboratories implemented the test 
method in their own laboratory. Their results were evaluated to verify if the laboratories were sufficiently trained with 
the application of this test method. EURL ECVAM's GLP laboratory had carried out a GLP study with the test method 
(SOP version 03) and generated GLP compliant test data which would serve as a reference data set when assessing the 
transferability of the test method to the test facilities (see Annex 13.7.7).  
The Transfer phase was initiated by EURL ECVAM on June 15, 2015. The 3 laboratories started at different times 
within a time span of 3 months and data were received in April 2016 (RISE) and June 2016 (CitoxLAB and ENVIGO). 
The data analysed in this report are the verified (QC) data from the 3 laboratories. During the course of the Transfer 
phase, EURL ECVAM visited the 3 laboratories to discuss the ongoing validation study and help out with issues 
encountered. CitoxLAB had a transfer phase which consisted of two parts (July 2015 - July 2016, and, November 2016 
- June 2017) due to technical issues encountered. Additional training was given by EURL ECVAM in April 2017.  
Prior to the initiation of the Transfer phase, the 3 participating laboratories were given training on the usage of the test 
method. Training was provided by EURL ECVAM in collaboration with the test method developer BDS at the premises 
of the Joint Research Centre in Ispra. 
 
5.2 Training 
SOP V03 was used for the training. The training included theoretical components such as detailed review and 
discussion of the SOP, the DAFs, study plans and reports. Hands-on training was offered for the usage of the DAFs 
with a set of fictive data and the use of CIRCABC for retrieving and uploading files. CIRCABC is the European 
Commission platform for data exchange and was the tool for data and documentation transfer between each laboratory 
and EURL ECVAM. Experimental training was provided where the participants either observed or performed the 
critical elements of the SOP such as plating of cells, preparing dilutions of few test chemicals and treating the cells, 
luciferase measurements. 
At the end of the course, the participants were presented with a questionnaire about the theory/practical sessions 
covered during the previous days, to challenge what they learned during the course.  
 
5.3 Transfer of the Test Method to the Naïve Laboratories 
SOP V04 was used for the Transfer assessment. The testing comprised out of pre-screen testing to deduce the correct 
dose response, followed by comprehensive testing. For the antagonist assay, a specificity control test was also required.  
The 3 participating laboratories had been asked to test 6 test chemicals with both agonist and antagonist assay (see 
Table 11). Classification was not required given that the SOP did not include yet the classifier. For each test, 
cytotoxicity was measured. Each laboratory was required to achieve 3 valid runs. Laboratories had been given DAFs to 
record the RLUs. These forms had imbedded calculations for the Induction factor, Z-factor, etc. Dose responses, EC 
and IC values for the test chemicals had to be obtained by using GraphPad or other similar statistical software. 
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Table 11: Test chemicals for the Transfer phase 
Test chemical CAS No. AR reference list EURL ECVAM's ARTA data list 
AGONIST ANTAGONIST AGONIST ANTAGONIST 
Testosterone 58-22-0 Strong  Negative  
4-Androstenedione 63-05-8 Moderate  Negative  
Procymidone 32809-16-8 NA Very weak  
p,p’-Methoxychlor 72-43-5 NA Weak  
Sodium azide 26628-22-8 N, N, N N, N, N 
Di-n-butyl phthalate 84-74-2 N, N, N N, N, N 
N= negative response 
AR reference list: ICCVAM list of AR Reference chemicals (Kleinstreuer et al, 2017) 
EURL ECVAM's ARTA data list is described in Annex 13.3 
A summary overview of the obtained results is given in Table 12. More information and details can be found in Annex 
13.7.5. 
Transfer to RISE 
RISE observed few times high values for the Vehicle Control (VC) in the antagonist assay (2 runs out of 5 valid runs) 
though this did not affect acceptance of the run. The VC did not have an Acceptance criterion. In discussion with the 
laboratory the reason for these high values was not discovered. The high values for the VC however were of concern 
given that also CitoxLAB obtained high values (see further). Therefore EURL ECVAM discussed with the VMG to 
introduce a monitoring guidance for the VC. 
Transfer to ENVIGO 
ENVIGO reported early on about difficulties with the luminescence readings which they thought was due to cross 
contamination in the plates. They therefore proposed to use the Steady Glo kit for luminescence measurements because 
of previous good experience from ERTA measurements. Using this particular kit does not require an injection 
luminometer. The usage of such luminometer however had been one of the requirements in the invitation to participate 
in this validation study as it was the equipment proposed by the test method submitter. ENVIGO carried out the 
experiments for the agonist assay with the Steady Glo kit (and without double injection luminometer) and provided data 
of good quality. 
EURL ECVAM visited ENVIGO (April 2016) to understand the issues with the luminescence measurements. It was 
discovered that ENVIGO's equipment was calibrated with very sensitive settings. While faithfully following the 
example setting indicated in the SOP V04 (4 seconds integration time), this time span was too high for the given 
settings. With lower integration time, the readings were fine. Given that ENVIGO had already carried out the agonist 
part with the Steady Glo mix (and had obtained good data), EURL ECVAM allowed them to continue with this kit for 
the antagonist part. The data nevertheless would be carefully analysed for acceptability and subject to review and 
approval by the VMG. EURL ECVAM considered that, under the condition that the generated data would be similar to 
the data of the other laboratories, the usage of another kit and a luminometer without injection by one laboratory could 
be of benefit for the test method, for the validation study and for the future TG on ARTAs. The current SOP V04 
restricted the luminometer to those with double injection which can be a limiting factor in the application of the test 
method in many laboratories. 
When comparing the number of valid/invalid runs across the 3 laboratories, ENVIGO had the lowest number of invalid 
runs: 1 out of 8 agonist runs, and, 1 out of 7 antagonist runs.  
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Table 12: Overview of some results obtained in the 3 laboratories and EURL ECVAM  
AGONIST ASSAY ANTAGONIST ASSAY 
 RISE CitoxLAB ENVIGO EURL ECVAM  RISE CitoxLAB ENVIGO EURL ECVAM 
# of total runs 
# of valid runs  
# of partially valid runs 
8 11 4 8 # of total runs 8 15 7 6 
3 3 3 7 # of valid runs  3 4 6 4 
1 2 0 1 # of partially valid runs 2 1 1 0 
Average across runs Average across valid runs 
DHT EC50 (M) 2.5E-10 2.7E-10 3.8E-10 3.1E-10 Flutamide IC50 (M) 6.2E-07 7.3E-07 5.2E-07 6.6E-07 
CV(logEC50) 0.41% 0.53% 0.60% 0.47% CV(logIC50) 0.84% 0.98% 0.90% 0.61% 
IF 47 83 78 76 IF 31 44 30 32 
ZF 0.84 0.83 0.72 0.84 ZF 0.79 0.79 0.74 0.82 
  
Variability of plate triplicates CV (test chemicals only, RLU where RI>2.5%) Variability of plate triplicates CV (test chemicals only, averaged over runs, RLU where RI>2.5%) 
DHT 7.9% 8.4% 9.8% 7.4% Flutamide 8.5% 8.9% 10.2% 6.8% 
Methoxychlor 
not reported, in absence of agonist response 
Methoxychlor 6.2% 6.8% 9.0% 5.7% 
Procymidone Procymidone 6.7% 5.2% 8.8% 7.6% 
Dibutylphtalate Dibutylphtalate 5.7% 6.4% 9.6% 9.1% 
Androstenedione 9.6% 5.7% 9.8% 8.0% Androstenedione 5.4% 4.2% 8.0% 6.2% 
Testosterone 7.3% 5.4% 11.0% 7.1% Testosterone 4.9% 5.1% 9.3% 6.0% 
Sodium azide not reported, in absence of agonist response Sodium azide 6.5% 5.5% 9.0% 9.2% 
average CV of all triplicates 9.3% 6.8% 10.2% 7.5% average CV of all triplicates 6.3% 6.0% 9.1% 7.2% 
           
DHT Within and Between runs variability Flutamide Within and Between runs variability 
within run variability 
 [average CV(log EC50)] 
0.36% 0.46% 0.51% 0.43% 
within run variability  
[average CV(log IC50)] 
0.74% 0.92% 0.83% 0.56% 
between runs variability 
 [CV(log EC50)] 
0.61% 0.82% 1.44% 0.76% 
between runs variability 
 [CV(log IC50)] 
1.45% 1.56% 1.03% 1.89% 
      
 
Main reasons for invalid runs 
* DHT curve 
failed (1run) 
* SC too high  
(3 runs) 
* plate reader 
error (1 run) 
* triton 
incorrect (5 
runs) 
*wrong plates 
used (2runs) 
*DMSO 
incorrect in 
solvent (3runs) 
*DMSO 
incorrect as 
solvent (1 run) 
all criteria 
failed in one 
run 
* No NaOH 
injected into the 
plate (part of 1 run) 
* DHT dilution 
series incorrectly 
prepared (1 run) 
 
Main reasons for invalid runs 
* IC50 
Flutamide out 
of range (1run) 
* IF out of 
range (1run) 
*plate reader 
error (1run) 
* NC an PC 
not on plate 
(1run) 
* triton 
incorrect (3 
runs) 
*wrong plates 
used (2runs) 
*DMSO 
incorrect in 
solvent (2runs) 
*incorrect 
preparation, 
criteria not 
met(2 runs) 
Z-factor not 
met in one 
plate of one 
run 
Relative induction of 
control chemicals 
criteria not met 
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Transfer to CitoxLAB 
Similar to RISE, CitoxLAB obtained few times high values for the Vehicle Control (VC) in the antagonist assay (2 runs 
out of 5 valid runs). 
A larger number of runs to arrive to the required 3 valid runs for agonist and antagonist assays had to be carried out, 
mainly due to the usage of a too high concentration of Triton-X (the positive control for cytotoxicity in all plates, placed 
in row 1). Such had influenced the cells in the neighbouring row (row 2 with SC). This was obvious in the antagonist 
assay as the wells with SC (assay medium with DHT, normally leading to high RLUs) had too low RLU values. It was 
not immediately picked up in the agonist assay as the Triton-X wells were bordering the SC wells (assay medium only, 
normally leading to low values). Several invalid runs for the agonist assay can be noticed (see Table 12; first 6 out of 11 
runs) due to a relabelling as invalid because of the discovery of issues with the use of Triton-X. On EURL ECVAM's 
recommendation, all experiments where Triton-X may have been used at an incorrect concentration were repeated. The 
laboratory purchased ready to use 10% Triton-X solution what solved the issue. The laboratory reported on not clear 
enough instructions in the SOP V04 leading to different interpretations in terms of pipet use and calculations. 
CitoxLAB reported for few antagonist runs SC data that increased with increasing plate number. The SC is present on 
each plate in the second row (6 wells). EURL ECVAM visited the facility (May 2016) and advised on strictly following 
the instructions of the SOP V04 for thawing the luciferase mix until room temperature before usage. CitoxLAB's 
practice of placing the mix from the freezer in a beaker with tap water of which the temperature was not controlled may 
have led to the observed variability in the results. The mix could have been used at temperatures lower than room 
temperature, and, slowly warmed up in the instrument during the measurements. This may explain why the SC data 
increased over time (with increasing plate number). When the laboratory changed its practice of thawing, the issue was 
remediated.  
CitoxLAB provided graphs for the antagonist assay (for the reference chemical Flutamide and for the test chemicals) 
which sometimes displayed a deviating dose response (2 runs out of 5). In particular, the lowest tested concentrations 
(C1 and higher) should normally lead to responses at the 100% SC level (the plateau phase). This laboratory obtained 
responses that decreased up to 50% and not all parameters could be calculated anymore. The reason was not known. 
EURL ECVAM proposed a monitoring guidance for the next version of the SOP.  
The VMG reviewed all data from all 3 laboratories (September 2016) and recommend CitoxLAB to perform some 
additional tests for the implementation of the antagonist assay. Seven additional tests were performed (within the time 
span November 2016 - June 2017) of which the last 2 could be concluded as valid. The technical issues that were 
observed in the Transfer phase could be remediated during the course of the testing. Investigative tests that were run 
alongside the test of the test chemicals seemed to indicate that the usage of a certain type of glass tube (big glass tubes) 
increased the RLU values. Irregularities in the RLU values were occasionally still noted in the usage of plastic tubes. 
 
5.4 Discussion and Conclusion of the VMG 
The VMG reviewed the data of all 3 laboratories in September 2016 and concluded on the following. 
The analysis of the Transfer data showed for the Agonist protocol  
 Agonist positive and negative responses were correctly obtained 
Concentration responses were comparable across runs and laboratories, some differences were observed in 
few runs in 1 or two concentrations.  
Estimates of DHT EC50 were around the value 3x10-10 M except for RISE where all the values were 
slightly lower but within the acceptance range.  
Within run variability was measured via CV of DHT logEC50 and was comparable across laboratories 
except slightly higher variability at ENVIGO  
Between run variability was measured via CV of DHT logEC50 with similar observation.  
The analysis of the Transfer data showed for the Antagonist protocol  
 Antagonist positive and negative responses were correctly obtained 
Concentration responses were comparable across runs and laboratories, some differences were observed in 
few runs, mainly by CitoxLAB, where the responses started well below or above the solvent control (SC) 
level.  
Estimates of Flutamide IC50 were comparable (with slightly lower values for ENVIGO) and all within the 
acceptance range.  
Within run variability was measured via CV of Flutamide logIC50 and was comparable across laboratories 
except slightly higher variability at CitoxLAB.  
Between run variability was measured via CV of Flutamide logIC50 and was comparable across 
laboratories with EURL ECVAM having slightly higher values.  
The data presented by ENVIGO, using Steady Glo mix for luciferase measurements and a luminometer without 
injectors, were quite similar to the data obtained by the other 2 laboratories. The variability (within runs and between 
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runs) was slightly higher for certain runs but was considered not to pose a problem. Therefore, ENVIGO was allowed to 
continue with the Steady Glo mix for the remainder of the validation study.  
The VMG decided to have monitoring guidance in the SOP for the RLUs of VC and SC values. The guidance consists 
of observing the RI of the VC and when higher than 5%, the cause and the impact on the data shall be identified. In 
addition, the RI of the Flutamide C1 concentration (the lowest concentration) shall be monitored. If its value is above 
120% or below 80%, the cause shall be identified, e.g. too high SC response, and the impact on the calculation of the 
parameters investigated.  
The laboratories ENVIGO and RISE had demonstrated a successful transfer of the test method in their facility and were 
allowed to continue with the next study (Module 4). For CitoxLAB, a successful transfer of the agonist assay was 
concluded. To be considered fully successful with the transfer of the antagonist assay, the laboratory was recommended 
to investigate and to try to remediate the issue with the SC level in order to swiftly progress in the following study. The 
laboratory was recommended to perform 2 to 3 additional antagonist experiments. Upon receiving the data from these 
additional runs, the VMG reconvened in July 2017 to review these data and discuss the observed influences of glass 
ware on the results. CitoxLAB seemed to have remediated the technical issue of high SC values by changing the glass 
tubes for preparing chemical's working solutions, leading to acceptable dose responses in the two last tests. It was 
concluded that apparently the usage of certain glass tubes resulted in complications and that the change to other tubes 
had improved the implementation of the test method. The laboratory could continue the validation study. The laboratory 
was recommended to keep investigating its tubes (glass or plastic) for proper use with ED methods (see further 
information in section 6.5). 
On the basis of the Transfer phase results, and observations from the 3 laboratories, few modifications were 
recommended to be taken up in the AR-CALUX® SOP as follows: 
 Broadening up the SOP for the usage of other luminometers and not only the double injector luminometer 
 An additional guidance for the antagonist assay to monitor carefully the VC response and the SC response  
 Minor rewording and correction of certain sections in order to make the instructions clearer and less prone to 
different interpretations. 
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6 WITHIN LABORATORY REPRODUCIBILITY (MODULE 3 / STUDY 2)  
Reference documents: 
 Statistical report (Annex 13.1) 
 SOP versions V05 and V06, and, SOP for solubility ASY15-V01 (Annex 13.6) 
 Study plans and study reports of the participating laboratories for Study 2 (Reproducibility) (Annex 13.7.2)  
 
6.1 General Aspects 
WLR was assessed on the data obtained from 20 coded test chemicals, tested in 3 independent and valid runs. Before 
applying the AR-CALUX® SOP, the laboratories were required to assess the solubility of each of the test chemicals, 
both in the solvent and in the assay medium. Hereto, the SOP ASY15 V01 had been provided (visual inspection). The 
results of all laboratories are summarised and discussed in section 6.2. 
WLR of the AR-CALUX® method was assessed on the concordance of classification between the 3 independent runs. 
Additionally, a reproducibility analysis of the EC50 and IC50 values was performed. 
The classifier proposed in the AR-CALUX® method SOP V06 allowed besides "Negative" and "Positive" classification 
also the option of "Inconclusive" or "I" (see section 4.6). This option was introduced by the VMG for cases where the 
test chemical displays an activity for only one concentration point above the threshold of 10% (agonist) or below the 
threshold of 80% (antagonist).  
The VMG had introduced for the antagonist assay a specificity control. The criterion R2 had been introduced 
immediately in the classifier of SOP V06. A R2 > 0.9 would indicate a false positive and would therefore be classified 
as a negative.  
During the final review of the obtained data in the validation study, the VMG opted to modify the classifier and the 
SOP. The application of the modified SOP/classifier to the data of the validation study is discussed in section 10. 
 
N= negative response 
 P= positive response 
 AR reference list: ICCVAM list of AR Reference chemicals (Kleinstreuer et al, 2017) 
 EURL ECVAM's ARTA data list is described in Annex 13.3 
   
Table 13: Test chemicals for assessment of reproducibility (20 coded test chemicals) 
TEST CHEMICAL  CAS No. AR reference list EURL ECVAM'S ARTA data list 
  
AGONIST ANTAGONIST AGONIST ANTAGONIST 
Fluoxymestrone 76-43-7 Strong/moderate  NA   
17β-Trenbolone 10161-33-8 Strong  NA   
Medroxyprogesterone acetate 71-58-9 Moderate/weak  NA   
Stanozolol 10418-03-8 Moderate  NA   
Spironolactone 52-01-7 NA Strong/moderate    
Hydroxyflutamide 52806-53-8 NA Strong    
Bisphenol A 80-05-7 NA Moderate/weak    
Vinclozolin 50471-44-8 NA Moderate/weak    
Prochloraz 67747-09-5 Negative  Moderate/weak    
Bicalutamide 90357-06-5 NA Strong    
Butylbenzyl phthalate 85-68-7 Negative NA   
Tamoxifen 10540-29-1 Negative  NA   
Atrazine 1912-24-9 Negative Negative   
Sodium azide 26628-22-8   N, N, N N, N, N 
Methyldihydrotestosterone 521-11-9   P, P, P, P N, N, N 
Propylthiouracil 51-52-5   N, N, N, N N, N, N, N, N 
Diethylhexyl phthalate 117-81-7   N, N, N, N, N N, N, N, N, N 
17β-Estradiol 50-28-2   P, P, P, P, P P, P, FP, N 
17α-Ethinyl estradiol 57-63-6     N, P, N, P, N P, P, P, P 
Disulfiram 97-77-8     N, P, N FP, FP, FP 
 
33 
 
6.2 Solubility Data of the 4 Laboratories for 20 coded Test Chemicals 
The data reported by each of the 4 laboratories for 20 test chemicals is summarised below. The laboratories had been 
asked to find for each of the test chemicals the appropriate solvent, to determine the highest solubility in the chosen 
solvent starting from a concentration of 50 mg/ml, to determine the highest solubility in assay medium. The 
measurements are reported in mg/ml and µg/ml. 
All 4 laboratories reported slightly different soluble concentrations but the variation was always between 50 and 1.5 
mg/ml or µg/ml. The laboratory RISE was more conservative than the other laboratories in its observations and 
determinations. The test chemical Sodium Azide was found to be soluble in water by all 3 EU NETVAL laboratories 
while BDS choose for DMSO.  
In few cases, the differences in determined solubility between the labs influenced the classification in the antagonist 
assay, i.e. inconclusive classification was obtained.  
 Test chemical 1, scored "I" 3 times by ENVIGO, "I" one time by BDS, due to a higher tested concentration 
 Test chemical 18, scored "P" by 3 labs and "I" for one run in RISE, due to lower concentrations tested  
 Test chemical 19 where BDS started with one higher concentration point (150 µg/ml) in its comprehensive 
testing with the antagonist assay which led to the different classifications.   
For the purpose of the validation study, the laboratories had received instructions to start from 50 mg/ml as the maximal 
concentration. Converted in molar, the range for the chemicals tested would be between 40 mM and 330 mM with few 
at higher concentrations e.g. 769 mM for Sodium Azide.  
 
 
Table 14: Solubility results of all 4 laboratories 
Solubility in DMSO [mg/ml]  Solubility in medium [ug/ml] 
Chem ID CitoxLAB ENVIGO RISE BDS  Chem ID CitoxLAB ENVIGO RISE BDS 
1 50 50 50 50  1 5 50 15 50 
2 50 50 5 15  2 5 5 5 2 
3 50 50 15(15) 50  3 50 50 15(15) 50 
4 5 15 1.5 15  4 5 5 1.5 15 
5 50 50 50 50  5 50 50 15 50 
6 50 50 50 50  6 50 50 50 50 
7 50 50 50 50  7 15 15 5 15 
8 15 15 5 15  8 5 15 5 15 
9 5 50 15 50  9 5 15 15 15 
10 50 50 15 50  10 15 15 15 15 
11 15 15 15 15  11 5 15 15 15 
12 50 50 15 50  12 50 15 15 50 
13 15 5 5 15  13 5 5 5 5 
14 50 50 50 50  14 15 15 5 15 
15 50 50 50 50  15 50 50 50 50 
16 50 5 50 50  16 15 5 5 5 
17 50 50 50 50  17 5 15 5 15 
18 50 50 50 50  18 15 50 1.5 15 
19 50 50 50 50  19 50 50 50 50 
20 50 50 1.5 50  20 50 50 1.5 50 
Green: identical values 
Yellow: lowest reported value(s) 
Values in bracket for chemical 3 means it was tested twice (in Study 2 and 3) 
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6.3 Reproducibility (Concordance of classifications) 
The data reported by the labs, including dose responses for 20 coded test chemicals for each of the 4 laboratories, can be 
found in the Statistical report. Tables 15 and 16 (below) show the overview of the classifications as reported by all 4 
laboratories except for the test chemicals 1 to 10 analysed by RISE and ENVIGO. The SOP used by these 2 laboratories 
did not contain the classifier yet and classification has been assigned by EURL ECVAM's statistician according to the 
classifier of SOP V06 (indicated in light green shade in Tables 15 & 16).   
Verification of all other classifications was carried out by EURL ECVAM's statistician by re-applying the classifier on 
the reported data. This re-analysis led to few changes in the antagonist classifications due to few laboratories not 
applying the "Inconclusive" option of the classifier. These changes are denoted in the tables with * and + and explained 
briefly under the table.   
WLR of the AR-CALUX® method was assessed on the concordance of classification between the 3 independent runs.  
 
AGONIST assay 
 
The classification "I" for "Inconclusive" was reported 4 times by only 2 of the 4 laboratories. Each time it was just one 
of the 3 runs within a lab resulting in such "I" (see Table 15A). Despite this one concentration slightly above the 
threshold, the dose responses per test chemical showed very good reproducibility (see dose response figures of test 
chemicals 3, 8, 17 and 20 in the Statistical report – Annex 13.1).  
Including the "I" classification for the WLR assessment (e.g. NIN is considered as not concordant classification), the 
evaluation for the 4 laboratories resulted in 89%, 95%, 100% and 100%. 
 
 
Table 15: Within Laboratory Reproducibility 
AGONIST 
TEST CHEMICAL RISE ENVIGO BDS CitoxLAB 
1 17β-Trenbolone P P P P P P P P P P P P 
2 Stanozolol P P P P P P P P P P P P 
3 Spironolactone(#) N N N N I (1) N N N N N N N 
4 Medroxyprogesterone acetate P P P P P P P P P P P P 
5 Bisphenol A N N N N N N N N N N N N 
6 Bicalutamide N N N N N N N N N N N N 
7 Disulfiram N N N N N N N N N N N N 
8 Tamoxifen N N N ** 
(2) 
N N N N N N N N 
9 Atrazine N N N N N N N N N N N N 
10 17α-Ethynyl estradiol N N N N N N N N N N N N 
11 Sodium azide N N N N N N N N N N N N 
12 Diethylhexyl phthalate N N N N N N N N N N N N 
13 Methyldihydrotestosterone P P P P P P P P P P P P 
14 Vinclozolin N N N N N N N N N N N N 
15 Prochloraz N N N N N N N N N N N N 
16 Fluoxymesterone P P P P P P P P P P P P 
17 17β-Estradiol P P I (3) P P P P P P P P P 
18 Benzylbutyl phthalate N N N N N N N N N N N N 
19 Propylthiouracil N N N N N N N N N N N N 
20 Hydroxyflutamide N N N N I (4) N N N N N N N 
 WLR 95% 89% 100% 100% 
 Concordant/total classifications 19/20 17/19 20/20 20/20 
 
P = Positive response, N= Negative response, I=Inconclusive, as defined by the application of the classifier in SOP V06.  
** = disqualified (chemical not included for WLR assessment) 
  (#): was tested twice by RISE under two different codes and resulted in the same outcome  
Green left upper corner section: classification by EURL ECVAM as defined by the classifier in SOP V06  
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Summary notes: 
(1) Border case, the second highest tested concentration has a RI of 10.3% 
(2) Data points with lots of variability between the technical replicates, leading to 3 mean values > 10% threshold. 
Disqualified for analysis. Run would have been best repeated. 
(3) Though 3 runs started with the same highest concentration, in only one run this concentration was scored as 
cytotoxic 
(4) Border case, the highest tested concentration has a RI of 11.7% 
  All inconclusive cases are described in detail in the Statistical report page 18. 
 
 
 
 
ANTAGONIST assay 
 
As was observed in the agonist assay, the classification "I" was obtained few times by all the laboratories, due to the 
highest tested concentration below the 80% threshold (for the test chemicals 1, 4, 8, 9, 18 and 19). For details see Notes 
below Table 15B and the Statistical report – Annex 13.1).  
Including the "I" classification for the WLR assessment of the 4 laboratories, WLR resulted in 75%, 80%, 85% and 
90%.  
Test chemical 1, 17β-Trenbolone, was consistently scored as "I" for ENVIGO but not so in the other laboratories. This 
was due to one higher tested concentration by ENVIGO which was recorded at the other laboratories as cytotoxic and 
excluded from further testing. At BDS, it was scored as "I" once due to the usage of also one higher test concentration 
only in this particular run. This concentration was scored cytotoxic in the other 2 runs.  
Test chemicals 4, 8 and 9, displayed RI values close to the 80% threshold value for one or two runs 
Test chemical 19, Propylthiouracil, yielded a mix of classifications between all 4 laboratories due to its response at the 
highest concentration around the 80% threshold.  
The lower WLR in RISE (75%) is due to the test chemical 4 (Medroxyprogesterone acetate) and test chemical 15 
(Prochloraz) where different classifications were scored amongst the 3 runs.   
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P = Positive response, N= Negative response, I=Inconclusive, as defined by the application of the classifier in SOP V06 
N(FP)= Negative classification due to false positive (FP) outcome by R2 > 0.9  
(#): was tested twice by RISE under two different codes and resulted in the same outcome  
Green left upper corner section: classification by EURL ECVAM as defined by the classifier in SOP V06 
* Was reported by the lab as "N" due to lab not applying the Inconclusive option 
+ Was reported by the lab as "N" due to lab not applying the Inconclusive option 
All inconclusive cases are described in detail in the Statistical report page 18. 
 
Summary notes: 
(1) Highest tested concentration in 3 runs with a RI of 19.9%, 12.7%, 7% at ENVIGO. This concentration point 
was not considered in 2 other laboratories due to cytotoxic scoring except by BDS (see below in (2)).  
(2) Run 1 with one higher tested concentration with a RI 28.7% (this concentration point was scored as 
cytotoxic in the other 2 runs)  
(3) Border case of being "N" due to 3rd highest concentration with a RI of 77.5%. 
(4) Border case of highest tested concentration with a RI of 77.2% 
(5) Border case of highest tested concentration with a RI of 76.7% 
(6) Border case of highest tested concentration with a RI of 77.6% 
(7) Border case of highest tested concentration with a RI of 77.9% 
(8) Border case of being "P" due to only highest tested concentration with RI of 48.1% and 2nd highest with a RI 
of 83%  
(9) Border case in 2 runs of highest tested concentration with a RI of 78.8% and 76.4 % 
(10) Two runs with highest tested concentration with a RI of 66.3% and 71.6% 
(11) Two runs with highest tested concentrations with a RI of 70.2% and 63.7% 
(12) Two runs with highest tested concentration with a RI of 69.1% and 77.5% 
(14) One run yielded a "P" conclusion due to 2 consecutive concentration points just below 80% (79.2% and 
79.8%) which are the 3rd and 4th highest tested concentrations. The second run yielded a RI between 70.2 and 
77.3% for the 4 highest tested concentrations 
(15) The "N" is due the specificity control response with R2 = 0.91 which is > 0.9 and hence indicates a false 
positive FP, leading to N.  
 
  
Table 15B: Within Laboratory Reproducibility 
ANTAGONIST 
TEST CHEMICAL RISE ENVIGO BDS CitoxLAB 
1 17β-Trenbolone N N N I (1) I I I (2)+ N N N N N 
2 Stanozolol N N N N N N N N N N N N 
3 Spironolactone(#) P P P P P P P P P P P P 
4 Medroxyprogesterone acetate N(14) P P I (3) N N N N N N N N 
5 Bisphenol A P P P P P P P P P P P P 
6 Bicalutamide P P P P P P P P P P P P 
7 Disulfiram N N N N N N N N N N N N 
8 Tamoxifen N N N I(4) N N N I (5)+ N N N N 
9 Atrazine I (6) N N N N N N N N N N I (7) 
10 17α-Ethynyl estradiol P P P P P P P P P P P P 
11 Sodium azide N N N N N N N N N N N N 
12 Diethylhexyl phthalate N N N N N N N N N N N N 
13 Methyldihydrotestosterone N N N N N N N N N N N N 
14 Vinclozolin P P P P P P P P P P P P 
15 Prochloraz P N(15) P P P P P P P P P P 
16 Fluoxymesterone N N N N N N N N N N N N 
17 17β-Estradiol P P P P P P P P P P P P 
18 Benzylbutyl phthalate P P I (8) P P P P P P P P P 
19 Propylthiouracil I (9) I  N I (10)* N I* I (11)+ P I+ I (12) N I 
20 Hydroxyflutamide P P P P P P P P P P P P 
 WLR 75% 80% 85% 90% 
 Concordant/total classifications 15/20 16/20 17/20 18/20 
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6.4 Reproducibility of EC50 and IC50 values 
EC50, PC10, IC50 and IC80 values and the mean, SD and CV's per item and per lab can be found in the Statistical report 
(see section of Potency statistics, page 29 and further, and, Appendix B, page 61 and further). Shown below are the 
calculated average CV's of all data in this study for the reference chemicals and test chemicals. These values show a 
good reproducibility of the method within each lab.  
 
Table 16A: Average coefficients of variation of the reference chemicals for EC50 and IC50 (in M) 
AGONIST  ANTAGONIST 
 
CitoxLAB ENVIGO RISE BDS   CitoxLAB ENVIGO RISE BDS 
DHT      Flutamide     
CV log(EC50) 0.96% 
1.37% 
2.54% 
0.72% 0.96%  CV log(IC50) 1.97% 
2.72% 
1.47% 
0.67% 1.09% 
The following values are reported: for ENVIGO: study2A and 2B, for RISE, BDS and CitoxLAB: study 2 
 
 
Table 16B: Average coefficients of variation of the test chemicals  
          where EC50/IC50 could be calculated (in mg/ml) 
AGONIST - CV log(EC50)  ANTAGONIST - CV log(IC50) 
 
CitoxLAB ENVIGO RISE BDS  CitoxLAB ENVIGO RISE BDS 
1 0.80% 0.54% 0.50% 0.32%      
2 1.14% 1.54% 0.37% 0.84%      
3      0.32% 0.78% 0.31% 0.37% 
4 0.57% 6.42% 1.21% 1.01%          
5      0.97% 0.82% 0.15% 0.32% 
6      1.64% 0.30% 2.77% 1.26% 
7          
8          
9          
10      1.45% 2.12% 0.90% 1.69% 
11              
12              
13 0.82% 0.47% 0.44% 0.28%          
14          0.32% 2.02% 0.47% 3.93% 
15          1.08% 1.44% 0.95% 0.62% 
16 1.46% 1.82% 0.74% 1.00%          
17      2.22% 2.30% 0.96% 0.98% 
18      1.97% 1.87% 1.56% 1.79% 
19              
20      0.87% 0.57% 0.46% 0.83% 
 
 
Table 16C: Average coefficients of variation of all test chemicals where EC50/IC50 could be calculated (in M) 
AGONIST  ANTAGONIST 
 
CitoxLAB ENVIGO RISE BDS   CitoxLAB ENVIGO RISE BDS 
All test items      All test items     
CV log(EC50) 0.96% 2.16% 0.65% 0.69%  CV log(IC50) 1.20% 1.28% 0.95% 1.31% 
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6.5 Conclusion of the VMG  
Visual inspection of the dose responses of all tested chemicals, and a first inspection of the concordance of the 
classifications as reported by the labs, led already to the conclusion that the results are reproducible.  
The classifier proposed by the test method developer had originally no conclusion for cases where the test chemical 
would display only one concentration passing the threshold. The option "Inconclusive" was introduced by the VMG for 
these cases. Such conclusion would trigger further testing though this had not been required for the validation study. 
From the study, it can be concluded that "I" was obtained for 4 chemicals in the agonist assay and 9 chemicals in the 
antagonist assay, mostly in only one of the 12 runs performed by the 4 labs. Most of the time, the "I" classification was 
due to the RI value of the highest tested concentration (C8) close to the threshold and a repeated test could likely result 
in "P" or "N". The labs had been asked to test 50 mg/ml as the maximal concentration which corresponds to a range of 
39.8 mM to 769 mM for all chemicals tested in this validation study. For about half of the observed "I" conclusions, the 
concentration of test chemical used was higher than 100 mM which is the maximal concentration recommended in TG 
455. The VMG considered that 100 mM as highest stock concentration would be sufficient for testing.  
The WLR for all 4 laboratories, with inclusion of the "I", could be calculated to be 89%, 95%, 100% and 100% for the 
agonist testing. For antagonist testing, the WLR is 75%, 80%, 85% and 90%.   
The VMG agreed that the WLR results were sufficient though impacted by the "I" option of the classifier. It was 
concluded that this classification of "I" would benefit from some modifications. Reviewing all data obtained at the end 
of the validation study, the VMG decided on providing instructions in the SOP on how to handle cases where the test 
chemical would display activity only at the highest tested concentration and pass the threshold values of 10% (agonist 
testing) and 80% (antagonist testing). In addition, a reformulation of the classifier was suggested. Application of this 
new guidance in the SOP/classifier to the validation study results resolved the situations where chemicals were 
classified as "I". The WLR values would increase to 95%, 100%, 100% and 100% for agonist testing, and, 94.7%, 
100%, 100% and 100% for antagonist testing (see further in section 10). 
The measurements of the parameters (EC50 and IC50) within the laboratories were very reproducible. The overall CV's 
for the reference chemicals were between 0.69% and 2.72% and for all the test items between 0.65% and 2.16% for the 
agonist assay, and, between 0.95% and 1.28% for the antagonist assay. 
Within the 20 coded test chemicals, 9 showed a positive antagonist response even when cytotoxic concentrations had 
been removed from the dose response. The specificity control, introduced to identify competitive antagonists, proved to 
be helpful. Dose responses were obtained where already visually one could deduce a clear shift between the dose 
responses of lower and higher supplemented DHT concentration. The introduction of the criterion R2 made the decision 
objective. Among the collection of 20 coded test chemicals, only one test chemical was reported false positive in only 
one of the 3 technical replicates (test chemical 15, Prochloraz). This will be further discussed in section 10. 
The chemical Disulfiram had been proposed by the VMG as a possible false positive given that it was scored as such in 
the Tox21 luc assay. This test chemical tested with the AR-CALUX® method was scored by all laboratories as cytotoxic 
at the higher concentrations leading to dose responses above the 80% RI and resulting in the conclusion of "N". The 
inconsistency of the response between the Tox21 luc assay and the AR-CALUX® assay is very likely due to the usage 
of a different test system (osteosarcoma AR-CALUX® cells versus breast cancer MDA-kb2 cells). 
At the start of Study 2 (testing 20 coded chemicals), one laboratory encountered technical issues which were also 
observed during the transfer phase. The cause of these technical issues could not be clearly identified but seemed to be 
linked to the usage of certain glass and plastic ware. Such issues were not reported by the other 3 laboratories. 
Remediation in this particular situation had been possible due to using plastic 24-well plates instead of glass tubes for 
the preparation of the test chemical working solutions. The VMG therefore suggested that the final version of the SOP 
would instruct to use either glass ware or 24-well plates. In addition, a warning would be issued to verify all material 
from interference or contamination. Hereto, the response to the vehicle control should be assessed to ensure no 
interference from glass or plastic ware before running studies.  
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7 BETWEEN LABORATORY REPRODUCIBILITY (MODULE 4 / STUDY 2) 
Reference documents: 
 Statistical report (Annex 13.1) 
 SOP versions V05 and 06, and, SOP for solubility (Annex 13.7.3) 
 Study plans and study reports of the participating laboratories for Study 2 (Reproducibility) (Annex 13.7.2) 
 
7.1 General Aspects 
BLR was assessed on the same set of data that was evaluated for WLR with inclusion of the "I" (see Statistical report 
page 27). It was assessed based on the concordance of classifications: this includes that the classifications from the 3 
valid runs per test chemical will lead to one classification per test chemical based on the mean of the 3 (majority rule, 
see Table 17). For example, a classification of NNN resulted in N; a classification of NPN resulted in N. Concordance 
of the classifications was subsequently evaluated for 3 labs by making all possible combinations. 
In addition, the reproducibility of the EC50 and IC50 values for the reference chemicals and the tested chemicals was 
evaluated. 
 
7.2 Reproducibility (concordance of classifications)  
Evaluating concordance of classification, an overall BLR of 100% was observed for agonist testing and an overall BLR 
of 87.5% for antagonist testing (Table 17 and 18). Two chemicals did not have a consistent classification: 17β-
Trenbolone, due to one "I" classification in the antagonist assay in one lab, and, Medroxyprogesterone acetate due to 
one "P" classification in one lab. Propylthiouracil yielded "I" in the antagonist assay in each lab. It was considered for 
BLR evaluation as displaying non concordant classifications (i.e. non conclusive result).   
 
 
 
 
  
Table 17: Between laboratory reproducibility with concordance of classifications 
          (majority rule) 
TEST CHEMICAL AGONIST ANTAGONIST 
 RISE ENVIGO BDS Citox 
LAB 
RISE ENVIGO BDS 
Citox 
LAB 
1 17β-Trenbolone P P P P N I N N 
2 Stanozolol P P P P N N N N 
3 Spironolactone N N N N P P P P 
4 Medroxyprogesterone acetate P P P P P N N N 
5 Bisphenol A N N N N P P P P 
6 Bicalutamide N N N N P P P P 
7 Disulfiram N N N N N N N N 
8 Tamoxifen N N N N N N N N 
9 Atrazine N N N N N N N N 
10 17α-Ethynyl estradiol N N N N P P P P 
11 Sodium azide N N N N N N N N 
12 Diethylhexyl phthalate N N N N N N N N 
13 Methyldihydrotestosterone P P P P N N N N 
14 Vinclozolin N N N N P P P P 
15 Prochloraz N N N N P P P P 
16 Fluoxymesterone P P P P N N N N 
17 17β-Estradiol P P P P P P P P 
18 Benzylbutyl phthalate N N N N P P P P 
19 Propylthiouracil N N N N I I I   I 
20 Hydroxyflutamide N N N N P P P P 
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Table 18: BLR calculations 
 
AGONIST 
 
ANTAGONIST 
Lab 1 
Lab 2 
Lab 3 
CitoxLAB 
ENVIGO 
RISE 
CitoxLAB 
ENVIGO 
BDS 
ENVIGO 
RISE 
BDS 
CitoxLAB 
RISE 
BDS 
 
CitoxLAB 
ENVIGO 
RISE 
CitoxLAB 
ENVIGO 
BDS 
ENVIGO 
RISE 
BDS 
CitoxLAB 
RISE 
BDS 
Majority rule 
# 
test chemicals 
20 20 20 20  20 20 20 20 
# 
Concordant  
classifications 
 
20 20 20 20  17 18 17 18 
BLR 100% 100% 100% 100%  85% 90% 85% 90% 
Overall BLR 100%  87.5% 
 
 
 
7.3 Reproducibility of the EC50 and IC50 Values  
The reference chemicals 
The statistical report (Appendix B, page 61 and further) shows all results obtained per laboratory with mean, SD and 
CV. 
Table 19 (below) shows average calculations of the results obtained for the acceptance criteria by all 4 laboratories. 
Each lab obtained few invalid runs/plates (acceptance criteria not met). Absolute numbers cannot be compared as the 
number of test chemicals included per run could be different between runs and between labs. For details, see Statistical 
report in Annex 13.1. 
The values for the acceptance criteria are quite comparable. It can be observed that CitoxLAB obtained higher values 
for the negative control in both agonist and antagonist assay but still within the criterion values set: < 10% in the 
agonist assay, and, > 85% in the antagonist assay. The vehicle control (VC) in the antagonist assay with CitoxLAB 
revealed higher values than with the other labs. 
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Table 19: Overview of obtained results for number of runs and acceptance criteria in the 4 laboratories for all 
chemicals tested 
AGONIST ASSAY ANTAGONIST ASSAY 
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# of total runs 24 17 13 10 # of total runs 27 24 19 17 
# of valid runs  20 15 13 10 # of valid runs  20 15 16 17 
Average across valid runs Average across valid runs 
DHT EC50 (M) 
2.7 
E-10 
 
 3.5 
E-10 
 
3.23 
E-10 
3.57 
E-10 
Flutamide IC50 (M) 
4.56 
E-07 
5.11 
E-07 
6.01 
E-07 
4.91 
E-07 
CV(logEC50) 0.31% 
 
0.41% 
 
0.58% 0.42% CV(logIC50) 0.68% 0.61% 1.02% 0.57% 
Induction factor (IF)  71 
 
129 
 
69 84 IF 33.7 51.5 31.2 29.6 
ZF 0.85 
 
0.86 
 
0.79 0.86 ZF 0.78 0.8 0.7 0.81 
Positive control (PC) 
relative induction  
78.9 78.2 76.9 77.1 
Positive control (PC) 
relative induction  
13.4 11.9 13.1 12.4 
Negative control 
(NC) relative 
induction 
0.1 6.2 0.9 0.2 
Negative control (NC) 
relative induction 
144 177.3 123.6 139 
     
Vehicle control (VC) 
Relative induction 
 
0.1 5.7 1.6 5.4 * 
Indicated in blue: highest value obtained 
* Overall average with elimination of one (high) value. After receipt of the DAFs and the final report, it was noted that the 
VC values of one run were exceptionally high, resulting in an overall average VC of 11%. While inquiring about this high 
VC value, BDS informed about an operator error made. 
 
 
 
The Test Chemicals  
Where it was possible, EC50 and IC50 values were calculated, as well as PC10 and PC80 for the tested chemicals (see 
Statistical report section of Potency statistics, page 29 and further). The values were very reproducible within the 
laboratories as well as between the laboratories. 
Table 20 (below) shows the average of all EC50 and IC50 values obtained per test chemical per lab (20 coded chemicals 
for ENVIGO, BDS and CitoxLAB and RISE).  
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Average log(EC50) value result from the log(EC50) from 3 valid and independent runs (in mg/ml). Mean, SD and CV are taken from   
all values per test chemical 
 NA = not available, value could not be calculated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
          Average log(IC50) value result from the log(IC50) from 3 valid and independent runs (from mg/ml). Mean, SD and CV are taken from 
          all values per test chemical.  
  
Table 20 A: Average EC50 values of the test chemicals in agonist testing (in mg/ml) 
  CitoxLAB ENVIGO RISE BDS    
No. TEST CHEMICAL Log(EC50) average of all runs Mean SD CV 
1 17β-Trenbolone -7.06 -7.23 -7.26 -7.18 -7.18 0.09 1.2% 
2 Stanozolol -6.15 -6.31 -6.26 -6.27 -6.25 0.07 1.1% 
3 Spironolactone(#) NA -5.16 NA NA -5.16   
4 Medroxyprogesterone acetate -5.22 -6.01 -5.52 -5.53 -5.57 0.32 5.8% 
5 Bisphenol A        
6 Bicalutamide        
7 Disulfiram        
8 Tamoxifen        
9 Atrazine        
10 17α-Ethynyl estradiol        
11 Sodium azide        
12 Diethylhexyl phthalate        
13 Methyldihydrotestosterone -6.96 -7.03 -6.98 -7.00 -6.99 0.03 0.4% 
14 Vinclozolin        
15 Prochloraz        
16 Fluoxymesterone -4.91 -5.47 -5.28 -5.50 -5.29 0.27 5.1% 
17 17β-Estradiol NA -3.39 NA NA -3.39   
18 Benzylbutyl phthalate        
19 Propylthiouracil        
20 Hydroxyflutamide        
Table 20 B: Average IC50 values of the test chemicals in antagonist testing (in mg/ml) 
  CitoxLAB ENVIGO RISE BDS    
No. TEST CHEMICAL Log(IC50) average of all runs Mean SD CV 
1 17β-Trenbolone        
2 Stanozolol        
3 Spironolactone(#) -4.82 -4.81 -4.84 -4.82 -4.82 0.02 0.3% 
4 Medroxyprogesterone acetate        
5 Bisphenol A -3.51 -3.48 -3.52 -3.49 -3.50 0.02 0.5% 
6 Bicalutamide -4.29 -4.21 -4.27 -4.50 -4.32 0.12 2.9% 
7 Disulfiram        
8 Tamoxifen        
9 Atrazine        
10 17α-Ethynyl estradiol -4.93 -4.94 -4.95 -4.94 -4.94 0.01 0.1% 
11 Sodium azide        
12 Diethylhexyl phthalate        
13 Methyldihydrotestosterone        
14 Vinclozolin -4.57 -4.39 -4.52 -4.73 -4.55 0.14 3.1% 
15 Prochloraz -3.06 -3.13 -3.08 -3.07 -3.08 0.03 1.0% 
16 Fluoxymesterone        
17 17β-Estradiol -5.82 -5.40 -5.63 -5.61 -5.62 0.17 3.1% 
18 Benzylbutyl phthalate -2.75 -2.69 -3.26 -2.77 -2.87 0.26 9.1% 
19 Propylthiouracil        
20 Hydroxyflutamide -5.20 -5.13 -5.28 -5.29 -5.23 0.08 1.5% 
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Relative potency measures, i.e. log(EC50)/log(DHT EC50), log(PC10)/log(DHT PC10), log(IC50)/log(FLUTAMIDE 
IC50) and log(PC80)/log(FLUTAMIDE PC80) were calculated and compiled in tables 21A and B below. Values above 1 
are referring to more potent chemicals than reference item (DHT or Flutamide) whereas values below 1 to less potent 
chemicals than reference item. The test chemicals are ordered vertically in the tables from lowest potency to highest 
potency. The order is identical when assessing EC50 or PC10 values, or, IC50 or PC80 values. 
 
Table 21A 
log(EC50) / log(DHT EC50) log(PC10) /log (DHT PC10) 
averaged values averaged values 
Test chemical CitoxLAB ENVIGO RISE BDS CitoxLAB ENVIGO RISE BDS 
17β-Estradiol   
  
  0.58 0.61 0.60 0.63 
Fluoxymesterone 0.79 0.84 0.82 0.84 0.81 0.84 0.83 0.85 
Medroxyprogesterone acetate 0.83 0.90 0.84 0.85 0.83 0.90 0.83 0.86 
Stanozolol 0.91 0.93 0.91 0.93 0.91 0.93 0.91 0.92 
Methyldihydrotestosterone 1.00 1.01 1.00 0.99 1.00 1.00 1.00 1.01 
17β-Trenbolone 0.99 1.02 1.01 1.01 1.00 1.02 1.00 1.02 
    
  
  
   
  
Norethindrone acetate   
 
0.85   
  
0.83   
Norethindrone   
 
0.85   
  
0.85   
Levonorgestrel   
 
0.92   
  
0.92   
Methyltestosterone   
 
0.94   
  
0.95   
Nandrolone   
 
0.98   
  
0.99   
Methyltrienolone (R1881)     0.99       0.99   
 
 
Table 21B 
log(IC50) / log(FLUTAMIDE IC50) log(PC80) / log(FLUTAMIDE PC80) 
averaged values averaged values 
Test chemical CitoxLAB ENVIGO RISE BDS CitoxLAB ENVIGO RISE BDS 
Benzylbutyl phthalate 0.83 0.83 0.91 0.84 0.86 0.84 0.86 0.83 
Prochloraz 0.91 0.92 0.89 0.89 0.95 0.90 0.89 0.90 
Bisphenol A 0.94 0.93 0.94 0.93 0.95 0.94 0.96 0.93 
Vinclozolin 1.12 1.04 1.10 1.13 1.13 1.04 1.09 1.12 
Bicalutamide 1.11 1.09 1.10 1.12 1.10 1.08 1.11 1.14 
Spironolactone(#) 1.19 1.18 1.19 1.19 1.19 1.20 1.19 1.15 
17α-Ethynyl estradiol 1.20 1.18 1.18 1.19 1.25 1.18 1.20 1.18 
Hydroxyflutamide 1.22 1.22 1.21 1.22 1.24 1.22 1.22 1.21 
17β-Estradiol 1.33 1.28 1.27 1.27 1.33 1.26 1.27 1.24 
    
  
    
  
  
Ketoconazole         
2-tert-Butylanthraquinone   
 
0.89     
 
0.84   
Linuron   
 
0.91     
 
0.91   
Diethylstilbestrol   
 
0.91     
 
0.94   
Finasteride   
 
0.92     
 
0.95   
2-sec-Butylphenol   
 
0.93     
 
0.95   
Arochlor1254   
 
0.97     
 
0.97   
Cycloheximide   
 
0.97     
 
0.99   
o,p’-DDT   
 
0.99     
 
1.01   
Corticosterone   
 
1.00     
 
1.03   
Mifepristone   
 
1.19     
 
1.16   
Progesterone   
 
1.26     
 
1.27   
Cyproterone acetate   
 
1.27     
 
1.27   
Actinomycin D     1.37       1.29   
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7.4 Conclusion of the VMG  
The main focus of the BLR evaluation for 20 coded test chemicals was on the concordance of the classifications. 
Overall BLR was 100% for agonist testing, and, 87.5% for antagonist testing. By applying the new guidance in the 
SOP/classifier to the obtained data, the BLR values would increase to 100% for both agonist and antagonist testing (see 
further in section 10). 
When evaluating the standard deviations and the CVs of the average EC50 and IC50 values for the 20 coded test items in 
all labs tested, the VMG agreed that these values were low. The highest CV% was noted for Benzylbutyl phthalate in 
the antagonist assay, being 9.1%. All other tested chemicals had CVs of lower than 4 %.  
The VMG agreed that the BLR results were very good for the AR-CALUX® method. 
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8 PREDICTIVE CAPACITY FOR 46 CODED TEST CHEMICALS (MODULE 5 / 
STUDY 2 AND 3)  
Reference documents: 
 Statistical report (Annex 13.1) 
 SOP V06 and SOP for solubility V01 (Annex 13.7.3) 
 Study plan and study report of RISE for Study 3 (Annex 13.7.2) 
 
8.1 Additional Data set on 26 Test Chemicals 
In addition to the data of 20 coded test chemicals (assessed for BLR), a set of data was generated for 26 test chemicals 
by one laboratory only (RISE), to be considered as well for predictive capacity. Solubility data and classifications can 
be found below and in the statistical report. 
 
Solubility results 
 
Table 22: Solubility results  
Chem ID  Solubility in DMSO [mg/ml] Solubility in medium [µg/ml] 
21 Levonorgestrel 15 1.5 
22 Cyproterone acetate 50 15 
23 2-tert-Butylanthraquinone 15 5 
24 Arochlor1254 50 5 
25 Nandrolone 50 50 
26 o,p’-DDT 50 1.5 
27 Phenolphthalin 15 15 
28 2,4,5-T 0.15 0.15 
29 Methyltrienolone (R1881) 50 50 
30 Actinomycin D 5 5 
31 Diethylstilbestrol 50 15 
32 L-Thyroxine 50 50 
33 Haloperidol 50 5 
34 Norethindrone acetate 5 5 
35 Pimozide 5 5 
36 Progesterone 50 15 
37 Linuron 50 15 
38 Methyltestosterone 50 15 
39 2-sec-Butylphenol 15 15 
40 Corticosterone 50 50 
41 Ketoconazole 15 15 
42 Finasteride 50 50 
43 Fulvestrant 50 1.5 
44 Cycloheximide 50 50 
45 Norethindrone 50 5 
46 Mifepristone 50 5 
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Classifications  
 
Table 23: Classifications  
No. TEST CHEMICAL AGONIST  ANTAGONIST 
21 Levonorgestrel P P P  N N N 
22 Cyproterone acetate N N N  P P P 
23 2-tert-Butylanthraquinone N N N  P P P 
24 Arochlor1254 N N N  P P P 
25 Nandrolone P P P  N N N 
26 o,p’-DDT N N N  P P P 
27 Phenolphthalin N N N  N N N 
28 2,4,5-T N N N  N N N 
29 Methyltrienolone (R1881) P P P  N N N 
30 Actinomycin D N N N  I (1) I I 
31 Diethylstilbestrol N N N  P P P 
32 L-Thyroxine N N N  N N N 
33 Haloperidol N N N  N N N 
34 Norethindrone acetate P P P  I(2) P I 
35 Pimozide N N N  N N N 
36 Progesterone N N N  P P P 
37 Linuron N N N  P P P 
38 Methyltestosterone P P P  N N N 
39 2-sec-Butylphenol N N N  N(FP)(3) P P 
40 Corticosterone N N N  P P P 
41 Ketoconazole N N N  N(FP) N(FP) N(FP) 
42 Finasteride N N N  P P P 
43 Fulvestrant N N N  N(FP) I(4) P 
44 Cycloheximide N N N  N(FP) N(FP) N(FP) 
45 Norethindrone P P P  N N N 
46 Mifepristone N N N  P P P 
 WLR 100%  84.6% 
 Concordant/total classifications 26/26  22/26 
P = Positive response, N= negative response, I=Inconclusive, as defined by the application of the classifier in SOPV06 
N(FP)= Negative classification due to false positive (FP) outcome by R2 > 0.9  
 
 
 
Summary notes: 
(1) Chemical 30: only the highest tested concentration has RI < 80% in 3 runs (57.2%, 39%, 37.5%). R2 is > 0.9 in all 3 
runs what indicates FP but with the classifier it gets classified as "I" due to only one concentration below the threshold 
value. 
(2) Chemical 34 has a dose response with the specificity control that declines before the standard response (shift in the 
opposite direction). "I" is scored in 2 runs due to the highest tested concentration with RI of < 80%: 54.2% and 56.2%. 
(3) Chemical 39: classified as N(FP) in the 1st run due to R2 = 0.95 
(4) Chemical 43: yielded 3 different classifications though the dose responses are quite comparable (see Index in the 
statistical report). The 2nd run (run 7) had one concentration point with RI of 111.5% and is likely an outlier.  
 
 
WLR and variability for the 26 additional chemicals 
For the chemicals tested under the agonist assay,  
WLR was found to be 100 % and  
% CV for log(EC50) was 0.92. 
 
For the chemicals tested under the antagonist assay,  
WLR was found to be 84.6% and  
% CV for log(IC50) was 1.55. 
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8.2 Comparison of Classifications 
The predictive capacity was evaluated on the basis of comparing the mean classifications of each laboratory in this 
validation study (as was done for the assessment of the BLR) for the 46 coded test chemicals with reported 
classifications from  
1) ICCVAM AR-Reference chemical list published in 2017 (Kleinstreuer et al, 2017) (AR REF)
2) EURL ECVAM's list of publicly available data for ARTAs (for detailed info, see Annex 13.3). This list includes the
classifications of 2 Tox21 ARTA assays for which the data were revisited in 2018 given the availability of cytotoxicity
values, the results of the AR pathway computational model (Kleinstreuer et al, 2017) and the results of the 2 validated
ARTAs (Japan ARTA of OECD TG 458, 2016; Korean ARTA, personal communication). Given the limited data
sources in this list, caution has to be taken with the comparison and interpretation e.g. the chemicals Arochlor and 2-
tert-butylanthraquinone were added in 2015 to the list because they were proposed as test chemicals for the validation
study of the Korean ARTA but finally were not retained for generating data. Korea provided a provisional classification
for these chemicals.
An overview of the comparison of the classifications in the validation study with the two lists is presented in Tables 25 
and 26. It includes the results from the 20 test chemicals that were tested for BLR by all 4 laboratories, and, the 
additional 26 test chemicals tested by the laboratory RISE. 
Comparison to the AR-Reference list (AR REF) 
For 23 chemicals tested in the AR-CALUX® validation study, the classification could be compared to the AR-Reference 
list. An identical classification was observed for all tested chemicals where information was available in the AR-
reference list with exception of Cyproterone acetate in the agonist assay (scored as "N" with the AR-CALUX® method 
and reported as "P" in the AR- Reference list). With the AR-CALUX® method (tested by one lab), the dose response is 
below the 10% threshold with a very slight increase at the highest concentration tested (4 µM). It is reported in the AR- 
Reference list that this chemical has a weak positive behaviour. Possibly, the reported values in literature, used for the 
AR-reference list, may have resulted from higher tested concentrations.  
Performance values 
Concordance of classifications were calculated versus the AR-Reference list only given that this list is the most 
trustable source of in vitro data. The values are listed in the Tables 24A and B below. Of the 23 test chemicals that 
could be compared, 13 were tested for (ant)agonist activity in all 4 laboratories and an additional 10 in one laboratory.  
The AR-Reference list does not always provide info on both agonist and antagonist behaviour, leading to 8 chemicals 
that could be scored for agonist behaviour, and, 7 for antagonist behaviour for 3 of the 4 laboratories. The lab RISE 
tested more chemicals (16 for agonist, 12 to for antagonist, to be compared with the AR-Reference list). Only one 
chemical had a different classification (Cyproterone acetate, see also Table 25).  
Table 24A: AGONIST 
AR Reference RISE ENVIGO BDS CitoxLAB 
P N P N P N P N 
P 10 1 4 0 4 0 4 0 
N 0 5 0 4 0 4 0 4 
Positive  
concordance 
90.9% 100% 100% 100% 
Negative  
concordance 
100% 100% 100% 100% 
Overall  
concordance 
93.8% 100% 100% 100% 
Table 24B: ANTAGONIST 
AR Reference RISE ENVIGO BDS CitoxLAB 
P N P N P N P N 
P 10 0 6 0 6 0 6 0 
N 0 2 0 1 0 1 0 1 
Positive  
concordance 
100% 100% 100% 100% 
Negative  
concordance 
100% 100% 100% 100% 
Overall  
concordance 
100% 100% 100% 100% 
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Grey shading: AR-CALUX® classification consistent with at least one other ARTA classification; yellow shading: the inconclusive classification 
Black box: AR-CALUX® classification not consistent with the AR-reference chemicals list (AR REF)  
Blank: not tested in the ARTAs or not available in the AR REF 
In straight brackets []: plausible classification with modified SOP/classifier as discussed in section 10 
FP?: A shift of the specificity dose response in the opposite direction 
?: classification could not be assigned due to incomplete data  
AR REF: ICCVAM list of AR- Reference chemicals (Kleinstreuer et al, 2017) 
ARTA Japan: classifications from validated ARTA; ARTA Korea: classifications from validated ARTA 
In comparison to AR REF: all identical but not no. 22 in the agonist; in comparison to ARTA JP: all identical; in comparison to ARTA KR: all identical but not no. 20 in agonist. 
Table 25: Comparison to the 1st set of 23 tested chemicals with the AR-Reference chemical list and other ARTA classifications 
No TEST CHEMICAL AGONIST ANTAGONIST 
R
IS
E
 
E
N
V
IG
O
 
B
D
S
 
C
it
o
x
 
L
A
B
 
AR 
REF 
ARTA 
JAPAN 
ARTA 
KOREA 
Tox21 
Luc 
Tox21 
Bla 
AR 
pathway R
IS
E
 
E
N
V
IG
O
 
B
D
S
 
C
it
o
x
 
L
A
B
 AR 
REF 
ARTA 
JAPAN 
ARTA 
KOREA 
Tox21 
Luc 
Tox21 
Bla 
AR 
pathway 
1 17β-Trenbolone P P P P P P P P N I[N] N N N P N 
2 Stanozolol P P P P P N N N N N 
3 Spironolactone N N N N P P N P P P P P P P FP? 
4 Medroxyprogesterone acetate P P P P P P P P P N N N N N N P 
5 Bisphenol A N N N N N N N N N P P P P P P P P P P 
6 Bicalutamide N N N N N N N N P P P P P P P P P 
8 Tamoxifen N N N N N N P N N N N N P ? N 
9 Atrazine N N N N N N N N N N N N N N N N N N N 
14 Vinclozolin N N N N N N N N P P P P P P P P P P 
15 Prochloraz N N N N N N N N N P P P P P P P P FP P 
16 Fluoxymesterone P P P P P P P N N N N N N 
18 Benzylbutyl phthalate N N N N N N N N N N P P P P P P N N 
20 Hydroxyflutamide N N N N N P P N P P P P P P P P P P 
21 Levonorgestrel P P P P P P N N N P N 
22 Cyproterone acetate N P weak P N P P P P P P 
25 Nandrolone (19-Nortestosterone) P P P P N N N 
26 
o,p’-DDT N N N N N N P 
P 
weak 
P P FP P 
29 Methyltrienolone (R1881) P P N 
34 Norethindrone acetate P P P P I[P] ? P 
37 Linuron N N N N N P P P P P P 
38 Methyltestosterone P P P P P P N N N N N N 
45 Norethindrone  P P P P P N N P N 
46 Mifepristone N P N N P P P P FP? 
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Comparison to EURL ECVAM's list of ARTA classifications 
The remaining 23 tested chemicals (for which there was no info in the AR-reference list) were compared with all the 
classifications compiled in the EURL ECVAM list. For 19 tested chemicals, an identical classification could be found 
with one or more reported ARTA classification in agonist and antagonist assay (see Table 26 below).  
Few chemicals tested with the AR-CALUX® method were found to have consistent behaviour across all the ARTAs and 
the AR pathway model: Diethylhexyl phthalate (N) in the agonist and antagonist assay, 17β-Estradiol (P) in the agonist 
assay, Propylthiouracil (N) in the antagonist assay. Given that more comparisons could be made with the Tox21 assays 
and the AR pathway model, 13 chemicals were found with identical classifications in agonist assay and 9 chemicals in 
the antagonist assay. 
For few chemicals, the AR-CALUX® classification was different from all other classifications: no. 24, 36 and 40 for 
agonist testing; no 39 and no 43 in antagonist testing. 
Arochlor (no 24): scored clearly "N" for the agonist testing with the AR-CALUX® method. Only a provisional 
classification was provided by Korea as "P". 
Progesterone (no 36): scored as "N" for the agonist testing with the AR-CALUX® method and "P" in 3 other ARTAs 
and the AR-pathway model. Inspection of the dose responses shows that there is a slight increase at the highest tested 
concentration (4 µM) but still below the 10% threshold. The higher tested concentrations were found to be cytotoxic. 
Possibly, the chemical may have been tested at higher concentrations in the other ARTAs. 
Corticosterone (no 40): scored as "N" in the agonist testing with the AR-CALUX® method and "P" in 3 other ARTAs 
and the AR-pathway model. AR-CALUX® cells are reported to have no GR activity due to absence of the GR receptor. 
Testing Corticosterone for agonist properties confirmed this. In other ARTAs, this chemical may display a "P" response 
for which a possible GR interference cannot be excluded. Moreover, this chemical is also used as the negative control 
item in the agonist assay of the AR-CALUX® method. Inspection of the dose responses shows that there is a slight 
increase at the highest tested concentration (171 µM). 
2 sec Butylphenol (no 39) scored as a clear "P" in the agonist testing with the AR-CALUX® method though seems to be 
negative in 2 other ARTAs and the AR-pathway. 
Fulvestrant (no. 43) scored a FP with the AR-CALUX® method though the classifications in the Tox21 ARTAs and AR 
pathway are reported as "P" and "N" respectively.  
Disulfiram (no 7) was included as a potential FP antagonist for the AR- CALUX® method due to such classification in 
the Tox21 luc assay. It was observed in this assay that the chemical was active (dose response declining) at 
concentrations that were not cytotoxic. With the AR-CALUX® method, this chemical displayed cytotoxicity already at 
high concentrations, leading to a negative response. Non conformity in the classification is due to cell line species 
differences (osteosarcoma cell line versus breast cancer cell line). 
17β-Estradiol (no 17), scored in the AR-CALUX® as "P" for both agonist and antagonist response by all 4 laboratories. 
It shows the same dual response in most of the other ARTAs and the AR pathway model (agonist). 
Three (possibly 4) FP classifications were observed due to R2 > 0.9: Actinomycin D (no 30), Ketoconazole (no 39), 
Fulvestrant (no 43) and Cycloheximide (no 44). This is further discussed in section 10.3. Only for Ketoconazole, the FP 
response is also observed with the other Tox21 assays and the AR-pathway model.  
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 Table 26: Comparison of 2nd set of 23 tested chemicals with the EURL ECVAM's list of ARTA classifications (no AR-Reference chemical list info available)  
No. TEST CHEMICAL  AGONIST  ANTAGONIST 
   
RISE ENVIGO BDS 
Citox 
LAB 
ARTA 
Japan 
ARTA 
Korea 
Tox21 
Luc 
Tox21 
Bla 
AR 
Pathway 
 
RISE ENVIGO BDS 
Citox 
LAB 
ARTA 
Japan 
ARTA 
Korea 
Tox21 
Luc 
Tox21 
Bla 
AR  
Pathway 
7 Disulfiram  N N N N   N P N  N N N N   FP FP FP 
10 17α-Ethynyl estradiol  N N N N N P N P N  P P P P  P P P P 
11 Sodium azide  N N N N   N N N  N N N N   N N N 
12 Diethylhexyl phthalate  N N N N N N N N N  N N N N N N N N N 
13 Methyldihydrotestosterone  P P P P P P p P   N N N N N N ? N  
17 17β-Estradiol  P P P P P P P P P  P P P P  P P FP N 
19 Propylthiouracil  N N N N  N N N N  I[N] I[N] I[N] I[N] N N N N N 
23 2-tert-Butylanthraquinone  N     (N)     P     (P)    
24 Arochlor1254  N     (P)     P     (P)    
27 Phenolphthalin  N      N N N  N      N N N 
28 2,4,5-
Trichlorophenoxyacetic 
acid 
 
N      N N N 
 
N      N N N 
30 Actinomycin D  N      N N   I [FP]      FP P  
31 Diethylstilbestrol  N      N N N  P      P FP P 
32 L-Thyroxine  N      N N   N      N N  
33 Haloperidol  N      N N N  N      FP N FP? 
35 Pimozide  N      N N   N      ? FP  
36 Progesterone  N     P P P P  P     P FP N FP 
39 2-sec-Butylphenol  N      N N N  P      N N N 
40 Corticosterone  N     P P P P  P     P N N N 
41 Ketoconazole  N      N P N  FP      FP FP FP 
42 Finasteride  N      N N N  P      P P P 
43 Fulvestrant  N      N N N  I[FP]      P P N 
44 Cycloheximide  N      N N N  FP      FP N FP 
Grey shading: AR-CALUX® classification consistent with at least one other ARTA classification; yellow shading: the inconclusive classification 
Blank: not tested in the ARTAs or not available in the AR REF 
(): Provisional classification reported by Korea 
?: classification could not be assigned due to incomplete data  
Black box: AR-CALUX® classification different from all others  
In straight brackets []: plausible classification with modified SOP/classifier as discussed in section 10 
AR REF: ICCVAM list of AR-Reference chemicals (Kleinstreuer et al, 2017) 
ARTA Japan: classifications from validated ARTA 
ARTA Korea: classifications from validated ARTA 
 
In comparison to ARTA JAPAN (validated): all identical 
In comparison to ARTA KOREA (validated): all identical but not no. 10, 24, 36 and 40 in agonist 
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8.3 Conclusion of the VMG 
To investigate potential androgenic and anti-androgenic effects of chemicals in vivo, the rodent Hershberger assay had 
been developed and standardised. However, a high degree of variability in the results of Hershberger studies, including 
disagreements between the results for the same chemical, have been reported (Browne et al, 2017). In addition, the 
Hershberger assay is capable of detecting several modes of action, whereas the AR-CALUX® method assesses only 
directly acting AR (ant)agonists. A comparison between these assays may therefore not be helpful. 
In the absence of good in vivo reference data, a comparison was made in this validation study to the published AR-
reference list (Kleinstreuer et al, 2017). This list results from a targeted literature search for AR in vitro reference data, 
including AR binding data and transactivation data, for which a range of quality criteria were applied. The comparison 
showed that of 26 chemicals tested with the AR-CALUX® method, all but one of the chemicals tested displayed an 
identical classification.  
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9 APPLICABILITY DOMAIN (MODULE 6) 
Limitations were not reported by the test submitter other than the generic ones related to working with in vitro systems. 
Poor solubility of the chemical or physico-chemical properties can be incompatible with the standard serum-containing 
tissue culture media. Metabolism of a chemical cannot be evaluated with this test system. 
The method allows testing of liquids and solid chemicals as long as they can be solubilised in a solvent. DMSO and 
water were both used in this validation study as solvents. 
The chemicals tested in this validation study have a spectrum of chemical classes that cover pharmaceutical usage (e.g. 
cancer treating drugs and antibiotics), industrial usage (e.g. plasticizers, lubrificants) and agricultural usage (pesticides, 
fungicides). When compared to the REACH chemical space (structural diversity) the ARCALUX® validation set covers 
a rather large area (see Annex 13.03). 
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10 DISCUSSION 
10.1 Qualitative assessment of the results 
10.1.1 Classification of the 20 tested chemicals (for WLR and BLR assessment) 
During the final review of the data, the VMG decided on the following points regarding classification of the test 
chemicals: 
 Expert judgement would be applied in those cases where the RI values obtained were border line close to the
threshold values taking into account the value of the RI and the shape of the dose response (see Notes under tables
27 and 28).
 By applying the classifier of SOP V06, several "I" classifications were observed for test chemicals displaying
activity for only one concentration above the threshold of 10% in the agonist assay or below the 80% in the
antagonist assay. This situation occurred mostly at the highest tested concentration (C8). A modified classification
was considered that would not include "I" given that such conclusion would not be preferable for regulatory testing.
In addition, a closer dose range testing at the highest test range (C8 to C4) was considered. Therefore, instructions in
the final version of the SOP were recommended for when a tested chemical displays in the pre-screen test (where
dilution factor 10 is used) an activity at only the highest tested concentration passing the threshold of 10% or 80%.
In such case, comprehensive testing would be performed with a dilution factor 2 instead of the default dilution factor
3.3. This would generate more data points at the right end of the dose response curve, i.e. for the highest tested
concentrations.
 The criterion R2 was found to have some limitations (as discussed in section 10.2). In order to improve the
application of the specificity control, a normalisation of the specificity control values was carried out, with an
evaluation of the tested concentration points above or below the threshold of 80%. If a chemical would display
activity at all tested concentrations > 80%, it would be classified as "P"; if the activity at the highest tested
concentration (C8) would be < 80%, the R2 criterion would be applied. This would lead to an additional
modification of the classifier.
 The maximal highest concentration to be tested was 50 mg/ml which would correspond to concentrations in the
range of 39.8 mM to 769 mM. In view of the TG to be drafted, it was decided to recommend 100 mM as maximal
test concentration. This concentration was also used for the ER-CALUX® method (TG 455). It was verified that
lowering the highest concentration(s) tested to 100 mM would not affect the "P" classifications. At least two
consecutive concentrations above or below the threshold values (as indicated by the classifier) remained below the
100 mM. For few test chemicals the maximal concentration of 50 mg/ml corresponded to values below 100 mM
(39.8 mM to 94.1 mM). The increase to 100 mM as start concentration would not affect the "N" classification
because the 50 mg/ml was found to be already insoluble and/or cytotoxic. The change to the 100 mM as maximal
concentration would eliminate for some chemicals tested in the validation study the highest tested concentrations,
leading to "I" becoming "N".
The revised classifier, as proposed by the VMG, is as follows: 
Agonism: For each run, a test item is considered  
A. Positive when the relative induction (Yc) of the test item is ≥ 10% (REF RPC10) for two or more consecutive
concentrations. 
B. Negative in all other cases
Antagonism: For each run, a test item is considered 
A. Positive (competitive antagonist) when the relative induction (Yc) of the test item is ≤ 80% (REF RPC80) for two or
more consecutive concentrations and
Either 
 the relative induction of the test items normalised specificity control sc
n > 80% at all concentrations
or when the following two conditions are met: 
 the relative induction of the test items normalised specificity control at the highest concentration sc8
n  is ≤ 80%, 
 the square of the correlation coefficient (R2) is ≤ 0.9 between the relative induction of the test item (Yc) and its
specificity control (Sc)
B. Negative in all other cases
Explanation in the text under the classifier: 
Negative classification for antagonism would include that the relative induction (Yc) of the test item is > 80% (REF 
RPC80) at all concentrations or only one concentration is < 80%. Negative classification would also be applied when 
the following 2 conditions are met: 
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 the relative induction (Yc) of the test item is ≤ 80% (REF RPC80) for at least 2 consecutive concentrations and
the relative induction of the test item's specificity control (Sc) at the highest tested concentration sc8
n  is ≤ 80%,
 the square of the correlation coefficient (R2) is > 0.9 between the relative induction of the test item (Yc) and its
specificity control (Sc) (false positive)
WLR assessment with application of the modified SOP/classifier 
The outcome of applying expert judgement (EJ) and applying the modified SOP instruction (dilution factor 2 for 
chemicals displaying in the pre-screen only the highest tested concentration passing the classification threshold value) 
as well as the modified classifier is shown in Tables 27 and 28 alongside the reported classifications by the lab (as 
discussed in the previous sections).  
Given that the data reported in the validation study are the result of using the default dilution factor 3.3 when a 
comprehensive test was carried out, an approximation of what could be the second highest tested concentration with the 
dilution factor 2, was calculated. Hereto, the intermediate concentration between the 2 highest concentrations was 
calculated by interpolation. This concentration point cannot be considered as reflecting the real situation but gives 
nevertheless a good view on the possible outcome. It is envisioned that the application of the modified instructions and 
the modified classifier will lead to an objective conclusion of "P" and "N". 
Detailed info per test chemical where this modified approach has been applied is provided below. In the statistical 
report, the interpolated values for the second highest non cytotoxic concentration by applying a dilution factor 2 can be 
found (see tables per test chemical stating interp value (x,y) and graphs showing a green square sign).  
The assessment by applying the modified SOP and the classifier, resulted in higher levels of WLR and BLR. 
Detailed information for re-assessment of tested chemicals in the AGONIST assay: 
WLR assessment after expert judgement and application of the modified instruction in the SOP / classifier would be 
95%, 95%, 100% and 100%.  
Test chemical 3, Spironolactone, led to N, I, N. VMG expert judgement changed the "I" to "N" due to the borderline 
response of the second highest tested concentration of 10.3 % RI.  
Test chemical 8, Tamoxifen, as discussed before, yielded in one lab a run that shall be disqualified. This run would have 
been best repeated due to much variability within the triplicate samples. 
Test chemical 17, 17β-Estradiol, led to P, P, I in one lab. "I" is due to the highest tested concentration being scored as 
cytotoxic. With the modified SOP/classifier it could become "N" but the RI of the approximated intermediate 
concentration between C8 and C7 (equalling the concentration point resulting from DF 2) has a borderline value of 9.7 
%). 
Test chemical 20, Hydroxyflutamide, led to N, I, N in one lab. With the modified SOP/classifier, it would become "N" 
(approximated intermediate concentration with RI of 9.5%). In addition, the highest tested concentration is above the 
100 µM (171 µM). With 100 µM as maximal concentration, the classification would be immediately "N". 
Detailed information for re-assessment of tested chemicals in the ANTAGONIST assay: 
WLR calculation after expert judgement and application of the modified instruction in the SOP/ classifier would be 
90%, 95%, 95% and 100%. If 100 µM would be the maximal concentration to be used, the WLR would increases to 
100% for 3 labs and 90% for one lab. 
Test chemical 1, 17β-Trenbolone, consistently scored as "I" at ENVIGO, would become with the modified 
SOP/classifier N, FP, FP (approximate intermediate concentration with RI of 97.7% in 1st run, 53.1%, 60.8% in 2nd and 
3rd run; R2 of 0.94in 2nd run and 0.99 3rd run). At BDS, the one "I" could become "P" (approximated intermediate 
concentration with RI of 78.8%) or maybe N(FP) which cannot be assessed due to lack of the specificity control.  The 
chemical was tested at a maximal concentration of 50µg/ml or 184 µM. With 100 µM as maximal test concentration, 
the classification would be immediately "N". 
Test chemical 4, Medroxyprogesterone acetate, was scored as N, P, P for the results of RISE. The 3nd run yielded a "P" 
conclusion due to 2 consecutive concentration points just below 80% (79.2% and 79.8%) which are the 3rd and 4th 
highest tested concentrations. VMG expert judgement changes the "P" to "N" given the borderline response which 
occurs in the middle of the response. The 2nd run yielded a RI between 70.2 and 77.3% for the 4 highest tested 
concentrations. The response however starts with C1 at 81% (instead of 100%) what renders the analysis difficult. This 
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chemical was therefore not classified. The result would be N, +, N. At BDS, the chemical was scored once as I. VMG 
expert judgement is "N" due to the high variability in all the triplicate data points and trend of the response is "N".  
Test chemical 8, Tamoxifen, was scored as "I" by 2 labs due to RI % just below 80%. With the modified SOP/classifier 
it would lead to "N" in both cases (approximation of intermediate concentration with RI of 84.6% and 83.3 %).  
Test chemical 9, Atrazine, was scored as "I" by 2 labs. VMG expert judgement led to "N" for the 3rd run in CitoxLAB 
due to variability in the technical replicates. With the new SOP/classifier, the 2nd run for RISE would lead to "N" 
(approximated intermediate concentration RI of 84.1%)  
Test chemical 15, Prochloraz, was scored as P, N(FP), P. The FP is due to R2 = 0.91. It would not change with the new 
SOP/classifier (see further section 10.2). 
Test chemical 18, Benzylbutyl phthalate, was scored once as "I" by RISE. The response has clearly a negative trend. 
This lab was conservative with its solubility observations leading to less high tested concentrations than the other labs. 
With the modified SOP/classifier, it would likely result in "P" (approximated intermediate concentration with RI of 
68.2%) 
Test chemical 19, Propylthiouracil, yielded a mix of classifications between all 4 laboratories due to its response that 
are border line for the highest tested concentration. With the modified SOP/classifier, the "I" results could become all 
"N" (approximated intermediate concentration with RI of 83.6% and 83.4% for CitoxLAB; 87.7% and 83% for RISE; 
80.5% for BDS) except for one run at ENVIGO where it could be "P" (RI 74.1%). This "P" could possibly also be 
N(FP) if results of a specificity control test would be available. With 100 µM as maximal concentration, the 
classification would be immediately "N" for all labs given that concentrations up to 293 µM were tested. For BDS, the 
highest tested concentration of 881 µM was excluded given that such high concentration was not required to be tested. 
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P = Positive response, N= Negative response, I=Inconclusive, as defined by the application of the classifier in SOP V06. Green left upper corner section: classification by 
EURL ECVAM according to classifier in SOP V06. 
(#): was tested twice by RISE under two different codes but with same outcome 
(**): disqualified 
(red colour): Application of new classifier for the "I" with approximation of the intermediate additional concentration point between C8 and C7  
($): Application of new classifier but border line value for the approximation of the intermediate concentration (9.7%) when DF 2 would have been applied 
EJ stands for VMG expert judgement.  
Grey highlight: Tested at higher concentration than 100 µM.  
 
 
Table 27A and B: Within Laboratory Reproducibility of 20 coded test items 
(A) AGONIST- reported by the laboratories (B) AGONIST – classifications with modified SOP/classifier and EJ (in red) 
TEST CHEMICAL RISE ENVIGO BDS CitoxLAB  RISE ENVIGO BDS CitoxLAB 
1 17β-Trenbolone P P P P P P P P P P P P  P P P P P P P P P P P P 
2 Stanozolol P P P P P P P P P P P P P P P P P P P P P P P P 
3 Spironolactone(#) N N N N I (1) N N N N N N N N N N N 
N 
EJ 
N N N N N N N 
4 
Medroxyprogesterone 
acetate 
P P P P P P P P P P P P P P P P P P P P P P P P 
5 Bisphenol A N N N N N N N N N N N N N N N N N N N N N N N N 
6 Bicalutamide N N N N N N N N N N N N N N N N N N N N N N N N 
7 Disulfiram N N N N N N N N N N N N N N N N N N N N N N N N 
8 Tamoxifen N N N **(2) N N N N N N N N N N N ** N N N N N N N N 
9 Atrazine N N N N N N N N N N N N N N N N N N N N N N N N 
10 17α-Ethynyl estradiol N N N N N N N N N N N N N N N N N N N N N N N N 
11 Sodium azide N N N N N N N N N N N N N N N N N N N N N N N N 
12 Diethylhexyl phthalate N N N N N N N N N N N N N N N N N N N N N N N N 
13 Methyldihydrotestosterone P P P P P P P P P P P P P P P P P P P P P P P P 
14 Vinclozolin N N N N N N N N N N N N N N N N N N N N N N N N 
15 Prochloraz N N N N N N N N N N N N N N N N N N N N N N N N 
16 Fluoxymesterone P P P P P P P P P P P P P P P P P P P P P P P P 
17 17β-Estradiol P P I (3) P P P P P P P P P P P N$  P P P P P P P P P 
18 Benzylbutyl phthalate N N N N N N N N N N N N N N N N N N N N N N N N 
19 Propylthiouracil N N N N N N N N N N N N N N N N N N N N N N N N 
20 Hydroxyflutamide N N N N I (4) N N N N N N N N N N N N N N  N N N N N 
 WLR 95% 89% 100% 100%  95% 100% 100% 100% 
 
Concordant/total 
classifications 
19/20 17/19 20/20 20/20 
 
19/20 19/19 20/20 20/20 
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Summary notes: 
(1) Spironolactone: Border case, the second highest tested concentration has a RI of 10.3%. EJ led to "N" due to borderline value and shape of the curve. 
(2) Tamoxifen: Data points with lots of variability between the technical replicates, leading to 3 concentration points > 10% threshold. Disqualified run. 
(3) 17 β -Estradiol: Though 3 runs started with the same highest concentration, in only one run this concentration was scored as cytotoxic leading to only one concentration 
point > 10%.  
(4) Hydroxyflutamide: Border case, the highest tested concentration has a RI of 11.7%. (Note: highest tested concentration is 171 µM. With 100 µM as maximal 
concentration, classification is immediately N)  
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P = Positive response, N= negative response, I=Inconclusive, N(FP) = Negative classification due to false positive (FP) outcome by R2 > 0.9, according to classifier SOPV06 
Green left upper corner section: classification by EURL ECVAM according to classifier SOP V06. 
 (#): was tested twice by RISE under two different codes and with the same outcome 
* Was reported by the lab as "N" due to lab not applying the Inconclusive option 
+ Excluded from classification due to data difficult to analyse 
(red colour): Application of new classifier for the "I" with approximation of the intermediate additional concentration point between C8 and C7  
($): Application of new classifier but FP call cannot be made due to lack of specificity control. Excluded from classification.  
 Grey highlight: Tested at higher concentration than 100 µM.  
Table 28A and B: Within Laboratory Reproducibility   
(A) ANTAGONIST- reported by the laboratories  (B) ANTAGONIST –classifications with modified SOP/classifier and EJ (in red) 
TEST CHEMICAL RISE ENVIGO BDS CitoxLAB  RISE ENVIGO BDS CitoxLAB 
1 17β-Trenbolone N N N I(1) I I I(2)* N N N N N 
 
N N N N 
N 
(FP) 
N 
(FP) 
$ 
P/FP 
N N N N N 
2 Stanozolol N N N N N N N N N N N N  N N N N N N N N N N N N 
3 Spironolactone(#) P P P P P P P P P P P P  P P P P P P P P P P P P 
4 
Medroxyprogesterone 
acetate 
N P(3) P(3) I (4) N N N N N N N N 
 
N + 
N  
EJ 
N 
EJ 
N N N N N N N N 
5 Bisphenol A P P P P P P P P P P P P  P P P P P P P P P P P P 
6 Bicalutamide P P P P P P P P P P P P  P P P P P P P P P P P P 
7 Disulfiram N N N N N N N N N N N N  N N N N N N N N N N N N 
8 Tamoxifen N N N I(5) N N N 
I 
(6)* 
N N N N 
 
N N N N N N N N N N N N 
9 Atrazine I (7) N N N N N N N N N N 
I 
(8) 
 
N N N N N N N N N N N 
N 
EJ 
10 17α-Ethynyl estradiol P P P P P P P P P P P P  P P P P P P P P P P P P 
11 Sodium azide N N N N N N N N N N N N  N N N N N N N N N N N N 
12 Diethylhexyl phthalate N N N N N N N N N N N N  N N N N N N N N N N N N 
13 Methyldihydrotestosterone N N N N N N N N N N N N  N N N N N N N N N N N N 
14 Vinclozolin P P P P P P P P P P P P  P P P P P P P P P P P P 
15 Prochloraz P 
N(FP) 
(9) 
P P P P P P P P P P 
 
P N(FP) P P P P P P P P P P 
16 Fluoxymesterone N N N N N N N N N N N N  N N N N N N N N N N N N 
17 17β-Estradiol P P P P P P P P P P P P  P P P P P P P P P P P P 
18 Benzylbutyl phthalate P P 
I 
(10) 
P P P P P P P P P 
 
P P P P P P P P P P P P 
19 Propylthiouracil 
I 
(11) 
I  N 
I 
(12)* 
N I* 
I 
(13)* 
P I* 
I 
(14) 
N I 
 
N N N 
$ 
P/FP 
N N N N N N N N 
20 Hydroxyflutamide P P P P P P P P P P P P  P P P P P P P P P P P P 
 WLR 75% 80% 85% 90%  94.7% 100% 100% 100% 
 
Concordant/total 
classifications 
15/20 16/20 17/20 18/20  18/19 19/19 19/19 20/20 
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Summary notes: 
17β-Trenbolone: (1) Highest tested concentration with a RI of 7 - 17% for 3 runs. This concentration point was not considered in 2 other laboratories due to cytotoxic scoring 
except by BDS. (2) Run 1 with one higher tested concentration with a RI 28.7% (this concentration point was scored as cytotoxic in the other 2 runs). (Note: highest tested 
concentration is 171 µM. With 100 µM as maximal concentration, classification is immediately "N").  
Medroxyprogesterone acetate: (3) Three runs with borderline RI values. 2nd run would have best been repeated due to C1 at 81%. Results are difficult to interpret. 3rd run 
with EJ is "N" (dose response shape and variability triplicate samples). (4) Border case due to 3rd highest concentration with a RI of 77.5%. EJ is "N" (mid dose response plus 
variability in the triplicate samples). 
Tamoxifen: (5) Border case of highest tested concentration with a RI of 77.2%. (6) Border case of highest tested concentration with a RI of 76.7%.  
Atrazine: (7) Border case of highest tested concentration with a RI of 77.6%. (8) Border case of highest tested concentration with a RI of 77.9% EJ is "N" due to borderline 
value and variability data points 
Prochloraz: (9) FP due to R2.  
Benzylbutyl phthalate: (10) One run is "I" though there is a clear decline of the response.  
Propylthiouracil: (11) Border case in 2 runs of highest tested concentration with a RI of 78.8% and 76.4 %. (12) Border case in 2 runs of highest tested concentration with a 
RI of 66.3% and 71.6%. (13) Border case of 1 or 2 highest tested concentrations with a RI of 70.2% and 63.7%. (14) Border case in 2 runs of highest tested concentration 
with a RI of 69.1% and 77.5%. (Note: highest tested concentration is 293 µM for 2 labs, 881 µM for one lab. With 100 µM as maximal concentration, classification is 
immediately "N" for all labs) 
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BLR assessment with application of the modified SOP/classifier 
 
 
For the agonist testing, the BLR (already 100%) would not change by the re-classification.   
For the antagonist testing, 5 classifications would be influenced by the re-classification, as shown below:  
test chemical 1 for one lab and test chemical 19 for four labs. The BLR would increase to 100%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary notes: 
For chemical 1: ENVIGO's WLR was previously 3 times "I". With the modified SOP/classifier, a "N" and two 
N(FP) are obtained, resulting in a mean of N(FP).    
 
For chemical 19: All labs had previously WLR of "I". With the modified SOP/classifier it becomes "N" in all labs. 
Table 29: Between laboratory reproducibility with concordance of classifications 
 (majority rule) 
TEST CHEMICAL AGONIST ANTAGONIST 
 RISE ENVIGO BDS Citox 
LAB 
RISE ENVIGO BDS 
Citox 
LAB 
1 17β-Trenbolone P P P P N N(FP) N N 
2 Stanozolol P P P P N N N N 
3 Spironolactone N N N N P P P P 
4 Medroxyprogesterone acetate P P P P N N N N 
5 Bisphenol A N N N N P P P P 
6 Bicalutamide N N N N P P P P 
7 Disulfiram N N N N N N N N 
8 Tamoxifen N N N N N N N N 
9 Atrazine N N N N N N N N 
10 17α-Ethynyl estradiol N N N N P P P P 
11 Sodium azide N N N N N N N N 
12 Diethylhexyl phthalate N N N N N N N N 
13 Methyldihydrotestosterone P P P P N N N N 
14 Vinclozolin N N N N P P P P 
15 Prochloraz N N N N P P P P 
16 Fluoxymesterone P P P P N N N N 
17 17β-Estradiol P P P P P P P P 
18 Benzylbutyl phthalate N N N N P P P P 
19 Propylthiouracil N N N N N N N N 
20 Hydroxyflutamide N N N N P P P P 
 WLR 100% 100% 
 Concordant/total classifications 20/20 20/20 
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10.1.2 The Specificity Control and Criterion R2 
For several chemicals, the specificity control was helpful in the designation of a classification as competitive antagonist 
on the basis of the criterion R2.  
For 3 tested chemicals the specificity control led to conclude on a false positive (FP) for only one of the 3 runs, see 
Table 30 below: Prochloraz, 2-sec Butylphenol and Fulvestrant.  
For 2 chemicals FP was scored in all 3 runs: Cycloheximide and Ketoconazole.  
Norethinodrone acetate (34) is also discussed in this section due to its interesting dose response(s). 
 
Table 30: Classification of false positive antagonist 
No. TEST CHEMICAL 
ANTAGONIST 
Classification under SOPV06 
R2 
Modified SOP/classifier with Scn > 
or < 80% 
15 Prochloraz P N(FP) P 0.62 0.91 0.8 P  N(FP) P 
39 2-sec-Butylphenol N(FP) P P 0.95 0.81 0.34 P P P 
43 Fulvestrant N(FP) P I 0.97 0.9 0.7 N(FP)     P1 N(FP)2 
44 Cycloheximide N(FP) N(FP) N(FP) 0.95 0.99 0.99 N(FP) N(FP) N(FP) 
30 Actinomycin D I I I 0.93 0.98 0.98 N N(FP) N(FP) 
41 Ketoconazole N(FP) N(FP) N(FP) 0.97 0.93 0.96 N(FP) N(FP) N(FP) 
           
34 
Norethindrone 
acetate 
I P I 0.85 0.73 0.62 P but questionable 
1 Due to borderline value of R2, the outcome could be P or N(FP) 
2 With removal of the outlier, R2 would be 0.98 leading to N(FP) 
 
From the data analysis, it was observed that the value of R2 can be influenced by 1) an outlier in the dose response with 
the lower concentration of DHT (the standard response) (chemical 43); 2) a dose response of the specificity control that 
is slightly declining but not more than 20% (chemical 39). Moreover, it was noted that for a chemical with a shift of the 
dose response from the specificity control in the opposite direction, the R2 is < 0.9 (chemical 34).   
For several tested chemicals, it was observed that the lowest tested concentration of the specificity control dose 
response C1 did not start around the 200 % RI. To ease visual inspection of the dose response shift and also to verify 
the decline the specificity control dose response, the VMG agreed to rescale (normalisation) this dose response to the 
100% (see figure 03). 
Prochloraz (no. 15) with R2 = 0.91. This chemical was the only chemical tested by all 4 labs but only one lab obtained 
one run out of 3 with a FP outcome. It deserves to be noted that the R2 has a borderline value (0.91). 
2-sec-Butylphenol (no. 39) was classified as FP for one out of 3 runs with a R2 clearly above the threshold value of 0.9. 
This is due to the shape of the specificity control curve which is slightly declining with increasing concentrations. This 
outcome shows that the application of the R2 criterion has some limitations. Normalisation of the specificity control 
values (rescaling to 100%) and visual evaluation of the dose response shift show it is "P" (see figure 03). All 
concentrations are above the 20% threshold. On the basis of this response, the VMG agreed to modify the classifier with 
inclusion of the normalised specificity control (Scn) (see Discussion section 10.1). 
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 Figure 03: Test chemical 39. Display of the dose responses when tested with the lower (standard response, red solid curve) 
and the higher (specificity control response, red dashed curve) spiking of DHT. Black curve indicates the reference 
Flutamide response. Figure at the right with re-scalement of the specificity control dose response (Scn) 
Fulvestrant (no. 43) was classified as FP, P, I though the dose responses are quite comparable. The 1st run has 2 
concentration points below 80% and R2 of 0.97. The 2nd run has a borderline value of 0.9 for the R2. The 3rd run had 
only one concentration point below 80% (RI of 42.5%) though the second concentration seems to have yielded an 
outlier (see figure 04). R2 is 0.76 and will be impacted by this outlier. VMG expert judgement led to interpolate the 
intermediate concentration between the highest and the third highest concentration (exclusion of the outlier). Such 
would lead to a R2 of 0. 98 and change the "I" to N(FP). Application of the modified SOP/classifier and EJ to all 3 runs 
would lead to N(FP), P, N(FP). Given the borderline value of 0.9 for R2 in the 2nd run, it may be a N(FP).  
This chemical is used in prostate cancer treatment and is thought to have its action by downregulating the expression of 
the androgen receptor (Bhattacharyya et al, 2019). This could possibly explain the observed result of FP. With 
increasing concentrations of Fulvestrant, AR expression would decrease, and less AR available for binding with the 
ligand DHT.  
 
        
 
 
 
                
Figure 04: Test chemical 43 (run 8). Display of the dose responses when tested with the lower (standard response, red solid 
curve) and the higher (specificity control response, red dashed curve) spiking with DHT. Black curve indicates the 
reference Flutamide response. Green curve indicates possible dose response when C7 (outlier) is excluded. Blue asterisk 
indicates the interpolated value between the highest (C8) and the 3rd highest concentration (C6) of what could be the result 
by applying dilution factor 2. Green square shows the interpolated value between C8 and C7. 
Actinomycin D (no. 30) and Cycloheximide (no. 44) are both antibiotics. Cycloheximide yielded 2 to 3 concentrations 
below the 80% in the comprehensive test for the 3 runs and R2 of 0.95, 0.99, 0.99, leading to FP. For Actinomycin D 
only one concentration was found to be below 80% in 3 runs, leading to "I". The modified classifier/SOP would instruct 
to perform dilution 2 after the pre-screen. This may lead to 2 concentrations below 80% for possibly 3 runs 
(approximated intermediate concentration of 64% and 65.3% and 80%) but the specificity control would still conclude 
to FP for each run (R2 > 0.9). The false positive behaviour of both tested chemicals may be due to the cytotoxicity that 
indeed was observed at higher concentrations (with the LDH test and with visual inspection) but could not be observed 
at the lower tested concentrations. Early events that lead to cell death are not picked up by the LDH test nor by visual 
inspection. 
Ketoconazole (no. 41) is reported to be a fungicide but also as a pharmaceutical (prostate cancer treating drug). It 
displayed an antagonist activity response in 3 runs, likely due to cytotoxicity.  The specificity control results in FP (R2 
> 0.9). 
Norethinodrone acetate (no. 34) displays 1 concentration point below the 80% threshold value in 2 of the 3 runs (RI of 
54.2% and 56.2%) (representative example, see figure 05). With the new SOP, a dilution factor of 2 would have been 
taken, leading to 2 concentrations in both runs below 80% and the Scn of C8 below 80%, with R2 is < 0.9, resulting in 2 
times "P" (approximated intermediate concentrations with RI of 73.1% and 79.1%). R2 values are below 0.9 in all 3 
runs indicating a competitive antagonist. This result however is questionable. The shift of the dose response curve of the 
specificity control is to the opposite direction (left shift) because it declines before the standard assay response. This 
situation reveals that the application of the criterion R2 has some limitations and expert judgement shall be made.  
Chemicals displaying this type of response have been described as well for the Tox21 lux assay. 65 chemicals were 
found to have a potency shift in the opposite direction. However, the chemical of this study was not tested with the 
Tox21 assay (Kleinstreuer et al, 2017). 
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Figure 05: Test chemical 34. Display of the dose responses when spiked with DHT: the lower (standard response, red solid 
curve) and the higher concentration (specificity control response, red dashed curve).  
10.1.3 Classifications of the additional 26 tested chemicals 
Shown below (Table 31) are the classifications as reported by the laboratory for agonist and antagonist testing (as 
discussed in section 6). For the agonist testing no "I" results were found and WLR is 100%. For the antagonist testing, 
the plausible outcome of the application of the modified instructions in the SOP / classifier is also shown in Table 31, 
alongside the reported classifications: WLR increases from 84.4% to 96.1%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary notes for the antagonist classifications (reported by the labs):  
(1) Chemical 30: only the highest tested concentration has RI < 80% in 3 runs (57.2%, 39%, 37.5%). R2 is > 0.9 in all 3 runs what 
indicates FP but with the classifier it gets classified as "I" due to only one concentration below the threshold value. 
(2) Chemical 34 has dose responses with the specificity control that declines before the standard response. "I" is scored in 2 runs due 
to only the highest tested concentration with RI of < 80%: 54.2% and 56.2%. &: Questionable result. Shift of the specificity control 
dose response curve in the opposite direction. Criterion R2 > 0.9 would not be applicable in this case. 
(3) Chemical 39 was reported as "P" but shall be FP due to R2 = 0.91 
(4) Chemical 43: second highest tested concentration has RI of 111.5% which is likely an outlier.  
Grey highlight: Tested at higher concentration than 100 µM.  
  
Table 31: Classifications  
No. TEST CHEMICAL 
AGONIST 
Reported by the 
labs 
 
ANTAGONIST 
 
Reported by the labs 
 
ANTAGONIST  
 
Modified SOP/classifier  
21 Levonorgestrel P P P  N N N  N N N 
22 Cyproterone acetate N N N  P P P  P P P 
23 2-tert-Butylanthraquinone N N N  P P P  P P P 
24 Arochlor1254 N N N  P P P  P P P 
25 Nandrolone P P P  N N N  N N N 
26 o,p’-DDT N N N  P P P  P P P 
27 Phenolphthalin N N N  N N N  N N N 
28 2,4,5-T N N N  N N N  N N N 
29 Methyltrienolone (R1881) P P P  N N N  N N N 
30 Actinomycin D N N N  I (1) I I  N N(FP) N(FP) 
31 Diethylstilbestrol N N N  P P P  P P P 
32 L-Thyroxine N N N  N N N  N N N 
33 Haloperidol N N N  N N N  N N N 
34 Norethinodrone acetate P P P  I(2) P I  P?&  P?& P?& 
35 Pimozide N N N  N N N  N N N 
36 Progesterone N N N  P P P  P P P 
37 Linuron N N N  P P P  P P P 
38 Methyltestosterone P P P  N N N  N N N 
39 2-sec-Butylphenol N N N  N(FP)(3) P P  P P P 
40 Corticosterone N N N  P P P  P P P 
41 Ketoconazole N N N  N(FP) N(FP) N(FP)  N(FP) N(FP) N(FP) 
42 Finasteride N N N  P P P  P P P 
43 Fulvestrant N N N  N(FP) P  I(4)  N(FP) P  N(FP)  
44 Cycloheximide N N N  N(FP) N(FP) N(FP)  N(FP) N(FP) N(FP) 
45 Norethindrone P P P  N N N 
 
N N N 
46 Mifepristone N N N  P P P P P P 
 WLR 100%  84.4% 96.1% 
 Concordant/total classifications 26/26  22/26 25/26 
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The tested chemicals with "I" or N(FP) result are discussed in detail in the previous section 10.2. A brief summary per 
chemical can be found below. 
Test chemical 30, Actinomycin D: classified as "I" under the classifier of SOP V06 but with the modified SOP/classifier 
the testing could result in 2 concentrations under the threshold of 80% for 2 of the 3 runs, leading to "P" (approximated 
intermediate concentrations with RI of 64 % and 65% ). The specificity control result however would lead to FP due to 
R2 > 0.9 what would result in N(FP). 
Test chemical 34, Norethinodrone acetate, is a positive agonist that displays an interesting dose response in the 
antagonist assay when tested with excess of DHT (specificity control). The specificity control response declines before 
the standard response leading to shift in the opposite direction. Applying the classification would lead to "P" but this is 
rather questionable given the left shift of the dose response.  
Test chemical 39, 2-sec-Butylphenol, has one N(FP) classification due to R2 = 0.95. By applying the new classifier (with 
the evaluation of normalised values of the specificity control) this would result in a P. 
Test chemical 43, Fulvestrant, showed 3 different classifications though the dose responses are quite comparable. VMG 
expert judgement and application of the modified SOP/classifier would lead to N(FP), P, P or FP. 
 
10.2 Quantitative assessment of the results 
Measurements of the EC50 and PC10 (agonism) and IC50 and PC80 values (antagonism) were very reproducible within the 
laboratories and between the laboratories (for overview tables of the values see Statistical report).  
Based on all the log(EC50), log(PC10) (agonism), and, log(IC50) and log(PC80) (antagonism) obtained by each of the 4 
laboratories, the average % CV's per laboratory was less than 2.5%. These values are comparable to what is reported for 
the ER-CALUX® method (less than 4%) which was adopted as part of TG 455, and, comparable to what is reported for 
the Japan ARTA (less than 2%) which was adopted as TG 458. 
 
 
Table 32: Range of average % CV of all tested chemicals for all labs from different validation studies 
Validation Study  AGONIST testing ANTAGONIST testing 
AR-CALUX® 
Log(EC50): 0.65% to 2.16% 
(5 test chemicals) 
Log(IC50): 0.95% to2.09% 
(9 test chemicals) 
ER-CALUX® 
Log(EC50): 1.2% to 3.1% 
(17 test chemicals) 
Log(IC50): 0.5% to 1.6% 
(4 test chemicals) 
Japan ARTA 
Log(PC50): 0.38% to 1.53% 
 (3 test chemicals) 
Log(IC50): 0.84% to 1.15% 
(3 test chemicals) 
Values taken from validation study reports: % CV taken from calculations expressed in molar.  
 
10.3 Additional observations from the validation study 
10.3.1 Usage of different luminescence kits and substrates and luminometers  
Amongst the 4 laboratories, 2 have used in-house prepared illuminate mix, one laboratory opted for the Promega 
luciferase kit while another laboratory chose the Promega Steady Glo mix kit. The last kit did not require a luminometer 
with double injection. 
Comparison of the potency measures (EC50, IC50, etc.) across the different laboratories did not show substantial 
differences (see variability measures in the Statistical report, page 38-39). 
 
10.3.2 Usage of frozen stock solutions for the reference chemicals 
The two reference chemicals DHT (for the agonist testing) and Flutamide (for the antagonist testing) are used for each 
run. Preparing these chemicals always fresh implies a significant work load. When the laboratory BDS joined the study, 
the VMG agreed that the two reference chemicals could be prepared up front and aliquots stored at - 20ºC. The test 
method developer reported on stability of these reference chemicals for a period up to 3 months. Once an aliquot is 
thawed, it can be stored at - 4ºC and used for up to 4 weeks. 
Comparison of the potency measures (EC50, IC50, etc.) of DHT and Flutamide did not show a significant difference (see 
variability measures in the Statistical report, page 38-39).  
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10.3.3 Usage of plastic plates and glass tubes 
The labs BDS and CitoxLAB used 24 well plastic plates for preparing the work solutions of the test chemicals while the 
other two labs worked with glass tubes. 
Comparison of the potency measures (EC50, IC50, etc.) obtained by BDS and CitoxLAB did not show a significant 
difference with the other 2 laboratories (see variability measures in the Statistical report, page 38-39).  
10.3.4 Invalid runs and reasons for rejection 
Table 33 shows a summary of the reasons for invalidity of runs as reported by the laboratories. Most invalid runs 
occurred in the antagonist assay. The 2 most reported criteria, leading to failure, were having a too low Inhibition factor 
and too low Plate Z factor.  
Table 33: Invalid runs 
AGONIST ANTAGONIST 
Acceptance criterion # Reported failures Acceptance criterion # Reported failures 
1 - Sigmoidal shape 0 1 - Sigmoidal shape 0 
2 - DHT EC50 out of range 1 2 - FLU IC50 out of range 5 
3 - DHT CV (LogEC50) ≥ 1.5% 1 3 - FLU CV (LogEC50) ≥ 3% 0 
4 - RI PC ≤ 30% 0 4 - RI PC ≥ 60% 6 
5 - RI NC ≥ 10%  3 5 - RI NC ≤ 85%  8 
6 - Induction factor ≤ 20 0 6 - Inhibition factor < 10 12 
7 - Plate Z-factor < 0.5 3 7 - Plate Z-Factor < 0.5 23 
8 - FLU R2 > 0.7 3 
Other reported issues # Reported Other reported issues # Reported 
DHT C1 > 10% 1 RI VC > 5% 4 
Test Item CV (LogEC50) > 3% 9 FLU C1 > 120% or < 80% 2 
Variable RLU values 1 Test item C1 > 120% or < 80% 2 
Test item EC50 inaccurate 1 Variable RLU values 2 
Test item too cytotoxic 2 
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11 VMG OVERALL CONCLUSIONS AND RECOMMENDATIONS 
The primary aim of this validation study was to assess the transferability, within laboratory (WLR) and between 
laboratory reproducibility (BLR) of the AR-CALUX® method with a number of relevant coded chemicals that were 
judged by the VMG to be suitable and sufficiently challenging to permit conclusions to be drawn. 
The VMG concludes that the test method can be transferred among properly equipped and staffed laboratories, 
including those having no prior experience in similar test methods. Experienced personnel can readily be trained for the 
test method and the necessary equipment and supplies can be readily obtained. Caution is however needed in handling 
chemicals that may be potent endocrine disruptors and the material used during the testing (e.g. glass tubes or plastic 
tubes) which should  be free of contamination. The VMG recommends that such caution shall be included in the SOP.  
The SOP is considered robust, the acceptance criteria values adequate. It allows flexibility in the usage of type of 
luminescence substrates or kits, and, type of luminometers. It is clearly written and the testing and analysis of results 
can be easily performed.  
The WLR based on concordance of classifications within the laboratories is 89%, 95%, 100% and 100% for agonist 
testing, 75%, 80%, 85% and 90% for antagonist testing. Overall BLR is 100% for agonist testing and 87.5% for 
antagonist testing. These values are influenced by the occurrence of the classification "I", especially in the antagonist 
testing.  
In order for an end user to arrive immediately to a classification of "N" and "P", without the option of "I", further 
instructions in the SOP are suggested (as detailed in the previous section). Applying these instructions in the SOP to the 
validation study data, by approximating the second highest concentration point that would result from applying a 
dilution factor 2, the reported classifications could be improved. This would lead to WLR values of 95%, 100%, 100% 
and 100% for agonist testing, and, 94.7%, 100%, 100% and 100% for antagonist testing; BLR of 100% for both 
agonist and antagonist testing. 
The application of a specificity control in the antagonist assay, to identify competitive antagonists, has proven to be 
useful, both for gaining more confidence that the positive classification is indeed correct, and, for defining false 
positives. The criterion R2 is a good measure but some caution is advisable as it was shown not be 100% reliable. A 
further amendment of the classifier, allowing normalisation of the specificity control values with evaluation of the 
values being above or below the threshold value of 80%, would improve the classification. Expert judgement 
nevertheless will be required.  
Comparison of the classifications of 23 tested chemicals shows a very good concordance with the classifications 
reported in the AR-reference list.  
Amendments and deviations to the studies, reported by the laboratories, are minor and have no impact on the results. 
For example, one laboratory substituted during the transfer phase the recommended luciferase kit by another, leading to 
data of similar quality to the other laboratories. 
This validation study was conducted with a gravimetric method using 50 mg/ml as the highest stock concentration. In 
view of the drafting of a TG, the VMG recommends to use 100 mM as the highest stock concentration. When the 
molecular weight of a test chemical cannot be calculated such as for multi constituent substances, polymers, mixtures, 
UVCBs etc., the gravimetric method should be used starting from 50 mg/ml. 
Overall, the VMG concludes that the information generated in this validation study shows that the AR-CALUX® 
method is a reliable test method that can contribute to the determination of (anti)-androgen potential of substances. 
 
The recommendations by the VMG after the transfer phase were as follows, and were introduced in the following 
versions of the SOP used in the validation study: 
 Broadening up the SOP for the usage of other luminometers and not only the double injector luminometer 
 An additional guidance for the antagonist assay to monitor carefully the VC response and the SC response  
 
The recommendations by the VMG after evaluation all data, and to be introduced in the final version of the SOP, are as 
summarised below: 
 After the section of the pre-screen, to identify which dose range is appropriate and also which dilution factor to 
use for preparing the working solutions. Dilution factor 2 is recommended for chemicals displaying activity at 
only the highest tested concentration above the 10% threshold (agonist) or below the 80% threshold 
(antagonist).  
 Highest stock concentration to be used for testing of chemicals: 100 mM. 
 Modification of the classifier to arrive to a "P" or "N" classification. 
 Normalisation of the specificity control values. 
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 A warning for the use of plastic/glass before running studies (the response to the vehicle control should be 
assessed to ensure no interference).  
 
In addition, the VMG suggests that end users can choose to use glass tubes or plastic plates for the preparation of 
working solutions for the test chemicals, and, to prepare fresh or to freeze down stock solutions of the reference 
chemicals.   
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ANNEX 13.1 
 
 
STATISTICAL REPORT  
 
 
Available at EURL ECVAM's  
Tracking system for alternative methods towards regulatory acceptance (TSAR) 
( https://tsar.jrc.ec.europa.eu/test-method/tm2010-07) 
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List of abbreviations 
 
ARTA: Androgen Receptor Transactivation Assay 
AR-CALUX method: the transactivation in vitro method to measure (anti)androgenic potential of chemicals using the 
AR-CALUX® cells 
ARE: Androgen Responsive Elements 
BDS. BioDetectionSystems 
BLR: Between Laboratory Reproducibility 
CV: Coefficient of variation 
DB-ALM: EURL ECVAM DataBase service on ALternative Methods to animal experimentation 
DMSO: dimethyl sulfoxide 
EC: European Commission 
EC50: half maximal effective concentration 
ED: Endocrine Disrupter 
ER TA: Estrogen Receptor Transactivation Assay 
ESAC: ECVAM's Scientific Advisory Committee 
EU-NETVAL: European Union Network of Laboratories for the Validation of Alternative Methods  
EURL ECVAM: European Union Reference Laboratory for Alternatives to Animal Testing  
GLP: Good Laboratory Practice 
IATA: International Air Transport Association 
IC50: half maximal inhibitory concentration 
ICATM: International Cooperation on Alternative Test Methods 
ICCVAM: Interagency Coordinating Committee for the Validation of Alternative Methods 
LDH: Lactate DeHydrogenase 
MSDS: Material Safety Data Sheet 
NCP: National Contact Point 
OECD: Organisation for Economic Cooperation and Development 
OHS: Occupational Health and Safety 
PALM: PC-3 human prostate carcinoma cells 
PBTG: Performance Based Test Guideline 
SARM: Selective Androgen Responsive Modulator 
STTA: Stably Transfected Transactivation Assay 
SOP: Standard Operating Procedure 
STR: Short Tandem Repeats 
TA: Transactivation Assay 
TG: Test Guideline 
ToR: Terms of Reference  
VMG: Validation Management Group 
VMG-NA: OECD Validation Management Group Non Animal 
WLR: Within Laboratory Reproducibility 
YAS: Yeast Androgen Screening assay 
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1 SUMMARY 
The European Commission (EURL ECVAM) proposed to OECD to develop a Performance Based Test 
Guideline (PBTG) and related Performance Standards for Androgen Receptor Transactivation Assays 
(ARTAs). Such PBTG and standards will be drafted on the basis of ARTAs for which the validation is 
ongoing, and the EURL ECVAM coordinated validation study on the AR-CALUX method.  
The AR-CALUX in vitro method was submitted by the Dutch company BioDetectionSystems (BDS) to 
EURL ECVAM to be considered for a EURL ECVAM coordinated validation process. The method is 
applied for the detection of compounds with (anti)androgenic potential. The AR-CALUX® cells are 
osteosarcoma U2OS cells which are transfected with the cDNA of a human androgen receptor and a 
luciferase encoding reporter gene preceded by AR response elements (ARE), hence responding to chemicals 
with endocrine disrupting activity.  
EURL ECVAM is both sponsor and coordinator for this validation study. Three test facilities have been 
selected from the recently established European Union Network of Validation laboratories for alternative 
methods (EU-NETVAL) to participate in this validation study. A Validation Management Group (VMG) has 
been established consisting of EURL ECVAM internal staff and external experts in the field with as main 
task the oversight of activities. 
Within this validation study, the following will be addressed: experimental definition of the in vitro method 
following OECD principles of GLP by EURL ECVAMs GLP test facility, assessment of the transfer of the 
method to each of the 3 laboratories (Study 1 – Transferability), the reproducibility within each laboratory 
and between laboratories (Study 2 – Reproducibility), as well as the predictive capacity and the applicability 
domain of the AR-CALUX method (Study 3 – Predictive capacity). Hereto, the 3 test facilities are requested 
to test 3 sets of chemicals (2 sets will be blinded) with the SOP version provided by EURL ECVAM and to 
report the data according to predefined Data Analysis Forms. A list of chemicals to be tested has been 
compiled on the basis of a weight of evidence approach as well as in-house (EURL ECVAM) generated data 
on the dose response and solubility in DMSO/assay medium. The list is composed of a balanced number of 
agonists, antagonists and those without any response. 
This validation project plan details the objectives of the validation study, the managerial aspects, the overall 
content of the tasks for the test facilities, the expected deliverables and the respective time periods to be 
respected. 
 
78 
 
2 INTRODUCTION AND OBJECTIVES 
2.1 General introduction 
Endocrine disruptors (EDs) are a high priority topic on the agenda of several national and international 
governmental institutions given the observed and documented adverse effects on humans and animals' health 
(UNEP WHO, 2013). These substances impact development and reproduction by disturbing the functioning 
of the endocrine (hormone) system. The definition of an endocrine disrupting substance has been put forward 
in 2002 by WHO as "An endocrine disruptor is an exogenous substance or mixture that alters function(s) of 
the endocrine system and consequently causes adverse health effects in an intact organism, or its progeny, or 
(sub) populations” (WHO/IPCS, 2002). The criteria for defining a substance as an ED are still under debate. 
National and international governments are in the process of establishing testing programs and strategies to 
assess the safety of currently used chemicals with regard to their potential to interfere with the endocrine 
system. Several pieces of European legislation are addressing EDs, reflecting also the need of scientific 
criteria to identify EDs: the REACH regulation No 1907/2006; the Regulation No 1107/2009 on Plant 
Production Products; the Regulation No 1223/2009 on Cosmetic Products; Regulation 528/2012 on Biocidal 
Products. The European Commission launched in 1991 a work program "Community strategy for endocrine 
disruptors" (EC, 1997) addressing several actions to establish criteria and identify EDs for further evaluation, 
to develop and validate test methods to assess EDs, to fund research for understanding the ED mechanisms 
and to adapt present EU legislation to take account of ED effects. The United States Environmental 
Protection Agency (EPA) developed i.e. the Endocrine Disruptor Screening Program (EDSP) as one of the 
first national programs. In Japan, the Japan Environment Agency initiated the Strategic Programs on 
Endocrine Disruptors (SPEED) to promote e.g. test method development while in the republic of Korea, the 
relevant ministries developed mid and long term research plans mainly dealing with environmental 
monitoring (Hecker and Holler, 2011; WHO, 2014).  
The Organisation for Economic Co-operation and Development (OECD) recognised the impact of ED 
substances on human health and environment. Since 1996, effort has been spent in developing Test 
Guidelines and other tools to support countries' needs for testing and assessment of chemicals for endocrine 
disruption. In terms of providing overview and guidance, a number of important documents have been 
drafted, e.g. a Conceptual Framework for testing and assessment of EDs was adopted in 2002, and revised in 
2011. It lists OECD Test Guidelines and standardized test methods available, under development or 
proposed to be used to evaluate chemicals for ED. It is structured over different levels where level 2 includes 
in vitro assays (data about selected endocrine mechanism) and levels 3, 4 and 5 handle in vivo assays (data 
about selected endocrine mechanism and on adverse effects on endocrine relevant endpoints) (OECD, 
2012a). 
The OECD Conceptual Framework as well as the EPA have recommended in vitro assays, and more 
precisely hormone receptor binding assays and transactivation assays, as important tools for the fast 
screening of putative EDs and prioritisation purposes. Within the transactivation assays, the Estrogen 
Receptor Activation Assays (ERTAs) have ligand bound estrogen receptors (ER) leading to transactivation 
while the Androgen Receptor Activation Assays (ARTAs) have activated androgen receptors (AR) initiating 
the transcription. Since few years, OECD has initiated the concept of Performance Based Test Guidelines 
(PBTGs) where similar methods can be included in the same Test Guideline. Performance Standards 
accompany such PBTG, including a set of Reference Chemicals, accuracy and reliability performance 
values, applicable for all annexed in vitro methods. For ERTAs, such PBTG has been already developed and 
includes the assays STTA and BG1luc (OECD, 2012b, 2012c). A PBTG for ARTAs is currently under 
development (see further). 
 
AR-CALUX cells were identified within the EU funded project ReProTect (LSHB-CT-2004-503257) which 
aimed at optimizing an integrated set of tests as a basis for a reproductive/developmental battery, in order to 
provide detailed understanding of the main chemical target tissues or biological mechanisms in reproduction. 
The AR-CALUX cells were considered as addressing a critical biological mechanism (androgen receptor 
interaction) and therefore a relevant test system for the development of a method for ED screening. The test 
developer of the AR-CALUX method carried out a pre-validation (van der Burg et al, 2010) and the in vitro 
method was subsequently submitted to EURL ECVAM for a validation process. EURL ECVAM considered 
the in vitro method as sufficiently developed for entering a validation.  
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2.2 Goal and Objectives 
The European Commission submitted in 2012 a Standard Project Submission Form (SPSF) to OECD for the 
development of a PBTG on ARTAs and this proposal was accepted and inserted in the OECD 2013 work 
plan. Several ARTAs are currently undergoing a validation process, and when successful, they can be 
considered to be annexed to the PBTG: 
 the AR-STTA assay of Japan, using the AR-EcoScreen Chinese hamster ovary cell line (validation study 
finalized and validation report under review by OECD VMG-NA) 
 the ARTA assay of Korea, using the 22Rv1/MMTV human prostate cancer cell line (validation ongoing) 
 the YAS assay of BASF (Germany), using yeast cells (validation study finalized and considered for peer-
review) 
 
While EURL ECVAM will coordinate the validation of the AR-CALUX assay of BioDetectionSystems 
(BDS) (the Netherlands), using the human osteosarcoma based cell line AR-CALUX, it will investigate 
simultaneously the existing validation data of the Japanese ARTA and follow closely the ongoing validation 
study of the Korean ARTA. The data of all 3 ARTA validation studies will be analysed to conclude on a set of 
Performance Standards for ARTAs and hence the drafting of a PBTG to which the 3 methods will be annexed. 
If the YAS assay will be submitted for peer-review and has a successful outcome, also this assay will be 
considered in the drafting of the Performance Standards. 
 
The objective of this validation study is to test the AR-CALUX method for its reliability and its relevance, 
concluding on Performance Standards.  
For this purpose, the following tasks will be carried out according to the Terms of Reference (ToR) for EU 
NETVAL:  
 ToR Task i: Definition and description of in vitro methods 
 ToR Task ii (Study 1): Transfer of in vitro methods between laboratories 
 ToR Task iii (Study 2): Assessment of the reproducibility of in vitro methods 
 ToR Task iv (Study 3): Assessment of the predictive capacity and applicability domain of in 
vitro methods 
EURL ECVAM will take care of the first task, while 3 European Union test facilities (selected from the 
European Union Network of Laboratories for the validation of alternative methods (EU NETVAL) will carry 
out the following 3 tasks with an increasing number of chemicals. With the first study, the successful transfer 
of the method to the 3 test facilities will be evaluated while studies 2 and 3 will lead to the generation of data 
to assess within and between lab reproducibility (reliability) as well as predictive capacity and the 
applicability domain (relevance). 
Data generated by the 3 test facilities will be compiled in Data Analysis Forms and Final reports which will be 
collected, analysed and evaluated by a Validation Management Group (VMG). The data analysis, the 
conclusions on the method's performance and deduced Performance Standards will be gathered in a validation 
report. After a positive evaluation by ECVAM's Scientific Advisory Committee (ESAC), a EURL ECVAM 
recommendation will be formulated.  
This validation study will be carried out according to the EURL ECVAM modular approach (Hartung et al, 
2004). The modules to be covered include Module 1 (test method definition), Module 2 (within-laboratory 
reproducibility), Module 3 (transferability between laboratories), Module 4 (between-laboratory 
reproducibility) and Module 5 (predictive capacity). The data will also be used for Module 6 (applicability 
domain) and Module 7 (minimal performance standards) for this class of method.  
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3 THE TEST METHOD TO BE VALIDATED 
3.1 Description of the in vitro method 
The AR-CALUX cell based assay provides information on the endocrine activity of chemicals, and more 
specifically the (anti-)androgenic activity, when the AR-CALUX cells are exposed to substances. This in 
vitro method is a transactivation assay where the reporter gene luc (encoding luciferase) is activated by the 
androgen receptor but only when bound to a ligand, i.e. a chemical with androgen receptor affinity. This 
receptor-ligand complex enters the nucleus where it will bind to specific recognition sequences in the 
promoter region of a target gene (so called androgen responsive elements or ARE). Hence, the target gene 
will be transcribed. When the target gene expresses the reporter (luciferase), in vitro hormonal activity of 
chemicals can be quantified as well as the agonistic or antagonistic mode of action. Such assays are called 
Androgen Receptor Transactivation Assays (ARTA).  
The AR-CALUX cell line was created via transfection of the human osteosarcoma cell line U2-OS (ATCC 
HTB 96) with 2 constructs: pSG5-neo-hAR carrying the cDNA of a human androgen receptor under a 
constitutive promoter, and, pGL3-3XAREtataLuc carrying the luciferase reporter gene which is preceded by 
a triple tandem of AREs in front of a TATA box.  
This cell line has been reported to stably express the human androgen receptor, to be highly selective in its 
response to low levels of different androgens (due to the multimerized ARE and a minimal promoter – 
TATA box only), and to have an insignificant response to other nuclear hormone receptor ligands such as 
estrogens and glucocorticoids (due to the cells not expressing other steroid receptors that can activate 
transcription via the same ARE as the androgen receptor). 
There are no specific limitations of the method reported except for the general limitations of TAs (being 
direct extrapolation to the in vivo complex network of signalling and regulation should not be made; 
information is gained on the parent molecule while in vivo other molecules may be generated due to the cells' 
metabolism). It can be performed in any laboratory with in vitro method expertise and does not require 
expensive equipment. The assay is a proprietary method of BDS and the cells, the protocol, training and 
technical support are available through a license agreement.  
 
3.2 Purpose and regulatory context of the in vitro method 
The AR-CALUX method is intended to be used for screening purposes due to an easy and time efficient 
application. 
Both the OECD Conceptual Framework and the US EPA have recommended transactivation assays as an 
important tool for fast screening of chemicals with expected endocrine disrupting properties. OECDs 
Conceptual Framework has identified several type of methods classified over levels, e.g. level 2 involves in 
vitro assays providing mechanistic data. Validated ERTAs are included at this level, but there is still a lack 
of validated ARTAs. The proposed AR-CALUX method, once validated, could be inserted at this level 2. 
Moreover, as detailed in section 2.2., this method has potential to be annexed to a PBTG for ARTAs.  
 
3.3 Principle of the in vitro method  
The method is described by the test submitter to measure the ability of a chemical to activate AR dependent 
transcription (i.e. act as an agonist) and to suppress AR dependent transcription (i.e. act as an antagonist).  
Hence, the method is composed of an agonist and an antagonist assay. 
Both assays include a pre-screen for determining the appropriate dose range, followed by comprehensive 
testing. To determine the agonistic or antagonistic nature of a test chemical, it will be tested in the following 
manner: 
1) A dilution series of the chemical is prepared in solvent (e.g. DMSO) and applied to the cells in assay 
medium. When the luminescent signal increases in a concentration dependent way in comparison to the 
solvent control, the chemical has an agonistic response. 
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2) A dilution series of the chemical is prepared in solvent (e.g. DMSO) and applied to the cells in assay 
medium supplemented with the EC50 concentration of Dihydroxytestosterone (DHT). When the luminescent 
signal decreases in a concentration dependent way in comparison to the solvent control, the chemical has an 
antagonistic response unless there is a non-specific response. Such is the case when: 
 the chemical provokes cytotoxicity which leads to decrease of the luminescent signal. Therefore, a 
cytotoxicity test must be performed. 
 the chemical interferes with the generation of the luminescent signal (e.g. at the level of receptor-ligand 
binding to the AREs, the transcription of the reporter gene, the translation of the reporter gene, stability 
of the reporter gene product). Therefore, a specificity control must be performed (based on competition 
of agonist and antagonist chemical for the receptor) during antagonism comprehensive testing 
 
In order to label a test chemical as an agonist or antagonist, a classification scheme will be applied. To 
classify a chemical as an antagonist, the outcome of the application of the specificity control is important. 
EURL ECVAM, while assessing the method (see section 3.6), proposed to include such control. A criterion 
for the specificity control and the classifier will be introduced in the SOP towards the end of the validation 
study, before the initiation of Study 3.  
 
 
3.4 Reference chemicals and control chemicals 
Agonist and antagonist assay have each a reference chemical for which the dose response is measured, EC50 
values, the induction factor and the Z factor (see tables 3 and 4) calculated. It is also the chemical to which 
the response of a test chemical is compared (normalisation). For both assays, the maximal response of the 
reference chemical is set at 100% (this is in the agonist assay the highest concentration of the reference 
chemical and in the antagonist assay the lowest concentration).  
The positive control and negative control include the addition of a chemical to the test medium (including 
DMSO) for which respectively a response or no response is expected. 
Both assays have a vehicle control which is the test medium including DMSO (0.1%) while the antagonist 
testing includes also a solvent control which is the vehicle control plus EC50 of DHT. 
Table 1: Proposed reference and control chemicals for the agonist assay 
 Name CAS 
Reference Dihydroxytestosterone (DHT) 521-18-6 
Positive control Methyl testosterone 58-18-4 
Negative control Corticosterone 50-22-6 
 
Table 2: Proposed reference and control chemicals for the antagonist assay 
 Name CAS 
Reference  Flutamide 13311-84-7 
Positive control  Linuron 330-55-2 
Negative control Levonorgestrel 797-63-7 
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3.5 Acceptance criteria 
Criteria for the reference chemical, positive and negative control have been established. An experiment is 
considered valid and will be accepted when all of these acceptance criteria are met.  
Table 3: Acceptance criteria in the agonist assay 
No Acceptance criterium Value 
 Reference chemical DHT  
1 Curve fitting Sigmoidal 
2 EC50 range  1.10-10 – 1.10 -9 M 
3 CV of estimated log(EC50) < 1.5% 
4 Induction factor  > 20 
5 Z-factor > 0.5 
 Positive control  
6 Relative induction for Methyl testosterone > 30% 
 Negative control  
7 Relative induction for Corticosterone < 10% 
 
Table 4: Acceptance criteria in the antagonist assay 
No Acceptance criterium Value 
 Reference chemical Flutamide  
1 Curve fitting Sigmoidal 
2 IC50 range  1.10-7 – 1.10 -6 M 
3 CV of estimated log(IC50) < 3% 
4 Inhibition factor  > 10 
5 Z-factor > 0.5 
 Positive control  
6 Relative induction for Linuron < 60% 
 Negative control  
7 Relative induction for Levonorgestrel > 85% 
 
 
3.6 Assessment of the AR-CALUX method by EURL ECVAM's GLP test facility 
Prior to the start of the validation study, EURL ECVAM has analysed, evaluated and modified in 
collaboration with the test submitter, the SOP of the AR-CALUX method. This included a technical 
assessment (paper based) of the SOP(s) in terms of their scientific basis, completeness and clarity, as well as 
for their suitability to be implemented within a GLP environment. EURL ECVAM's GLP test facility has 
carried out a GLP study with the method and has generated GLP compliant test data which will serve as a 
reference data set when assessing the transferability of the method to the test facilities. The experimental 
assessment and the GLP compliant study have led to a number of changes in the SOP e.g. modified 
acceptance criteria, inclusion of statistical tools, inclusion of a specificity control for the antagonist assay, etc. 
(see Annex 3).  
The SOP version to be used for the training phase: SOP-ASY06-v03 
The SOP version to be used for the transfer phase (Study 1): SOP-ASY06-v04 
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4 MANAGEMENT OF THE VALIDATION STUDY 
4.1 Sponsor 
EURL ECVAM accepted the AR-CALUX method, submitted by BDS, for carrying out a validation study and 
initiated the organisation of the study. Hence, EURL ECVAM is the sponsor. 
EURL ECVAM will take responsibility for: 
 Provision of relevant documentation: For proper implementation of the test method EURL ECVAM
will provide a complete SOP for all parts of the method, raw data recording forms, respective data
analysis forms, as well as an aid for planning and reporting (Study plan templates, Final report templates)
 Training on the in vitro method for the 3 participating test facilities at Ispra premises (conducted
February 10-13, 2015)
 Distribution of the test system to the participating test facilities (provided May 19 and June 16, 2015)
 Purchase and distribution of all reference chemicals, control chemicals and test chemicals to the 3 test
facilities; coding of the test chemicals (provided for Study 1 May 19 and June 16, 2015)
 Access to CIRCABC: Access will be provided to the test facilities for the EC database CIRCABC for
exchange of all documents (provided February 10-13, 2015).
 An independent data analysis and statistical support based on the Final reports generated by the 3
participating test facilities
 Publication of the method: At the end of the validation study, the final version of the SOP will be
prepared in a format fit for public dissemination through EURL ECVAM's database on alternative
methods, DB-ALM.
 Harmonisation and standardisation of in vitro methods: When the outcome of the validation study is
successful, the validation report will be sent to ESAC who provides an opinion on the fitness of the
method. Based on this input, EURL ECVAM will formulate a recommendation on the AR-CALUX in
vitro method and the outcome will be further elaborated in support of the development of an OECD
PBTG for ARTAs and Performance Standards
The 3 test facilities that participate in this validation study are responsible for covering the costs of their staff, 
costs of travel and subsistence for training and meeting(s), and costs of all experimentally related activities 
(e.g. cell culture medium, reagents, kits). 
Sponsor Address 
Maurice Whelan 
Email: Maurice. Whelan@ec.europa.eu 
The EU Reference Laboratory for Alternatives to Animal Testing 
(EURL ECVAM) 
European Commission Joint Research Centre 
Institute for Health and Consumer Protection 
Via E. Fermi, 2749 
I-21027 Ispra, Italy
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4.2 Coordination 
EURL ECVAM takes care of the coordination of the AR-CALUX validation study and has appointed a 
validation study coordinator for this particular trial. The coordinator will be supported by an EURL ECVAM 
biostatistician on a permanent basis and can at any moment, and when deemed necessary, asks for additional 
support from specific persons with appropriate knowledge in certain topics (e.g. the EURL ECVAM study 
director who assessed the test method, the Chemical Selection Team, the test method submitter etc.). 
The tasks of the coordinator are the following: 
 Establishing of and interacting with the VMG (see section 4.3);
 Establishing of and interacting with the Chemical Selection Team;
 Contact point for the managers of the 3 participating test facilities;
 Central point for receipt and/or distribution of all information, documentation and data between all parties
involved in the validation study;
 Drafting of the validation project plan with assistance of the biostatistician for the validation study design;
 Review, with assistance of the biostatistician, the Study plans and the Final reports from the test facilities
prior to providing them to the external members of the VMG;
 As part of the VMG, assessing and documenting the impact of any amendments and/or deviations in the
Study Plans on the quality and integrity of the ring trial;
 Preparing the draft validation report for review and approval by all VMG members;
 Preparing with all members of VMG the draft Performance Standards, draft EURL ECVAM
recommendations and a draft PBTG for ARTAs;
 Preparing the final version of the SOP and ensuring its publication in DB-ALM
A Chemicals Selection Team has been established including EURL ECVAM staff. The tasks of the Chemical 
Selection team are the following: 
 Compilation of a list of relevant test chemicals
 Solubility and stability assessment of the test chemicals
 Purchase, coding and distribution of all reference/control/test chemicals to the participating test facilities
4.3 Validation Management Group (VMG) 
The VMG encompasses collective expertise with similar test systems and test methods, within the field of 
developmental and reproductive toxicology, with the validation process of test methods and with 
management and evaluation of a validation study.  
The VMG for the AR-CALUX validation study will consist of external experts in the field, the validation 
study coordinator, the biostatistician from EURL ECVAM and representatives of the ICATM validation 
bodies. The latter ones do not participate in the decision-making of the VMG. 
The VMG will provide oversight on the validation study. Its responsibilities are defined in a Terms of 
Reference, and include: 
 To review and approve the validation project plan in all its components (objectives, validation study
design, organisation, statistical analysis methods, list of chemicals to be tested, the SOP to be
implemented);
 To monitor progress through setting key milestones and reviewing the results of the test facilities and to
provide assistance in troubleshooting when need be;
 To manage deviations to the validation study;
 To interpret the validation results and formulation of conclusions;
 To assist, review and approve the validation report;
 To assist in the drafting of the EURL ECVAM recommendation and the PBTG for ARTAs.
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Composition of the AR-CALUX VMG 
Name Role and expertise Affiliation 
EURL ECVAM members 
Anne Milcamps  Coordinator  
EURL ECVAM, Ispra, Italy 
Email: anne.milcamps@ec.europa.eu 
Phone: +39 0332785244 
Roman Liska  
Data analysis and preparation of 
biostatistics dossier 
EURL ECVAM, Ispra, Italy 
Email: roman.liska@ec.europa.eu 
External members 
Warren Casey 
Director NICEATM  
Expertise in toxicology, EDs, validation 
NIEHS/NICEATM, Research Triangle Park, 
North Carolina, USA 
Email: warren.casey@nih.gov 
Matt Dent 
Safety science leader 
Expertise in toxicology and risk 
assessment 
Unilever, Colworth Science Park, Bedford, 
UK 
Email: matthew.dent@unilever.com 
Jenny Odum 
Independent consultant toxicologist 
Expertise in toxicology, EDs, validation 
Stockport, UK 
Email: jenny.odum@regulatoryscience.com 
 
Representatives of ICATM bodies: to be nominated. 
 
 
4.4 Lines of communication 
In order to have a uniform distribution of information to all parties, each test facility is requested not to 
engage in any contact with the other test facilities neither with the test submitter nor with the VMG or any 
other third party during the course of the validation study. Such has also been stipulated in the signed 
collaboration agreements. All flow of information, data, inquiries, requests from each of the 3 participating 
test facilities, the VMG or the test submitter shall therefore go through one central contact point: the 
validation study coordinator.  
For the daily business, a designated email address for the validation study has been established: JRC-
ECVAM-NETVAL@ec.europa.eu. Details of the coordinator for phone calls have been provided in section 
4.3. Video-conferences can be arranged on a need be basis. 
The AR-CALUX validation study will make use of the European Commission's data application CIRCABC, 
a free and open source software for the creation of a collaborative workspace between geographically 
dispersed teams, that allows viewing, uploading, downloading, updating and copying of information. Test 
facility and the VMG members will be granted access to a specific workspace in CIRCABC (via password 
protected access) to which only the coordinator, the side manager and the EU-NETVAL coordinator have 
access. Each test facility and the VMG will have its own private space. This tool will be used for exchange 
of documents and data between the coordinator and the manager of each of the 3 participating test facilities, 
and, between the coordinator and the VMG. Whenever a document is uploaded, notice of insertion is 
automatically provided to the coordinator.   
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5 PARTICIPATING EU-NETVAL TEST FACILITES 
5.1 EU-NETVAL and procedure of selection 
EU-NETVAL was established in January 2014. It comprises 25 labs of the EU and EURL ECVAM's GLP 
test facility. Its tasks and responsibilities are formulated within a ToR with primary focus on the participation 
in a validation study. 
Beginning 2014, an invitation to the EU-NETVAL members for participation in the AR-CALUX validation 
study was launched. Several test facilities met the requirements and were ranked on the basis of a 
communicated selection procedure. The 3 highest ranked facilities were approved by the EU Member States 
via the National Contact Points. Collaboration agreements have been put in place between the JRC and each 
of the 3 participating test facilities.  
 
5.2 The 3 participating EU-NETVAL members 
 EU-NETVAL member / GLP test facility Country 
1 SP Technical Research Institute Sweden 
 Address: SP Sveriges Tekniska Forskningsinstitut Medicinteknik (KMm) Brinellgatan 4,  
501 15 Boras 
 
Test facility manager: Benny Lyven 
Study director: Emma Pedersen(*) 
Study personnel: Kristina Fant 
Study personnel: Lovisa Ringstad  
Study personnel: Jenny Johansson 
(*) Will be leaving October 2015 and replaced by K. Fant 
 
Email: benny.lyven@sp.se 
Email: emma.pedersen@sp.se 
Email: kristina.fant@sp.se 
 
2 CiToxLAB France 
 Address: CiToxLAB, BP 563, 27005 Evreux Cedex  
Test facility manager: in replacement 
Study director: Mylene Valin 
Study personnel: Rachel Larcier 
Study personnel: Megane Auvray 
 
Email:mylene.valin@fr.citoxlab.com 
3 Huntingdon UK 
 Address: Huntingdon Life Sciences Limited, Woolley Road, Alconbury, Huntingdon, 
Cambridgeshire, PE28 4HS 
 
Test facility manager: Leslie Akhurst 
Study director: Joanne Hubbard 
Study personnel: Joanne Kelsall 
Email: AkhurstL@UKOrg.Huntingdon.com 
Email: HubbardJ@UKOrg.Huntingdon.com 
Email: KelsallJ@UKOrg.Huntingdon.com 
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6 TEST CHEMICALS AND TEST SYSTEM 
6.1 Selection procedure of the test chemicals 
A list of 83 chemicals, and their reported classification as positive or negative (anti)androgen, was compiled 
on the basis of several data sources: literature (Araki et al, 2005; Freyburger et al, 2012; Van der Burg et al, 
2010; ICCVAM, 2003), Tox21 ARTA assay data, in-house high throughput screening data for the AR-
CALUX method, QSAR. The list was shared for an expert consultation and provided to all members of the 
VMG-NA in 2013, ICATM contact points and other experts. Details on the composition of this list can be 
found in the Report on the Chemical Selection (see Annex 2).  
From the list of 83 chemicals, a subset of 45 chemicals was selected for the AR-CALUX validation study, 
aiming at a balanced set of agonist, antagonist and negative chemicals (about 15 for each class). The criteria 
listed below were considered:  
 Dose responses and classifications  
 Availability and price  
 Solubility as stock solution and as working solution (in cell medium).   
 Potency  
 Structural diversity  
 Glucocorticoid receptor crosstalk  
 Requests from the VMG-NA 
 
Details on the selection strategy are outlined in the Report on the Chemical Selection (see Annex 2).  
 
The requests from VMG-NA at the meeting of December 2014 were taken into consideration. Amongst the 
chemicals with antagonistic response, an inclusion of pure (true) antagonists, unspecific (false) antagonists 
and SARMs (selective androgen receptor modulator) could be aimed for.  
o Chemicals with unspecific antagonist behaviour are those that do not compete for binding at the 
androgen receptor but interfere with the generation of the reporter enzyme (at the level of 
transcriptional activation, transcription, translation, stability). Few such chemicals have been 
described for ERTAs though for ARTAs not much (yet) is reported. Possible candidates will be 
discussed with the AR-CALUX VMG. 
o SARMs are molecules with a tissue selective activation of androgenic signalling. Examples of 
selective estrogen receptor modulator are known, though few information exists for SARM. In the 
original list of 83 chemicals, few could be found reported as agonist in certain assays (cell lines) 
while antagonist in other assays (cell lines) and hence could be potential SARMS. At the VMG-NA 
meeting of December 2014, the members proposed to include this type of chemicals. Possible 
candidates will be discussed with the AR-CALUX VMG. 
Overlap with the test chemicals of the Japanese ARTA (under validation) and the Korean ARTA (for which 
data were presented at the VMG-NA meeting Dec. 2014) was evaluated. During the course of drafting this 
validation project plan, the identity of the chemicals tested in these 2 ARTAs became available.  
o Most of the 15 chemicals from the Japanese ARTA list were already part of the selected 45 subset 
for AR-CALUX. Four have been added of which one is currently analysed in-house to check if its 
solubility is sufficiently high to be tested. The chemical R1881 was excluded (drug banned in several 
countries). 
o Of the 20 chemicals from the Korean presented study, several were already included in the subset for 
AR-CALUX. Three of that list could be interesting to be tested (described as agonist and dual 
behaviour) though information (data) are needed as well as solubility testing. 
 
 
The list of the subset of chemicals for the AR-CALUX validation is shown in Annex 1. This list currently 
includes 49 chemicals (including the reference and positive control chemicals for the AR-CALUX assay), 
and, 3 additional chemicals to be considered for inclusion.  
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6.2 Procurement and solubility testing of the test chemicals 
EURL ECVAM will be responsible for the acquisition of all chemicals (including reference and control 
chemicals). Previous validation studies at EURL ECVAM have shown that in many occasions the 
participating test facilities have solubility issues what leads to extra work, more consumption of chemicals, 
and significant time loss. Moreover, solubility testing usually relies on visual inspection which is rather 
subjective. For the AR-CALUX validation study, it was decided to measure in an objective manner (via 
nephelometry) the solubility of all the test chemicals at a maximal concentration of 50 mg/ml in the solvent 
DMSO or water and at the working concentration (1000 x diluted) in assay medium. Also the stability of the 
solubilised chemical over time was investigated (24 hours of incubation mimicking the test conditions of the 
SOP).  
For Study 2, the 3 labs will perform a solubility test with a SOP to be prepared by EURL-ECVAM. On the 
basis of the obtained results, a decision will be taken if further solubility testing for the test items of Study 3 
are needed. Chemicals will be tested at 50, 15 or 5 g/ml assay medium. Alternatively, the participating test 
facilities could be provided with information for the type of solvent to use and the maximal concentration to 
be prepared for their test chemicals  
 
6.3 Distribution and handling of the test/reference and control chemicals  
EURL-ECVAM will be responsible for chemical distribution to the participating laboratories (including 
reference and control items) assigning a unique random identity code to replicate test chemical aliquots. The 
vial labels will also include a cautionary toxic indication. 
In compliance with IATA (International Air Transport Association) regulations, the chemicals will be sent 
with MSDS copies enclosed in a single envelope, including a list of corresponding codes, indicated for 
customs use only.  
Relevant to remedial procedures at a test facility in case of accident or emergency, duplicate MSDS copies 
will also be included, sealed individually in opaque envelopes identified by code. Consultation of a particular 
MSDS, for reasons of safety only, would be reported as a study deviation. At the end of the validation study, 
the Safety Officer shall return the unopened MSDSs to the validation study coordinator. 
The test chemicals will be addressed to nominated personnel, informing them of imminent arrival (e-mail) 
and requesting acknowledgement of receipt confirming (or otherwise) integrity of the MSDS envelopes.  
The consignment will include a checklist of the test chemicals, including expiry dates, storage conditions, 
and material weight. The list will also indicate appropriate stock solution concentrations (and solvent) based 
on solubility determinations at EURL ECVAM, with summary preparation procedure. In addition, there will 
be a Chemicals Receipt Form to be signed and returned (via CIRCABC). 
Test Facility personnel shall be instructed to treat all coded test chemicals as potential EDs.   
 
6.4 Test system   
The test system constitutes of AR-CALUX® cells developed by the Dutch company BDS. EURL ECVAM 
has prepared a cell bank of this test system for distribution to the test facilities. Each test facility will receive 
at the onset of the trial 6 vials of frozen cells: one vial to be used to practice with the cells and the method, 
one vial for the cultivation of cells for Study 1, one vial for Study 2, two vials for Study 3, and an extra vial. 
The cells have been tested for purity by EURL ECVAM: 1) the absence of Hepatitis B and C, and HIV 1 and 
2; 2) the absence of mycoplasma; 3) authenticity: the absence of cross contamination from other cell lines 
(STR profiling). A Certificate of Analysis shall be provided with the shipment of the cells. Upon receipt, 
each test facility is requested to complete and return a Test System Receipt Form (via CIRCABC). 
Upon arrival of the cells, the internal procedures related to test system/mycoplasma testing prior to the 
initiation of a study and at completion of a study, should be followed.  
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6.5 Return of the test system and test chemicals to EURL ECVAM 
Each test facility commits to freeze down 2 vials of cells from the highest passage number for each of the cell 
vials used for the experimental testing phases. At the end of each study (Study 1, Study 2 and Study 3) the 
test facilities are requested to send these 2 vials to EURL ECVAM where they will be used for 
characterisation purposes.  
The test facility agrees not to use the test system for any other purposes than described in the validation 
project plan and to destroy the remaining test system (frozen or in culture) not later than 4 weeks after the 
completion of the validation study. The coordinator will communicate when the validation study is officially 
completed. 
Each test facility is also requested to keep the remainder, if any, of the test chemicals until the end of the 
validation study and all data have been analysed. In case of problematic results for a specific test chemical, 
EURL ECVAM may request to return the test chemical. At the end of the validation study, all chemicals 
should be disposed of according to the test facilities internal procedures.  
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7 VALIDATON STUDY DESIGN  
The following sections describe the experimental activities to be undertaken by the 3 participating test 
facilities.  
7.1 Participation in training 
Training for the 3 test facilities was carried out in February 10-13, 2015. This training was provided by EURL 
ECVAM, assisted by the test submitter, and aimed at an appropriate implementation of the AR-CALUX 
method by all participating test facilities in order to achieve a standardised and harmonised application of the 
method across the facilities.  
Staff of each participating test facility (Study Director and Study Personnel) was invited to receive training. 
It is mandatory that the staff trained will be those managing and executing the experimental work as 
described below.  
During the training, each test facility received all necessary documentation from EURL ECVAM for 
implementation of the AR-CALUX method (e.g. Standard Operating Procedure (SOP), related Data Analysis 
Forms). The training covered practical and theoretical sessions, e.g. hands-on execution of critical steps in 
the SOP, a correct compilation of the Data Analysis Forms, guidance on data analysis and acceptance 
criteria, information and awareness on critical steps, sharing of experiences and trouble shooting, usage of 
CIRCABC. At the end of the training, the required experience was tested via a questionnaire and a certificate 
was handed out.  
In the undesirable event that a test facility changes staff during the ring trial, the training and demonstration 
of competence of the new staff member(s) to correctly implement the method will be under the responsibility 
of the test facility. EURL ECVAM will need to be informed immediately and all relevant details should be 
reported in the Study plan and/or Study report. 
After the training, the test facilities have been asked for critical observations and comments on the SOP. The 
comments received have been considered for the updated version of the original SOP. 
 
7.2 Study 1: Transfer of the AR-CALUX method to the EU-NETVAL test facility 
The AR-CALUX method will be implemented by each test facility in its own laboratory. For this Study, 6 
non-blinded test chemicals will be tested (defined by EURL ECVAM). Prior to the initiation of the 
experimental work, a Study Plan template will be provided by EURL ECVAM to facilitate the drafting of the 
Draft Study plan by each test facility. This Draft Study plan will be provided to the coordinator for review 
and feedback. The finalised and signed Study plan shall be sent to the coordinator. 
The testing regime for the transfer phase will be identical to the regime required for Study 2 and Study 3 
(described in section 7.5).   
After completion of the experimental work, the results shall be reported with Data Analysis Forms and with 
a Draft Final report, to be send to the coordinator. The VMG will evaluate the results. Feedback on the Draft 
Final Report will be provided and the Final report can be completed by the test facility, and returned to the 
coordinator. 
Success of the transfer of the AR-CALUX method will be concluded on the basis of the criteria defined by 
VMG for a successful transfer. 
VMG will evaluate the data from the transfer phase from all 3 test facilities, as well as the observations made 
by the test facilities when implementing the in vitro method. Such will lead to conclusions regarding the 
robustness of the SOP. If deemed necessary, amendments may be made to the SOP. The test facilities will be 
informed regarding: 
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 Continuation (or not) of the validation study and to proceed to Study 2. 
 Any minor amendments to the SOP if deemed necessary and a new version of the SOP will be 
provided. 
The test facilities are requested to wait for the feedback from the coordinator before proceeding to Study 2.  
In case the results of the transfer phase would be exceptionally out of range, a face-to-face meeting of the 
test facilities with EURL ECVAM may be needed to discuss the data. Such meeting would last a maximum 
of one day.  
 
7.3 Study 2: Generation of data sets for the assessment of reproducibility (within and between 
laboratory) of the AR-CALUX method  
Assessment of reproducibility involves the generation of data sets under blinded conditions by applying the 
in vitro method to coded chemicals. Study 2 will consist of testing about 10 test chemicals (defined by the 
VMG). The exact number of chemicals to be tested will be communicated to the test facility upon 
completion of Study 1. 
Prior to the initiation of the experimental phase, the test facility will prepare a Draft Study plan to be 
provided to the coordinator for verification. Experimental work shall be carried out in accordance with the 
SOP and according to the testing regime as described in section 7.5.  
After finalisation of the experimental work, the following shall be provided to the coordinator: completed 
Data Analysis Forms and a Draft Final report. Feedback on the Draft report will be provided and the Final 
report can be completed by the test facility, and returned to the coordinator.  
The results (per test facility and between test facilities) will be discussed within the VMG. On the basis of 
the VMG conclusions, each test facility will be informed regarding: 
 Continuation (or not) of the validation study and to proceed to Study 3. 
 Any minor amendments to the SOP if deemed necessary.  
The test facilities are requested to wait for the feedback from the coordinator before proceeding to Study 3 
 
7.4 Study 3: Generation of data sets for the assessment of the predictive capacity and applicability 
domain of the AR-CALUX method 
Assessment of predictive capacity and applicability domain essentially involves the testing of a sufficiently 
large number of test chemicals to determine the accuracy of the method to detect agonist/antagonist activity 
of a test chemical. This study will consist of the testing of 30 to 50 chemicals (defined by the VMG). The 
exact number of chemicals to be tested will be communicated to the facility upon completion of Study 2. 
Prior to the initiation of the experimental phase, the test facility will prepare a Draft Study plan, to be 
provided to the coordinator for verification. Experimental work shall be carried out as described for Study 2. 
The reporting will be similar as described in Study 2.  
The results (per test facility and between test facilities) will be discussed within the VMG and conclusions 
will be drawn. When Study 3 is finalised by the 3 participating test facilities, all test facilities will be invited 
to a meeting at the JRC (Ispra, Italy, in order to present their results to the VMG. The overall outcome of the 
work, issues that arose, conclusions to be drawn from the validation study will be discussed.   
This meeting will last a maximum of one and a half days.  
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7.5 General work flow (testing regime) for Study 1, Study 2 and Study 3 
Each test chemical shall be tested with both agonist assay and antagonist assay. 
The testing regime for each test chemical typically consists out of pre-screen experiments followed by 
comprehensive testing for the generation of 3 valid data sets. This regime, including biological replicates and 
decisions to proceed to comprehensive testing, is presented in figure 1 and applies to each Study in this ring 
trial. For each study, the testing regime will be detailed in the Study plan.  
Pre-screen 
Pre-screen experiments are carried out to determine 1) if the test chemical displays a significant response 2) 
to determine the proper dose range, non-cytotoxic and soluble, for a test chemical showing a response (full 
or partial). The determination of a response being significant is imbedded in the Data Analysis Forms and 
relies on a Anova Test. For the dose range finding, the pre-screen will be carried out once (or more) to 
determine the appropriate range to be tested in the subsequent comprehensive tests. There is no requirement 
for 3 valid runs at the stage of pre-screens. The data generated in the pre-screen need to fulfil the acceptance 
criteria for reference and control chemicals as described in the SOP (valid run). 
Exceptions on the above regime:  
 If in the pre-screen (agonist or antagonist assay) the chemical displays no response, there is no need 
to proceed to comprehensive testing but a total of 3 valid pre-screen experiments is required. In the 
event that the second or the third pre-screen experiment would however show response, proceed 
with comprehensive testing. 
 If in a pre-screen experiment for an agonist assay a full dose response can be captured and all 
parameters can be estimated, proceed nevertheless to comprehensive testing (refinement of the 
calculations). If however the comprehensive test would reveal that part of the dose response cannot 
be captured, pre-screen experiments are sufficient (3 valid runs). 
 If in a pre-screen experiment for an antagonist assay, the data show a full dose response and all 
parameters can be estimated, comprehensive testing is mandatory. 
 In certain cases where a pre-screen experiment (leading to a comprehensive test) reveals the dose 
range to be chosen but it is not a valid run, the pre-screen test can be accepted when the invalidity is 
unmistakably due to manual errors (e.g. pipetting error leading to a single outlier) and can be clearly 
evidenced. 
 
Comprehensive testing 
  
The comprehensive testing (for test chemicals that show a response) needs to include 3 valid experiments 
per test chemical. An experiment is valid when all acceptance criteria have been met. If it is practically 
difficult to meet the acceptance criteria (e.g. for a problematic test chemical), leading to invalidity of 
experiments, it will suffice to perform a maximum of six biological replicates irrespective of their validity. 
For each comprehensive test, 8 concentrations per test chemical are tested. Each concentration is tested 3 
times as defined by the plate layout for both agonist and antagonist testing. 
In case of an agonistic response, the testing will proceed as described above. In case of an antagonistic 
response (full or partial) each comprehensive test will be accompanied by a specificity control. This 
specificity control will give additional information not only for the specificity of the response, but also 
(indirectly) about the cytotoxic effect.  
Cytotoxicity tests (LDH) are included for all plates in the pre-screen experiments. For comprehensive testing 
it is sufficient to perform this only for the first run. In case of only pre-screen runs, it suffices to perform 2 
LDH tests. Visual inspection will be applied for all runs regardless if they are pre-screen or comprehensive.  
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Figure 1: Testing regime for the AR-CALUX method 
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8 DATA COLLECTION AND ANALYSIS  
8.1 Data collection 
EURL ECVAM has prepared and will distribute validated Data Analysis Forms for the collection and 
analysis of the data:  
 Form DAT02-ASY06 for the agonist assay (pre-screen and comprehensive testing) 
 Form DAT04-ASY06 for the antagonist assay (pre-screen) 
 Form DAT05-ASY06 for the antagonist assay (comprehensive testing and specificity control) 
 Form DAT06-ASY06 for cytotoxicity data recording   
  
The test facilities will receive the validated forms with a data set that must be used to verify the correct 
functioning of the Data Analysis Forms at the test facilities premises. The test facilities will have procedures 
in place for quality control of correctly reporting the generated data.  
The validation study coordinator and the EURL ECVAM biostatistician will retrieve all data in a controlled 
manner (completed Data Analysis Forms, Draft Final reports and Final reports) of all test facilities via 
CIRCABC.   
 
8.2 Acceptance of data sets 
The test facility is required to provide all the obtained data, being either valid or invalid. "Valid" data sets are 
defined as data that are in accordance with the acceptance criteria of the AR-CALUX method. "Non valid" 
data sets are defined as the data from failed experiments (not meeting the acceptance criteria). The test facility 
is requested to report the measures that have been taken to overcome any failure to meet the acceptance 
criteria. Such can be reported in the Final report.  
 
8.3 Data analysis  
Upon receipt of the Final report and the completed Data Analysis Forms from each test facility, a 
completeness check will be carried out by EURL ECVAM with which will be verified that all Data Analysis 
Forms for all valid and invalid experiments are submitted with the Final report, and, that the parameters 
reported in the Final report correspond to the parameters calculated in the Data Analysis Forms. 
 
The EURL ECVAM biostatistician will provide statistical evaluation of all 3 studies on the basis of the 
following criteria:  
 The number of valid/invalid runs (acceptance criteria met or not) and the reasons for invalidity 
 Similarity of the obtained patterns (dose responses)  
 EC50/IC50 estimates of reference and test chemicals (where possible) and its variability 
 Comparison to data generated during EURL ECVAM's GLP study ST57 (especially for Study 1) 
 
The determination of reproducibility within laboratory (WLR) and between laboratories (BLR) will be based 
on a classifier to determine agonist and antagonist behaviour. The classifier is developed by EURL ECVAM, 
in collaboration with the test submitter, and includes a criterion for the specificity control to be applied in the 
antagonist assay. This classifier will be introduced in the SOP before Study 3 will start.  
The evaluation made by the biostatistician will be in the form a statistical report for each study (Study 1, 2, 
and 3). The report will be mainly based on 
 The results presented per test facility in their Final reports  
 An analysis of the data per study merged from the data provided by the 3 test facilities 
The statistical reports will be discussed with VMG. 
A final statistical report will be assembled, based on the statistical reports made for Study 1, 2 and 3. The 
main purpose will be to provide overall information about WLR, BLR and predictive performance of the 
AR- CALUX method.   
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9 RECORDS, OUTPUT, AND ARCHIVING 
9.1 The SOP 
EURL ECVAM will provide the SOP version to be used in the validation study. A GLP test facility may want 
to use its own in house template for the SOP. Based on the results of Study 1, the SOP may be subject to 
modifications in which case a new version will be issued. At the end of the validation study, and as a result of 
the observations during the validation, the SOP may be further modified. A final SOP version will be prepared 
by the coordinator for publication in DB-ALM.  
 
9.2 Study Plans 
Before starting Study 1, 2 or 3, a Draft Study plan has to be prepared by each test facility for each Study and 
be sent to the validation study coordinator for review. An example of a Study plan will be provided by EURL 
ECVAM. A GLP test facility may want to use its own in house template. After approval of the Draft Study 
plan, the test facility can finalise its Study plan (dated, signed and uploaded in CIRCABC) and may 
commence the experimental part.  
 
9.3 Raw Data Recording Forms 
EURL ECVAM will provide raw data recording forms together with the AR-CALUX SOP-ASY06. Test 
facilities may use their own developed forms, as long as the raw data requested in the SOP are recorded. 
These forms should be stored and archived by the test facility according to the provisions of their quality 
system. 
 
9.4 Data Analysis Forms 
Data Analysis Forms are the main manner of recording the obtained data. All information on the test items 
and the experiment, including test item ID, concentrations, plate numbers, cytotoxicity, non-solubility, RLU 
values, observations etc. are collected in these forms. Validated forms are provided by EURL ECVAM. Each 
test facility will validate the received Data Analysis Forms according to their internal procedures. For this 
purpose, a dedicated set of data will be provided by EURL ECVAM.   
For each study, the Data Analysis Forms need to be completed and to be sent, together with the Draft Final 
report, to the validation study coordinator.  
 
9.5 Final Reports 
If requested, an example of a Final report will be made available by EURL ECVAM. The GLP test facilities 
may want to use their own in house templates. At the end of each study, a Draft Final report will be prepared 
and provided to the validation study coordinator. VMG will provide comments in due time, hence a Final 
report can be prepared and returned to the coordinator.  
The results from the experiments (valid and invalid) shall be reported as a summary based on the Data 
Analysis Forms. Any observation during the planning and implementation of the studies shall be reported as 
well as, and if appropriate, recommendations on the performance of the in vitro method and the suitability of 
the protocols from the participating test facility perspective. In addition, any deviations and/or amendments 
from the original Study plan or the EURL ECVAM SOP(s) have to be reported.  
 
9.6 Validation Report 
A draft Validation report is prepared by the coordinator, based on the Final reports of the 3 test facilities and 
complemented with the overall data analysis from the biostatistician. Such report will be analysed and 
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reviewed by VMG and needs final approval from the VMG. The finalised Validation report will be shared 
with the test facilities and the test submitter. 
9.7 Archiving 
Raw and processed data produced in each GLP test facility shall be stored and archived in the individual 
GLP test facilities according to their GLP procedures.  
The documentation provided by the 3 GLP test facilities in CIRCABC (verified electronic copies of Draft 
Study plans, Study plans, Draft Final report, Final reports, completed Data Analysis Forms) will be retrieved 
by EURL ECVAM and safely stored. All SOP versions, the Validation project plan and the Validation report 
will also be archived. 
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10 TIME SCHEDULE AND OVERVIEW DELIVERABLES 
The timeframe for the completion of all experimental tasks is 18 months. The indicative time schedule is as 
follows: 
 
Months Tasks 
EURL ECVAM 
Deliverables/Actions 
Test facility  
Deliverables 
1 Training  
 Training Certificates    
2– 6 
Study 1. 
Transfer of the in vitro method to 
the EU-NETVAL test facility 
 Shipment of test system and 
chemicals 
 Validation project plan 
 Template Study plan  
 Template Final report 
 Data analysis report on of the 3 test 
facilities  
 Assessment of transferability and 
admission to Study 2  
 
 Approved Study plan on the 
transferability 
 Completed Data Analysis 
Forms  
 Final report verified by test 
facilities QA 
7 - 10  
 
Study 2. 
Generating data for the 
assessment of the 
reproducibility (within- and 
between laboratory) of the AR-
CALUX method 
 Shipment of coded chemicals 
 Data analysis report on Study 2 of 
the 3 test facilities 
 Assessment of the reproducibility 
and admission to Study 3 
 
 Approved Study plan  
 Completed Data Analysis 
Forms   
 Final report verified by test 
facilities QA 
 
11 – 18 
 
 
Study 3. 
Generating data for the 
assessment of the 
reproducibility (within- and 
between laboratory) and for the 
assessment of the predictive 
capacity and applicability 
domain of the AR-CALUX 
method 
 Shipment of coded chemicals 
 Data analysis report of the 3 test 
facilities  
 Assessment of the reproducibility 
(within- and between laboratory) 
and predictive capacity of all data 
generated in studies 1, 2 and 3 
 Approved Study plan  
 Completed Data Analysis 
Forms   
 Final report verified by test 
facilities QA 
 
19-22   
 AR-CALUX Validation report 
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11 PERFORMANCE OF WORK AND QUALITY ASSURANCE 
The GLP test facility should make all effort to ensure that the experimental work for the Studies 1 to 3 is 
performed using the same equipment, the same reagents (i.e. of the same supplier and the same batch) and 
the same staff for testing of all the test chemicals during the entire duration of the validation trial. Change of 
equipment, reagents or/and staff has to be reported in the Study plan or Final report(s) of the studies 
concerned. 
Each GLP test facility shall work according to their quality control procedures relating to the correct data 
reporting. 
Any deviations or amendments that the study director considers critical to the progress of the study should be 
reported to the coordinator. 
EURL ECVAM will inform the test facility in due time if GLP compliant studies are needed. In case of GLP 
compliant studies, a copy of the QA statement must be provided.   
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Annex 1: Update of the validation project plan 
Date of discussion with VMG: 21-12-2015 
1. Test chemicals for Study 2A (10 coded test chemicals) 
Seq. 
# 
Chemical name 
1 17β-Trenbolone 
2 Stanozolol 
3 Spironolactone 
4 Medroxyprogesterone acetate 
5 Bisphenol A 
6 Bicalutamide 
7 Disulfiram 
8 Tamoxifen 
9 Atrazine 
10 17α-Ethynyl estradiol 
 
Disulfiram was included as a potential false positive antagonist. Such behaviour was observed in the Tox21 
assay luc where it displayed its antagonist activity at concentrations that were not scored as cytotoxic. 
 
2. Solubility testing: Protocol  
A simple protocol was developed by EURL ECVAM (see below) based on visual inspection, to be used for 
the testing of the 10 test items for study 2.   
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Solubility Determination by Visual Inspection 
applicable to 'Transactivation assay for the detection of compounds with  
(anti)androgenic potential using AR-CALUX® cells' 
 
 
Standard Operating Procedure 
 
 
 
 
 
 
ID Version Date 
SOP-ASY15 Version 1 23/05/2016 
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Author 
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Review 
(Lead laboratory) 
Dr. Ingrid Langezaal 
 
  
Approval 
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1. PURPOSE AND APPLICABILITY 
This standard operating procedure (SOP) describes chemical solubility determination based on 
visual inspection, applicable to 'Transactivation assay for the detection of compounds with 
(anti)androgenic potential using AR-CALUX® cells'. 
The purpose is to assess stock solution solubility in solvent, with observation of stability on dilution 
(500-fold interim and 1000-fold complete) in medium, including 24 hours incubation equivalent to 
the conditions of assay cell culture/test item exposure. 
The solvent is DMSO (commonly applicable) with water as alternative (for inorganic salts).  
Solubility determination in solvent is based on visual inspection for signs of turbidity due to solid 
particulate or liquid droplet suspension. 
Stability determination in medium, where observation of dissolution may be obscured by foaming, 
is assisted by centrifugation to detect any insoluble suspension as a sediment deposit. Solubility in 
medium is also checked by microscope examination of a droplet. 
An overview (flowchart) of the procedure is included in Annex (section 3). 
 
 Definitions and Abbreviations 
Three trial concentrations are prescribed1 (abbreviated as C50, C15, C5): 
C50 
Solvent stock solution concentration: 50mg/mL 
Medium 1000-fold dilution concentration: 50μg/mL 
C15 
Solvent stock solution concentration: 15mg/mL 
Medium 1000-fold dilution concentration: 15μg/mL 
C5 
Solvent stock solution concentration: 5mg/mL 
Medium 1000-fold dilution concentration: 5μg/mL 
 
 
                                                 
1 in event of insolubility at C5, further 3-fold dilutions may be considered (i.e., C1.5, C0.5, C0.15) 
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2. PROCEDURE 
 Materials 
-  Balance (1 decimal place, mg) (with printer, optional). 
-  Vortex mixer. 
-  Ultrasonic water bath. 
-  Thermal water bath (37°C). 
-  Incubator (37°C, 5% CO2). 
-  Centrifuge (fixed head for spin at 10,000g). 
-  Microscope, for observation of clarity/turbidity of medium droplets. 
- Microplate (96-well flat-bottom, preferably seal wrapped individually to minimise interference 
from dust etc.) for observation of sample medium droplets. 
-  Clear glass vials (7mL size) with caps, for test item weighing and stock solutions. 
- Test tubes (clear plastic, 15mL size) with caps, for medium dilutions and incubation. 
-  Test tubes (clear plastic, 50mL size) with caps, for medium handling. 
-  Centrifuge tubes (conical, clear plastic, 1.5mL size).  
-  Micro-pipettes (ranges: 2 – 20μL; 10 – 100μL; 100 – 1000μL). 
-  Pipette (5mL). 
-  Polyfoam floating tube racks (suitable for the 7mL glass vials and 50mL test tubes). 
-  FRM01-ASY15: Stock Solution Solubility: Reporting Form. 
-  FRM02-ASY15: Medium Dilution Stability: Reporting Form. 
 Solubility in solvent (stock solutions) 
Note: Soluble stock solutions should be used for medium stability testing within 24 hours. 
1.  Add DMSO solvent to a weighed amount of test item in a clear glass vial (7mL size) sufficient 
for visual inspection of solubility, starting at the upper concentration, C50 (minimum weight: 
25mg, minimum volume: 0.5mL). Usually, several test items (e.g., 6) would be prepared 
together as a series. 
The chemical weight and solvent volume are calculated according to:  
Volume solvent [μL] =  
Weight chemical [mg] ∗ 1000
Concentration required [mg/mL]
 
2.  Record the test item weight(s) and solvent volume(s) on respective Form(s) FRM01-ASY15. 
3. Vortex mix 
3.1 Vortex mix for 1 minute (repeating, if appropriate) with visual check for dissolution against 
a suitable background illumination/contrast. A black background is recommended for 
effective observation of white suspension. 
3.2 If the test item is already soluble, indicate the vortex time and result (FRM01-ASY15) and 
set the solution aside for stability determination in medium (section 2.3). 
4. Ultrasonic immersion (for crystal disaggregation) 
4.1 If not completely soluble after vortex mixing, immerse the vials in the ultrasonic water bath 
for 15 minutes, supported in a polyfoam floating tube rack. 
4.2. Repeat the vortex mix for 10 seconds to ensure homogeneity, with visual check for 
dissolution against a suitable background illumination/contrast. 
4.3. If the test item is now soluble, indicate the sonication time and result (FRM01-ASY15) and 
set the solution aside for stability determination in medium (section 2.3). 
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5. Thermal immersion (to accelerate kinetic delay) 
5.1.  If not completely soluble after sonication, immerse the vials in the thermal water bath at 
37°C for 30 minutes, retained in the same polyfoam rack. NB: Also allow the mixture to 
cool for at least 30 minutes, checking for possible recrystallization. 
5.2. Repeat the vortex mix for 10 seconds to ensure homogeneity, with visual check for 
dissolution against a suitable background illumination/contrast. 
5.3. If the test item is now soluble, indicate the warming time and result (FRM01-ASY15) and 
set the solution aside for stability determination in medium (section 2.3). 
6. Solution standing (to ensure complete dissolution) 
6.1.  If the test item is evidently soluble but visible traces of undissolved material remain, allow 
the solution to stand at room temperature for 1 hour (approx.) to complete the dissolution. 
6.2. Repeat the vortex mix for 10 seconds to ensure homogeneity, with visual check for 
dissolution against a suitable background illumination/contrast. 
6.3. If the test item is now satisfactorily soluble, indicate the standing time (approx.) and result 
(FRM01-ASY15) and set the solution aside for stability determination in medium (section 
2.3). 
7. Stock solution insoluble at C50 
7.1 If the test item persists as insoluble at the upper concentration C50, then solubility is 
attempted at the intermediate concentration C15, preparing fresh stock solution. 
7.2 Repeat the above procedure (steps 1 – 6) using re-weighed test item, appropriate for 
concentration C15, recording weight(s) and volume(s) on respective Form(s) FRM01-
ASY15. 
8. Stock solution insoluble at C15 
8.1 If the test item persists as insoluble at the intermediate concentration C15, then solubility is 
attempted at the lower concentration C5, preparing fresh stock solution. 
8.2 Repeat the above procedure (steps 1 – 6) using re-weighed test item, appropriate for 
concentration C5, recording weight(s) and volume(s) on respective Form(s) FRM01-ASY15. 
9. If the test item is not soluble in DMSO, even at C5, repeat the above steps using water as 
alternative solvent (generally applicable for inorganic salts). In this case, compile another Form 
FRM01-ASY15. 
10. FRM01-ASY15 provides raw data for stock solution preparation and solubility (including, if 
applicable, confirmation of the duration of vortex mixing, sonication, warming and standing). 
FRM01-ASY15 also allows space for conclusion (e.g., C50 / C15 / C5 soluble, or C5 insoluble) 
and comment. 
 Stability in medium (with incubation) 
Note 1: Stability in medium is determined for interim (500-fold) and full (1000-fold) dilutions, 
including two time points for the latter: 
1) pre-incubation (time zero)  
2) post-incubation (24 hours).  
The observation at 500-fold dilution is for information only. 
Effective solubility is the highest concentration (C50, C15, C5) at 1000-fold dilution where no 
precipitation is observed at either time point. 
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Note 2: Although test items are generally soluble in solvent at C50, precipitation frequently occurs 
on aliquot addition to medium (dilution 500/1000-fold, pre/post-incubation).  
Therefore, medium stability testing of all soluble stock solution concentrations (in parallel) 
is standard procedure.  
Thus:  
- if stock solution is C50 soluble: medium stability tested at C50, C15 and C5;  
- if stock solution is C15 soluble: medium stability tested at C15 and C5;  
- if stock solution is C5 soluble only: medium stability tested at C5 only. 
1. Warm a sufficient volume of medium (10mL per test item, per concentration, and a blank) from 
its refrigerated storage temperature to 37°C in the thermal water bath, ready for use. 
2.  Pipette 10μL stock solution (highest available soluble concentration, determined according to 
section 2.2) to 5mL medium in 15mL clear plastic tubes (500-fold dilution) and vortex mix for 
10 seconds. 
3. Dilute the remaining stock solution (by simple addition of solvent) to the next lower 
concentration(s): 
For C15 stock solution, dilute the C50 stock 3.33-fold. 
For C5 stock solution, dilute the C15 stock 3-fold. 
Dilution volumes are calculated according to: 
Volume2 of solvent to add [μL] = Final Volume [μL] − Initial Volume [μL] 
where:  
Final Volume [μL] = Dilution Factor ∗ Initial Volume [μL] 
4.  Record the total and added solvent volumes (FRM01-ASY15). 
5.  Repeat the 500-fold medium dilution (step 2) for the lower concentration(s) of stock solution, 
prepared consecutively (steps 3 – 4) as applicable. 
6. Arrange an extra tube containing 10mL medium only, as reference blank. 
7. Transfer 950μL aliquot samples (including a blank) to 1.5mL clear plastic conical vials, for 
solubility determination (500-fold medium dilution) assisted by centrifugation. 
8. Pipette 50μL aliquot samples (including a blank) to a 96-well flat-bottom microplate, for 
solubility determination (500-fold medium dilution) assisted by microscopy. 
Note 3: For convenience, it is recommended to prepare the samples for centrifugation and 
microscopy together, enabling simultaneous observation. 
9. Centrifuge the vials (950μL aliquots) at 10,000g for 5 minutes at room temperature. 
10. Examine the microplates (50μL aliquots) under the microscope (e.g., 20X magnification) with 
reference to the blank, checking for occurrence of undissolved material, recording the solubility 
observations on respective Forms FRM02-ASY15. 
11. Check the centrifuge vials for occurrence of deposited precipitate (visible as a small speck or 
pellet) indicative of insolubility, alongside the blank for comparison, recording the solubility 
observations on respective Forms FRM02-ASY15. For effective observation of a white deposit, 
a contrasting black background is recommended. 
                                                 
2 rounded to nearest integer (μL). 
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12. Complete the dilution (1000-fold) by doubling the medium volume (4mL) remaining in the 
tube and vortex mix again for 10 seconds. 
13. Repeat steps 7 – 11 for pre-incubation solubility determination (1000-fold medium dilution, 
time zero). 
14. Incubate (37°C, 5% CO2) the medium dilutions (with tube caps loosened, blank included) for 
24 hours (approx.) equivalent to the conditions and duration of assay cell culture/test item 
exposure,  
15. Repeat the vortex mixing (10 seconds) and centrifugation (1000μL aliquots) with check for 
deposited precipitate, as post-incubation solubility determination (24 hours) recording the 
results (FRM02-ASY15). 
16. Repeat the microscope examination (50μL aliquot) as supplementary final solubility 
determination (24 hours) recording the results (FRM02-ASY15). 
17. From the two observations, pre- and post-incubation, note the effective solubility result 
(FRM02-ASY15). Effective solubility is the highest concentration (C50, C15, C5) at 1000-fold 
dilution where no precipitation is observed at either time point. 
18. FRM02-ASY15 provides raw data for medium dilution stability with incubation. FRM02-
ASY15 also allows space for comment / overall conclusion (e.g., explicit soluble 
concentration). 
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3. ANNEX 
Flowchart: solubility determination by visual inspection 
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Annex 2: Update of the validation project plan 
Date of discussion with VMG: 27-02-2017 
1. The experimental organisation of the studies was modified as indicated below, still following the 
modular approach as described by Hartung et al. Module 5 suggests assessing predictive capacity (PC) of the 
test method in one lab only instead of in all 3 laboratories. Such modification would benefit the time line of 
the validation study. BLR would be assessed on a total number of 20 test chemicals. 
As a consequence, the studies 1, 2 (10 coded chemicals) and 3 (36 coded chemicals) will be renamed as 
study 1 (no change), Study 2A (10 coded chemicals) and 2B (10 coded chemicals), Study 3 (26 coded 
chemicals). 
Study 1 (6 chemicals, transfer): to be carried out by all 3 laboratories ENVIGO, CitoxLAB and RISE. 
Study 2A (10 coded chemicals, WLR, BLR and PC):  
to be carried out by all 3 laboratories ENVIGO, CitoxLAB and RISE. 
Study 2B (10 coded chemicals, WLR, BLR and PC):  
to be carried out by all 3 laboratories ENVIGO, CitoxLAB and RISE.  
Study 3 (26 coded chemicals, WLR, PC):  
to be carried out by RISE 
 
2. Solubility testing  
The testing shall not be restricted to the chemicals of study 2A but shall be carried out for all test chemicals 
in this validation study.  
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Annex 3: Modification to the validation project plan 
Date of discussion with VMG: 21-12-2016 and 24-03-2017 
1. Modification of the SOP
1.1. Introduction of the criterion for the specificity control R2 
 True competitive antagonist: the coefficient of determination (R2) is less or equal to 0.9 for the linear
regression of relative induction of the test item's specificity control (Sc) versus the relative induction
(Yc).
 False competitive antagonist: the coefficient of determination (R2) is greater than 0.9 for the linear
regression of the relative induction of the test item's specificity control (Sc) versus the relative
induction (Yc).
1.2. Introduction of an acceptance criterion for the reference item flutamide when applying the specificity 
control. Table 4 becomes as follows: 
Table 4: Acceptance criteria in the antagonist assay 
No Acceptance criterium Value 
Reference chemical Flutamide 
1 Curve fitting Sigmoidal 
2 IC50 range 1.10-7 – 1.10 -6 M 
3 CV of estimated log(IC50) < 3% 
4 Inhibition factor > 10
5 Z-factor > 0.5
Positive control 
6 Relative induction for Linuron < 60% 
Negative control 
7 Relative induction for Levonorgestrel > 85%
8(*) 
R2 for the linear regression of Sc on Yc for 
Flutamide 
≤ 0.7 
(*) To be applied for assessment of the specificity response (Sc) of Flutamide 
1.3. Inclusion of the classifier in the SOP 
As decided at the onset of the validation study, a classifier was introduced in the last version of the SOP to 
be used by the laboratories. Hence a set of data would be generated where the laboratories could apply the 
classifier. The specificity control criterium R2 was included in the antagonist part of the classifier. For both 
agonist and antagonist parts, the option Inconclusive was included. The classifier was included in an updated 
version of the SOP (SOP V06). 
1.4. Progress of the validation study 
Given that the 3 laboratories have a different progress in the study, SOP V06 will be applied as follows: 
Study 2B 10 coded chemicals ENVIGO 
Study 2A and 2B 20 coded chemicals CitoxLAB 
Study 3 46 coded chemicals RISE 
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SOP V06 Section 2.5.4 Classification for agonist and antagonist properties 
 
Agonism 
 
For each run, a test item is considered  
 
A.  Positive when the relative induction (Yc) of the test item is equal or exceeds 10% (REF RPC10) for 
two or more consecutive concentrations. 
B.  Negative when the relative induction (Yc) of the test item does not exceed 10% (REF RPC10) for any 
concentration. 
C.  Inconclusive in all other cases. 
 
 
Antagonism 
 
For each run, a test item is considered  
 
A. Positive when the following two conditions are met: 
 the relative induction (Yc) of the test item is less or equal to 80% (REF RPC80) for two or more 
consecutive concentrations and  
 the coefficient of determination (R2) is less or equal to 0.9 for the linear regression of relative 
induction of the test item's specificity control (Sc) versus the relative induction (Yc).  
B. Negative  
Either  
 when the relative induction (Yc) of the test item is greater than 80% (REF RPC80) at all 
concentrations; 
or 
 when the relative induction (Yc) of the test item is less or equal to 80% (REF RPC80) for at least 2 
consecutive concentrations and the coefficient of determination (R2) is greater than 0.9 for the linear 
regression of the relative induction of the test item's specificity control (Sc) versus the relative 
induction (Yc).  
C. Inconclusive in all other cases. 
 
 
 
2. Update of the test chemicals for the validation study.  
The original list was updated with few chemicals as discussed and suggested by VMG. This included the 
addition of few chemicals with reported agonist behaviour from the recently published ICCVAM A- 
reference list: Cyproterone acetate, Methyltrienolone (R1881), Norethinodrone, Norethinodrone acetate, 19-
Nortestosterone (Nandrolone). Few other chemicals have been omitted from the original list. 
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3. Selection of the 36 coded test chemicals (for studies 2B and 3) 
Seq. 
# 
Chemical name 
11 Sodium azide 
12 Diethylhexyl phthalate 
13 Methyldihydrotestosterone 
14 Vinclozolin 
15 Prochloraz 
16 Fluoxymesterone 
17 17β-Estradiol 
18 Benzylbutyl phthalate 
19 Propylthiouracil 
20 Hydroxyflutamide 
21 Levonorgestrel 
22 Cyproterone acetate 
23 2-tert-Butylanthraquinone 
24 Arochlor1254 
25 Nandrolone 
26 o,p’-DDT 
27 Phenolphthalin 
28 2,4,5-T 
29 Methyltrienolone (R1881) 
30 Actinomycin D 
31 Diethylstilbestrol 
32 L-Thyroxine 
33 Haloperidol 
34 Norethindrone acetate 
35 Pimozide 
36 Progesterone 
37 Linuron 
38 Methyltestosterone 
39 2-sec-Butylphenol 
40 Corticosterone 
41 Ketoconazole 
42 Finasteride 
43 Fulvestrant 
44 Cycloheximide 
45 Norethindrone 
46 Mifepristone 
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Annex 4: Modification to the validation project plan 
Date of discussion with VMG: 26-06-2018 
One of the laboratories is experiencing technical issues on a regular basis. This challenges the timely 
finalisation of the validation study. In order to assess BLR, a 4th laboratory is added to the validation study to 
produce a set of data on 20 coded test chemicals. 
BioDetection Systems BV (BDS), Science Park 406, 1098 XH Amsterdam, The 
Netherlands 
Laboratory manager: Harrie Besselink 
Study director: Harrie Besselink 
Study personnel: Matthijs Naderman 
 
Email: Harrie.Besselink@bds.nl 
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Annex 13.3 
List and properties of  
reference, control and test chemicals used 
in the AR-CALUX® validation study 
1. List of the 53 chemicals used in the AR-CALUX
®
 validation study 
2. Source of the chemicals that led to the final list of a total of 53 chemicals
3. Compilation of properties for 53 chemicals used in the AR-CALUX
®
 validation study 
4. Selection strategy of 45 chemicals for the AR-CALUX
®
 validation study (Report by J. 
Burton) including mapping of the AR-CALUX
®
 chemicals versus the REACH chemicals. 
5. Compilation of publicly available data on ARTA's and the AR-pathway model, for 46
coded test chemicals to be used in the AR-CALUX
®
 validation study 
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1. List of the 53 chemicals used in the AR-CALUX
®
 validation study 
 
Chemical name CASNR 
Study 1 
(Transfer)  
Study 2A Study 2B Study 3 
5α-Dihydrotestosterone 521-18-6 REF Agonist      
Flutamide 13311-84-7 REF Antagonist      
Corticosterone 50-22-6 NC Agonist     x 
Levonorgestrel 797-63-7 NC Antagonist     x 
Methyl testosterone 58-18-4 PC Agonist     x 
Linuron 330-55-2 PC Antagonist     x 
Testosterone 58-22-0 x    
4-Androstenedione 63-05-8 x    
Procymidone 32809-16-8 x    
p,p’-Methoxychlor 72-43-5 x    
Di-n-butyl phthalate 84-74-2 x    
Sodium azide 26628-22-8 x  x  
17β-Trenbolone 10161-33-8  x   
Medroxyprogesterone acetate 71-58-9  x   
Stanozolol 10418-03-8  x   
Spironolactone 52-01-7  x  X 
Bisphenol A 80-05-7  x   
17α-Ethinyl estradiol 57-63-6  x   
Bicalutamide 90357-06-5  x   
Tamoxifen 10540-29-1  x   
Atrazine 1912-24-9  x   
Disulfiram 97-77-8  x    
Fluoxymestrone 76-43-7   x  
Methyldihydrotestosterone 521-11-9   x  
17β-Estradiol 50-28-2   x  
Hydroxyflutamide 52806-53-8   x  
Vinclozolin 50471-44-8   x  
Prochloraz 67747-09-5   x  
Propylthiouracil 51-52-5   x  
Diethylhexyl phthalate 117-81-7   x  
Butylbenzyl phthalate 85-68-7   x  
2-tert-butylanthraquinone 84-47-9    x 
Arochlor1254 11097-69-1    X 
Progesterone 57-83-0    X 
Mifepristone 84371-65-3    X 
Cyproterone acetate 427-51-0    X 
Methyltrienolone (R1881) 965-93-5    X 
Norethinodrone 68-22-4    X 
Norethinodrone acetate 51-98-9    X 
19-Nortestosterone 434-22-0    X 
ICI 182,780 (Fulvestrant) 129453-61-8    X 
Pimozide 2062-78-4    X 
Actinomycin D 50-76-0    X 
Diethylstilbestrol 56-53-1    X 
Ketoconazole 65277-42-1    X 
Cycloheximide 66-81-9    X 
o,p’-DDT 789-02-6    X 
Finasteride 98319-26-7    X 
L-Thyroxine 51-48-9    X 
Haloperidol 52-86-8    X 
Phenolphthalin 81-90-3    X 
2-sec-Butylphenol 89-72-5    X 
2,4,5-Trichlorophenoxyacetic 
acid 
93-76-5    
X 
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2. Source of the test chemicals that lead to the final list of a total of 53 chemicals 
 
 
 
 
 
3. Compilation of properties for 53 chemicals used in the AR-CALUX
®
 validation study 
See below  
Source of test items Items added 
Publications, ICCVAM list 
(2003), 2 Tox21 assays, 
consultations with VMG-NA 
and ICCATM. 
A first list of 83 chemicals was prepared from which a selection was 
made to lead to a list of 45 chemicals (see Report J.Burton in this 
Annex). From this list of 45 some were deleted to encompass the 
ones that were added later (see below). 
 
ARTA Japan validation study 
Hydroxyflutamide 
Diethylhexyl phthalate 
Butylbenzyl phthalate 
17α-Ethinyl estradiol 
 
ARTA Korea validation study 
Bicalutamide 
Fluoxymestrone, 2-tert-butylanthraquinone, Arochlor1254: included 
as they were initially proposed for the Korean validation study but 
during the course of the validation study they were not retained in 
the Korean ARTA final list of testing chemicals 
 
ICCVAM AR reference list 
Cyproterone acetate 
Methyltrienolone (R1881) 
Norethinodrone 
Norethinodrone acetate 
19-Nortestosterone (Nandrolone) 
 
VMG proposal 
Disulfiram 
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Nr. Name CAS Nr. Use State Source 
Toolbox 4.1 Organic 
functional groups, 
Norbert Haider 
(checkmol) 
Toolbox 4.1 OECD 
HPV Chemical 
Categories 
Toolbox 4.1 US-EPA 
New Chemical 
Categories 
Structure 
1 5α-
Dihydrotestosterone 
521-18-
6
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alcohol|Carbonyl 
compound|Hydroxy 
compound|Ketone|Secon
dary alcohol 
Not categorized Neutral Organics 
2 Methyl testosterone 58-18-4 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alcohol|Hydroxy 
compound|Tertiary 
alcohol 
Not categorized Not categorized 
3 Corticosterone 50-22-6 Biomedical 
research 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alcohol|Carbonyl 
compound|Hydroxy 
compound|Ketone|Secon
dary alcohol 
Not categorized Neutral Organics 
4 Testosterone 58-22-0 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Alcohol|Hydroxy 
compound|Secondary 
alcohol 
Not categorized Not categorized 
5 4-Androstenedione 63-05-8 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Carbonyl 
compound|Ketone 
Not categorized Neutral Organics 
6 Methyldihydro 
testosterone 
521-11-
9
Pharmaceutical 
ingredient 
(obsolete/restrict
ed) 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alcohol|Carbonyl 
compound|Hydroxy 
compound|Ketone|Tertiar
y alcohol 
Not categorized Neutral Organics 
7 17β-Trenbolone 10161-
33-8 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alcohol|Hydroxy 
compound|Secondary 
alcohol 
Not categorized Not categorized 
8 Stanozolol 10418-
03-8 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alcohol|Aromatic 
compound|Heterocyclic 
compound|Hydroxy 
compound|Tertiary 
alcohol 
Not categorized Not categorized 
9 Medroxyprogestero
ne  
acetate 
71-58-9 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Carbonyl 
compound|Carboxylic acid 
derivative|Carboxylic acid 
ester|Ketone 
Not categorized Esters (Acute 
toxicity) 
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10 Fluoxymestrone 76-43-7 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
LGC 
Standards 
(UK/Italy) 
Alcohol|Alkyl 
fluoride|Alkyl 
halide|Halogen 
derivative|Hydroxy 
compound|Secondary 
alcohol|Tertiary alcohol 
 
Not categorized Not categorized  
11 Progesterone 57-83-0 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Carbonyl 
compound|Ketone 
 
 
 
Not categorized Neutral Organics  
12 2-tert-
butylanthraquinone  
84-47-9 Industrial 
intermediate 
(dyes/pigments) 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Aromatic 
compound|Carbonyl 
compound|Ketone 
 
 
Not categorized Neutral Organics  
13 17β-Estradiol 50-28-2 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Alcohol|Aromatic 
compound|Hydroxy 
compound|Phenol|Secon
dary alcohol 
 
 
Not categorized Phenols (Acute 
toxicity) 
 
14 Spironolactone 52-01-7 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Carboxylic acid 
derivative|Carboxylic acid 
ester|Heterocyclic 
compound 
 
 
Not categorized Not categorized  
15 Mifepristone 84371-
65-3 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alcohol|Alkyne|Amine|Ar
omatic 
compound|Hydroxy 
compound|Tertiary 
amine|Tertiary mixed 
amine 
 
Not categorized Not categorized  
16 Hydroxyflutamide 52806-
53-8 
Flutamide 
metabolite 
solid (powder) 
white, crystalline 
Chemos 
(Germany) 
and 
Carbosynth 
(UK) 
Alcohol|Alkyl 
fluoride|Alkyl 
halide|Anion|Aromatic 
compound|Carboxylic acid 
amide|Carboxylic acid 
derivative|Carboxylic acid 
sec. 
amide|Cation|Halogen 
derivative|Hydroxy 
compound|Nitro 
compound 
 
Not categorized Not categorized  
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17 Arochlor1254 11097-
69-1 
PCB mixture 
(lubricant/coolant
) 
Liquid (oily) 
colourless, 
viscous 
Sigma/Merc
k 
(Italy/Germ
any) 
 
 
 
 
Aromatic compound|Aryl 
chloride|Aryl 
halide|Halogen derivative 
 
Not categorized Persistent, 
Bioaccumulative 
and Toxic (PBT) 
Chemicals 
 
18 Flutamide 13311-
84-7 
Pharmaceutical 
ingredient 
solid (powder) 
pale yellow, 
crystalline 
TCI Europe 
(Belgium) 
 
 
 
 
 
 
 
Alkyl fluoride|Alkyl 
halide|Anion|Aromatic 
compound|Carboxylic acid 
amide|Carboxylic acid 
derivative|Carboxylic acid 
sec. 
amide|Cation|Halogen 
derivative|Nitro 
compound 
 
Not categorized Not categorized  
19 Linuron 330-55-
2 
Herbicide solid (powder) 
white, crystalline 
Chemos 
(Germany) 
Aromatic compound|Aryl 
chloride|Aryl 
halide|Carbonic acid 
derivative|CO2 derivative 
(general)|Halogen 
derivative 
 
Not categorized Neutral Organics  
20 Levonorgestrel 797-63-
7 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Chemos 
(Germany) 
Alcohol|Hydroxy 
compound|Tertiary 
alcohol 
 
 
 
 
 
Not categorized Not categorized  
21 Procymidone 32809-
16-8 
Fungicide 
(agricultural) 
solid (powder) 
white, crystalline 
Chemos 
(Germany) 
Aromatic compound|Aryl 
chloride|Aryl 
halide|Carboxylic acid 
derivative|Halogen 
derivative|Heterocyclic 
compound 
 
Not categorized Imides (Acute 
toxicity) 
 
22 Pimozide 2062-
78-4 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
 
 
 
 
(N/A) (N/A) (N/A)   
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23 Vinclozolin 50471-
44-8 
Fungicide 
(agricultural) 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Alkene|Aromatic 
compound|Aryl 
chloride|Aryl 
halide|Carbonic acid 
derivative|Carboxylic acid 
derivative|CO2 derivative 
(general)|Halogen 
derivative|Heterocyclic 
compound 
Not categorized Neutral Organics  
24 Diethylstilbestrol 56-53-1 Pharmaceutical 
ingredient 
(obsolete/researc
h) 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
 
 
 
Alkene|Aromatic 
compound|Hydroxy 
compound|Phenol 
 
 
 
 
 
Not categorized Phenols (Acute 
toxicity) 
 
25 Cycloheximide 66-81-9 Biomedical 
research  
(antibacterial and 
antifungal)  
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Alcohol|Carbonyl 
compound|Carboxylic acid 
derivative|Carboxylic acid 
imide|Carboxylic acid 
unsubst. 
imide|Heterocyclic 
compound|Hydroxy 
compound|Ketone|Secon
dary alcohol 
 
Not categorized Imides (Acute 
toxicity) 
 
26 Prochloraz 67747-
09-5 
Fungicide 
(agricultural) 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Alkylarylether|Aromatic 
compound|Aryl 
chloride|Aryl 
halide|Carbonic acid 
derivative|CO2 derivative 
(general)|Ether|Halogen 
derivative|Heterocyclic 
compound 
 
 
 
Tertiary Amines Neutral Organics  
27 o,p’-DDT 789-02-
6 
Insecticide 
(agicultural)  
(obsolete) 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Alkyl chloride|Alkyl 
halide|Aromatic 
compound|Aryl 
chloride|Aryl 
halide|Halogen derivative 
 
 
 
 
 
Not categorized Neutral Organics  
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28 Bisphenol A 80-05-7 Industrial 
intermediate 
(plastics 
manufacture) 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
 
Aromatic 
compound|Hydroxy 
compound|Phenol 
 
 
 
 
Not categorized Phenols (Acute 
toxicity) 
 
29 Disulfiram 97-77-8 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
CO2 derivative 
(general)|Thiocarbonic 
acid derivative 
 
 
 
 
 
Tertiary Amines Dithiocarbamates 
(Acute toxicity) 
 
30 Ketoconazole 65277-
42-1 
Pharmaceutical 
ingredient 
(antifungal) 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alkylarylether|Amine|Aro
matic compound|Aryl 
chloride|Aryl 
halide|Carboxylic acid 
amide|Carboxylic acid 
derivative|Carboxylic acid 
tert. amide|Ether|Halogen 
derivative|Heterocyclic 
compound|Tertiary 
amine|Tertiary mixed 
amine 
 
Tertiary Amines Neutral Organics  
31 Finasteride 98319-
26-7 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Carboxylic acid 
amide|Carboxylic acid 
derivative|Carboxylic acid 
sec. amide|Heterocyclic 
compound 
 
 
 
 
 
 
 
Not categorized Not categorized  
32 p,p’-Methoxychlor 72-43-5 Insecticide 
(agicultural)  
(obsolete) 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium)  
Alkyl chloride|Alkyl 
halide|Alkylarylether|Aro
matic 
compound|Ether|Halogen 
derivative 
 
 
 
 
Not categorized Not categorized  
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33 Bicalutamide 90357-
06-5 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alcohol|Alkyl 
fluoride|Alkyl 
halide|Aromatic 
compound|Aryl 
fluoride|Aryl 
halide|Carboxylic acid 
amide|Carboxylic acid 
derivative|Carboxylic acid 
sec. amide|Halogen 
derivative|Hydroxy 
compound|Nitrile|Sulfone 
 
 
 
Not categorized Not categorized  
34 ICI 182,780 
(Fulvestrant) 
129453-
61-8 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Chemos 
(Germany) 
Alcohol|Alkyl 
fluoride|Alkyl 
halide|Anion|Aromatic 
compound|Cation|Haloge
n derivative|Hydroxy 
compound|Phenol|Secon
dary alcohol|Sufoxide 
 
 
Not categorized Not categorized  
35 Actinomycin D 50-76-0 Pharmaceutical 
ingredient 
(antibiotic) 
solid (powder) 
dark red, 
crystalline 
Chemos 
(Germany) 
and 
Carbosynth 
(UK) 
(N/A) 
 
 
 
 
 
 
 
 
 
 
(N/A) (N/A)  
36 Tamoxifen 10540-
29-1 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Alkene|Alkylarylether|Ami
ne|Aromatic 
compound|Ether|Tertiary 
aliphatic amine|Tertiary 
amine 
 
 
 
Tertiary Amines Aliphatic Amines  
37 17α-Ethinyl 
estradiol 
57-63-6 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
 
 
Alcohol|Alkyne|Aromatic 
compound|Hydroxy 
compound|Phenol 
 
 
 
Not categorized Phenols (Acute 
toxicity) 
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38 Sodium azide 26628-
22-8 
Vehicle 
manufacture 
Airbag detonator 
and  
gas (nitronen) 
source 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Anion|Cation Not categorized Undefined 
39 L-Thyroxine 51-48-9 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Alpha-
aminoacid|Amine|Aromat
ic compound|Aryl 
halide|Aryl 
iodide|Carboxylic 
acid|Carboxylic acid 
derivative|Diarylether|Eth
er|Halogen 
derivative|Hydroxy 
compound|Phenol|Primar
y aliphatic amine|Primary 
amine 
Not categorized Aliphatic 
Amines|Phenols 
(Acute toxicity) 
40 Propylthiouracil 51-52-5 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
(N/A) (N/A) (N/A) 
41 Dibutyl phthalate 84-74-2 Industrial 
intermediate 
(plasticizer) 
Liquid (oily) 
colourless, 
viscous 
Sigma/Merc
k 
(Italy/Germ
any) 
Aromatic 
compound|Carboxylic acid 
derivative|Carboxylic acid 
ester 
Not categorized Esters (Acute 
toxicity) 
42 2-sec-Butylphenol 89-72-5 Industrial 
intermediate 
(organic 
syntheses) 
Liquid 
colourless 
Sigma/Merc
k 
(Italy/Germ
any) 
Aromatic 
compound|Hydroxy 
compound|Phenol 
Not categorized Phenols (Acute 
toxicity)
43 2,4,5-
Trichlorophenoxyac
etic acid 
93-76-5 Herbicide  
(agricultural) 
solid (powder) 
white, crystalline 
Sigma/Merc
k 
(Italy/Germ
any) 
Alkylarylether|Aromatic 
compound|Aryl 
chloride|Aryl 
halide|Carboxylic 
acid|Carboxylic acid 
derivative|Ether|Halogen 
derivative 
Not categorized Neutral Organics 
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44 Diethylhexyl 
phthalate 
117-81-
7 
Industrial 
intermediate 
(plasticizer) 
Liquid (oily) 
colourless, 
viscous 
Sigma/Merc
k 
(Italy/Germ
any) 
Aromatic 
compound|Carboxylic acid 
derivative|Carboxylic acid 
ester 
 
 
 
 
 
 
 
High molecular weight 
phthalate esters 
Not categorized  
45 Butylbenzyl 
phthalate 
85-68-7 Industrial 
intermediate 
(plasticizer) 
Liquid (oily) 
colourless, 
viscous 
Sigma/Merc
k 
(Italy/Germ
any) 
 
 
 
 
 
 
 
Aromatic 
compound|Carboxylic acid 
derivative|Carboxylic acid 
ester 
 
 
 
 
 
 
 
 
Not categorized 
 
 
 
 
 
 
 
 
 
Esters (Acute 
toxicity) 
 
46 Atrazine 1912-
24-9 
Herbicide  
(agricultural) (EU: 
obsolete) 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Amine|Aromatic 
compound|Aryl 
chloride|Aryl 
halide|Halogen 
derivative|Heterocyclic 
compound|Secondary 
amine|Secondary mixed 
amine (aryl, alkyl) 
 
 
 
Not categorized Substituted 
Triazines (Acute 
toxicity) 
 
47 Haloperidol 52-86-8 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alcohol|Amine|Aromatic 
compound|Aryl 
chloride|Aryl fluoride|Aryl 
halide|Carbonyl 
compound|Halogen 
derivative|Heterocyclic 
compound|Hydroxy 
compound|Ketone|Tertiar
y alcohol|Tertiary aliphatic 
amine|Tertiary amine 
 
 
 
 
Tertiary Amines Aliphatic Amines  
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48 Phenolphthalin 81-90-3 Laboratory 
chemical  
(indicator dye) 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Aromatic 
compound|Carboxylic 
acid|Carboxylic acid 
derivative|Hydroxy 
compound|Phenol 
 
 
 
 
Not categorized Phenols (Acute 
toxicity) 
 
49 Cyproterone acetate 427-51-
0 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Carbosynth 
(UK) 
Carbonyl 
compound|Carboxylic acid 
derivative|Carboxylic acid 
ester|Halogen 
derivative|Ketone 
 
 
 
Not categorized Esters (Acute 
toxicity) 
 
50 Methyltrienolone 
(R1881) 
965-93-
5 
Pharmaceutical 
ingredient 
(obsolete/researc
h) 
solid (powder) 
white, crystalline 
Chemos 
(Germany) 
Alcohol|Hydroxy 
compound|Tertiary 
alcohol 
 
 
 
 
 
Not categorized Not categorized 
 
51 Norethinodrone 68-22-4 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Carbosynth 
(UK) 
Alcohol|Alkyne|Hydroxy 
compound 
 
 
 
 
 
 
Not categorized Not categorized  
52 Norethinodrone 
acetate 
51-98-9 Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
Carbosynth 
(UK) 
Alkyne|Carboxylic acid 
derivative|Carboxylic acid 
ester 
 
 
 
 
Not categorized Esters (Acute 
toxicity) 
 
53 19-Nortestosterone 
(Nandrolone) 
434-22-
0 
Pharmaceutical 
ingredient 
solid (powder) 
white, crystalline 
TCI Europe 
(Belgium) 
Alcohol|Alkene|Carbonyl 
compound|Hydroxy 
compound|Ketone|Tertiar
y alcohol 
 
 
 
Not categorized Neutral Organics  
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4. Selection strategy of 45 chemicals for the AR-CALUX validation study (Report by J. Burton) and 
mapping of the 53 chemicals versus the REACH chemicals 
 
 
Chemical selection for AR CALUX 
validation study 
Julien Burton - 18 Nov.2014 
Introduction 
 
This document aims at presenting the chemical selection strategy followed for the ARCALUX 
validation study. 
The strategy relied on a knowledge-driven weight of evidence approach, using previously 
generated results to select chemicals with consistent behaviours. The collected data on 83 chemicals 
was compiled from expert opinions, AR in vitro assays, ARCALUX assays and high-throughput 
screening. 
The behaviour (agonist, antagonist, negative) of the chemicals was assessed via a scoring 
methods and the actual selection was performed choosing compounds with robust observations 
while covering a satisfying diversity. 
Finally, we proposed a scheme for collecting further data on chemicals with the objective of 
defining the applicability domain of the validation study. 
Data sources 
 
The chemical selection strategy relied on data collection from several ARTA experiments, in-
house testings, literature findings and expert judgements coming from several reliable sources: 
Literature: 
 ICCVAM recommendations: ICCVAM Evaluation of In Vitro Test Methods for Detecting 
Potential Endocrine Disruptors: Estrogen and Androgen Receptor Binding and 
Transcriptional Activation Assays (Addendum, Tables 6-1 and 6-2) 
 AR Ecoscreen assay results: Evaluation of rapid in vitro androgen receptor transcriptional 
activation assay using AR-Ecoscreen cells (N.Araki, K.Ohno, M.Takeyoshi, M.Iida, Toxicology 
in Vitro (2005), 19, 335-352) 
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 AR CALUX assay results: Optimization and prevalidation of the in vitro AR CALUX method to 
test androgenic and antiandrogenic activity compounds (B.van der Burg, R.Winter, H.Man, 
C.Vangenechten, P.Berckmans, M.Weimer, H.Witters, S.van der Linden, Reproductive 
Toxicology (2010), 30, 18-24) 
 PALM assay results: Screening for (anti)androgenic properties using a standard operation 
protocol based on the human stably transfected androgen sensitive PALM cell line. First step 
towards validation (A.Freyberger, H.Witters, M.Weimer, W.Lofink, P.Berckmans, H.-J. Ahr, 
Reproductive Toxicology (2012), 30, 9-17) 
Tox21 assays (qualitative data provided by collaborators): 
 Tox21 AR-BLA assay 
 Tox21 AR-luc assay 
In-house HTS results on CALUX (by Jean-Michel Gineste and Roman Liska): 
 Runs (biological replicates) CALUX 01, 02, and 03 for agonism 
 Runs (biological replicates) CALUX 04, 05, and 06 for antagonism 
 
QSAR 
 PASS AR agonist model (http://www.pharmaexpert.ru/passonline/). Model relying on 
structural similarity toward a reference sample of AR agonists and non-agonists. Positive 
classification is achieved when the probability of being an agonist is higher than the 
probability of being inactive. 
 
Table 1 shows a comparison between the different experimental sources, including the cell line, 
biological construct, number of replicates, concentration range and classification criteria. 
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Experimental 
source 
Cell line Construct 
Replicates 
(technical) 
Concentration range 
(M) 
POS/NEG classification 
AR Ecoscreen 
Chinese Hamster 
Ovary 
cDNA human androgen receptor / firefly 
luciferase gene preceded by 4 ARREs of 
prostate C3 gene heat shock protein / 
renilla (frog) luciferase gene 
constitutively expressed 
3 10-9 – 10-4 
From table 5. 
Agonist: fold induction (FI) > 1.7  Positive 
Antagonist: DHT-induced relative luciferase activity (RLA) < 80% 
+ relative cell viability >80% at the same concentration tested  
Positive 
 
AR CALUX 
U2-OS human 
osteosarcoma 
full length cDNA human androgen 
receptor / luciferase gene preceded by 3 
ARREs coupled to a minimal adenovirus 
TATA promoter 
 
Min. 3 (up to 
8) 
Chemical-dependant 
(10-10 – 10-5?)  
2 consecutive values below/above a given threshold 
PALM 
human prostate 
cancer 
human prostate cancer cell 
line PC-3 stably transfected with human 
AR and a Luciferase gene 
under the control of mouse mammary 
tumour virus (MMTV) 
3 
Chemical-dependant 
(10-9 – 10-5?) 
Agonist: a sigmoid concentration response should be observed 
for MDHT. A maximally stimulating concentration of MDHT 
(100nM or above) should result in an induction factor of ≥4.0, 
whereas the EC50 of MDHT should be in the range 0.1–1 nM.  
Antagonist: 0.2nM MDHT should result in an induction factor of 
≥2.5, flutamide should concentration-dependently reduce the 
agonistic effect of 0.2nM MDHT, and at 10_Mflutamide should 
reduce the net increase of luciferase activity (brought about by 
0.2nM MDHT) by ≥70%. 
Tox21 AR-BLA  
Human Embryonic 
Kidney  
HEK293T 
 
stably transfected with human ER-α 
ligand-binding domain and a β-
lactamase reporter gene 
3 10-8 – 10-4 As provided by collaborators 
Tox21 AR-luc  
Human breast 
carcinoma 
MDA-kb2 
human breast carcinoma cell line stably 
transfected with luciferase reporter gene 
under control of MMTV promoter 
containing response elements for both 
androgen receptor (AR) and 
glucocorticoid receptor (GR). 
3 10-8 – 10-4 As provided by collaborators 
In-house HTS See AR CALUX See AR CALUX 1 
Chemical-dependant 
10-13 – 10-5 
Same ARCALUX 
Table 1. Comparison of the experimental sources supporting the chemical selection 
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Data collection 
Using the above-mentioned sources, supplemented with internal discussion with collaborators, data could be gathered for 83 chemicals. Table 2 
summarises the collected data with chemical identifiers (name and CAS number) and the associated classification (positive or negative, following the 
internal protocol of each study/document) for both agonism and antagonism tests. 
Name CAS AGONISM ANTAGONISM 
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17β-Trenbolone 10161-33-8 p p p p p n p n n n n 
Stanozolol 10418-03-8 p p n n n 
p-n-Nonylphenol 104-40-5 n n n n n p n p p n n p p 
Tamoxifen 10540-29-1 n n n n n n p n n n n 
4,4'-(1H-imidazol-1-ylmethanediyl)dibenzonitrile 112808-99-8 n n 
Diethylhexyl phthalate 117-81-7 n n n n n n n n n n p n n n n 
Ethyl paraben 120-47-8 n n n n n n n n n n n 
Anastrazole 120511-73-1 n n n n n n n n n n n 
ICI 182,780 129453-61-8 n n n n n n p n p p p p p 
Flutamide 13311-84-7 n n n n n n n n p p p p p p p p p p 
4-tert-Octylphenol 140-66-9 n n n n p p p p p 
Zearalenone 17924-92-4 n n n n p n p p n p p 
Atrazine 1912-24-9 n n n n n n n p n n n n n n n 
Pimozide 2062-78-4 n n n n n p p p p p 
Fluoranthene 206-44-0 n p n n n p p p n n n p p 
Sodium azide 26628-22-8 n n n n n n n n n n p n n n 
Procymidone 32809-16-8 n n n n n n n p p p p p p p 
 
130 
 
Linuron 330-55-2 p p n 
 
n n n n n n p p p p p n p p p 
Cyproterone acetate 427-51-0 p p 
  
n p 
  
n p p p 
  
p p p p p 
Genistein 446-72-0 n 
   
n n n n n 
 
n 
   
p n n n p 
Coumestrol 479-13-0 n 
   
n n n n n 
 
n 
   
n n n p p 
Morin 480-16-0 n 
   
n n 
  
n p n 
   
n n n n n 
Daidzein 486-66-8 n 
   
n n 
  
n 
 
n 
   
p n n n n 
Dexamethasone 50-02-2 p p 
  
p p 
  
n p n p 
  
n n n n p 
Corticosterone 50-22-6 n p n 
 
p p 
  
n p n n 
  
n n p p p 
17β-Estradiol 50-28-2 p p 
  
p p n n n p p p 
  
p n p p p 
Vinclozolin 50471-44-8 n n n 
 
n n n n n p p p p p p p 
 
p p 
Reserpine 50-55-5 n 
   
n n 
  
n n n 
   
p p n p p 
Actinomycin D 50-76-0 n p 
  
n n 
  
n 
 
n n 
  
p p p p p 
L-Thyroxine 51-48-9 n 
   
n n 
  
n n n 
   
n n n p n 
Propylthiouracil 51-52-5 n 
   
n n 
  
n 
 
n 
   
n n n n p 
Spironolactone 52-01-7 p p 
  
p p n n n p p p 
  
p p p p p 
Kaempferol 520-18-3 n 
   
n n 
  
n n n 
   
p p n n p 
Apigenin 520-36-5 n 
   
n n 
  
n 
 
n 
   
p n p n p 
Methyldihydrotestosterone/Mestanolone 521-11-9   
  
p p p 
  
p p   
   
n n n n n 
5α-Dihydrotestosterone 521-18-6 p p p 
 
p p p p p p n n 
  
n n p n n 
Flavone 525-82-6 n 
   
n n 
  
n n n 
   
p n p p p 
Hydroxyflutamide 52806-53-8 p n 
  
n p 
  
n p p p 
  
p p p p p 
Haloperidol 52-86-8 n 
   
n n 
  
n n n 
   
n p n n n 
Estrone 53-16-7 p p 
  
n p 
  
n p n p 
  
p p p p p 
Androsterone 53-41-8   
        
p   
        Dibenzo[a,h]-anthracene 53-70-3 p 
   
n n 
  
n p n 
   
n n n n p 
Diethylstilbestrol 56-53-1 n n 
  
n n n n n p p p 
  
p p p p p 
Phenobarbital 57-30-7 n 
   
n n 
  
n 
 
n 
   
n n n n p 
17α-Ethinyl estradiol 57-63-6 n 
   
p n n n n p n p 
  
p p p p p 
Progesterone 57-83-0 p p n p p p 
  
n p p p p p p p p p p 
17α-Estradiol 57-91-0 n n 
  
p p 
  
n p n p 
  
p p p p p 
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Apomorphine 58-00-4 n n n n n p p 
Methyl testosterone 58-18-4 p p p p p p p p n n n p n n n 
Testosterone 58-22-0 p p p p p p p p n n n n n n n 
4-androstanedione 5982-99-0 p 
4-Cumylphenol 599-64-4 n n n n p n p p n p p 
Fenarimol 60168-88-9 n n n n n p p p n n p 
Oxazepam 604-75-1 n n p n n n p 
Tetrahydrogestrinone 618903-56-3 p 
4-Androstenedione 63-05-8 p p p p p p p p n n n n n n n 
Nilutamide 63612-50-0 p n n n p p p p p p p 
Ketoconazole 65277-42-1 p n n n n n n p p p n p p 
Cycloheximide 66-81-9 n n n n n n p p p p p 
Prochloraz 67747-09-5 n n n n p p p p n n p 
4-Hydroxytamoxifen 68047-06-3 n n n n n n n n n n p p n n n 
Norethynodrel 68-23-5 p p p p p p p p n n p n n p 
Medroxyprogesterone acetate 71-58-9 p p p p p p p p n n p n p n n 
p,p’-Methoxychlor 72-43-5 n n n n n n n n p p p p p p p 
p,p’-DDE 72-55-9 p n n n n n p p n n p p p 
Fluoxymestrone 76-43-7 p p p p p n p p n n n n p n n 
Bisphenol B 77-40-7 n n n n n n p n p p p p p 
Ammonium perchlorate 7790-98-9 n n n n n n n n n n 
o,p’-DDT 789-02-6 n n n n n n n n n n p p p p p n p p 
Levonorgestrel 797-63-7 p p p p p p n p n n n n 
Bisphenol A 80-05-7 n n n n n p p p p p p p p 
Phenolphthalin 81-90-3 n n n n n n n n n p p 
meso-Hexestrol 84-16-2 n n n n n n p n p p p p p 
Mifepristone 84371-65-3 p p n p n p p p p p p p p 
Boldenone 846-48-0 p 
Di-n-butyl phthalate 84-74-2 n n n n n n n n n n n p n n n n n n n 
Butylbenzyl phthalate 85-68-7 n n n n n n n n n n p n 
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2-sec-Butylphenol 89-72-5 n n n n p n n n n n n 
Bicalutamide 90357-06-5 p n n n p p p p p p p 
Clomiphene 911-45-5 n n n n n p n 
2,4,5-Trichlorophenoxyacetic acid 93-76-5 n n n n n n n p n n n n n 
Methyltrienolone(R1881) 965-93-5 p p p n n 
Finasteride 98319-26-7 n n n n n p n p p n p p p 
Table 2. Summary of the data gathered on ARTA for 83 candidate compounds for the validation study. "p" and "n" stand for positive and negative 
responses, respectively. 
Compounds without actual data in the table come from an expert consultation advising the inclusion of such compounds. They were placed on hold list in 
case some more test chemicals were needed
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Class definition (scoring) 
The number of observed behaviour in the different source was summed up and divided by the total 
number of observation (associated ratio). From there it is possible to define four classes of compounds: 
agonists, antagonists, negatives, dual behaviour, and the rest (named here inconclusive) (see Table 3.). A 
first cleaning step was performed, removing unavailable, legally banned or expensive chemicals (15 
chemicals eliminated). After solubility tests, 4 insoluble compounds (Diethylhexyl phthalate, Estrone, 
Dibenzo[a,h]-anthracene, and p,p’-DDE) were also discarded (64 chemicals remaining). Note that, in this 
count, the AR CALUX in-house HTS accounts for a weight of three since it was performed on 3 biological 
replicates. 
Class Ratio of 
positive 
agonist 
Ratio of 
positive 
antagonist 
Total ratio of 
positive (both 
agonist and 
antagonist) 
Number of 
chemicals 
(original list of 83) 
Number of 
chemicals 
(after cleaning, 64 
remaining) 
Pure agonist >70% <25% 10 8 
Pure antagonist <25% >70% 19 17 
Negative <25% 23 17 
Dual behaviour >50% >50% 8 7 
Inconclusive 23 15 
Total 83 64 
Table 3. Chemicals list break down by classes based on the number of observation of agonist and 
antagonist behaviour in the different data sources 
Chemical selection 
The goal of chemical selection was to select 15 agonists, 15 antagonists, and 15 negative compounds. From 
Table 3, it is clear that negative and antagonist pools have to be downsized from 17 to 15 while the agonist 
set has to be supplemented with, for example, the chemicals showing a dual behaviour  
Negatives 
17 compounds were showing negative in both agonist and antagonist tests (total ratio of positive response 
in all assays < 25%). To reach the target number of 15, we had to discard two compounds. We decided to 
cluster the 17 negative candidates according to their chemical structure (Avalon structural fingerprint, 
Tanimoto similarity). Figure 1 shows the result of the complete linkage hierarchical clustering. Two pairs of 
similar compound appear quite obviously and could be considered as redundant.  
Those two pairs are: 
 Daidzein (486-66-8) and Genistein (446-72-0), both isoflavones. Genistein was considered more
interesting to keep because it is more data rich than Daidzein (e.g. 417 PubChem citations versus
141).
 Butylbenzyl phthalate (85-68-7) and Di-n-butyl phthalate (84-74-2), both belonging to the phthalate
family. Di-n-butyl phthalate is kept because we could gather more observation and have more
confidence in its behaviour (19 observations versus 12)
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Figure 1. Clustering dendrogram obtained on the Tanimoto similarity matrix calculated on Avalon 
fingerprints for the 17 negative candidates. 
The proposed list of 15 negatives to be tested is then:  
Name CASNR Name CASNR Name CASNR 
Tamoxifen 10540-29-1 Genistein 446-72-0 Haloperidol 52-86-8 
Ethyl paraben 120-47-8 Coumestrol 479-13-0 Phenolphthalin 81-90-3 
Anastrazole 120511-73-1 Morin 480-16-0 Di-n-butyl phthalate 84-74-2 
Atrazine 1912-24-9 L-Thyroxine 51-48-9 2-sec-Butylphenol 89-72-5 
Sodium azide 26628-22-8 Propylthiouracil 51-52-5 2,4,5-Trichlorophenoxyacetic acid 93-76-5 
Table 4. Proposed list of 15 negative chemicals 
 
Antagonists 
After data collection and cleaning, 17 compounds showed pure antagonist behaviour. 
When the same clustering strategy as for the negatives is applied, one can found 3 pairs of similar 
compounds (clustering below a distance value of 0.55) as seen in Figure 2 (clustering dendrogram) and 
Table 5 (table of pairs). 
  
Two isoflavones 
Two phthalates 
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# Name CASNR Name CASNR Commonalities 
1 Vinclozolin 50471-44-8 Procymidone 32809-16-8 Dicarboximide (fungicides) 
 
  
 
2 
Meso-Hexestrol 84-16-2 Diethylstilbestrol 56-53-1 
Structure differing only by 
one double bond 
 
  
 
3 Bisphenol A 80-05-7 Bisphenol B 77-40-7 Bisphenols 
 
  
 
Table 5. Three pairs of similar antagonist compounds (Tanimoto distance on Avalon fingerprint < 0.55) 
detected by clustering. 
 
Figure 2. Clustering dendrogram obtained on the Tanimoto similarity matrix calculated on Avalon 
fingerprints for the 17 antagonists’ candidates. Three pairs of similar compounds are detected (distance < 
0.55). 
 
If we apply a criteria of data richness within each pair (i.e. number of antagonist response observed), we 
select Vinclozilin (pair 1), Diethylstilbestrol (pair), and Bisphenol A (pair 3). However, since we only had to 
discard 2 compounds (and not 3), Procymidone (pair 1) is also kept in the selection as it was part of the 
initial selection used in the GLP study. That selection was performed previously with less data than this 
version of the strategy. 
  
1 2 
3 
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The proposed 15 antagonists are then: 
Name CASNR Name CASNR Name CASNR 
ICI 182,780 129453-61-8 Vinclozolin 50471-44-8 Cycloheximide 66-81-9 
Flutamide 13311-84-7 Actinomycin D 50-76-0 Prochloraz 67747-09-5 
Pimozide 2062-78-4 Diethylstilbestrol 56-53-1 p,p’-Methoxychlor 72-43-5 
Procymidone 32809-16-8 o,p’-DDT 789-02-6 Bisphenol A 80-05-7 
Linuron 330-55-2 Ketoconazole 65277-42-1 Finasteride 98319-26-7 
Table 6. Proposed list of 15 antagonists 
 
Agonists and dual behaviour 
 
Based on the classes defined, we collected 8 pure agonists. In order to reach the target number of 15, we 
decided to investigate the “inconclusive” and “dual behaviour” chemicals for which no clear behaviour 
could be observed, based on the defined criteria. 
Two compounds (Corticosterone and Dexamethasone) are added because of their potential to interact with 
the Glucocorticoid receptor (GR). Those two chemicals indeed show up positive agonists in several AR 
assays due to a crosstalk mechanism between AR and GR. One of the specificity of ARCALUX is to be able to 
avoid this phenomenon and, in order to demonstrate this characteristic, the two compounds are included 
in the list and should show up negatives in the AR CALUX agonists test. 
For the 5 spots left in the agonist lists, we simply include the compounds for which we have the higher 
number of positive agonist responses in the remaining list of “inconclusive” and “dual behaviour”. Table 7 
shows the top 6 “inconclusive”/”dual behaviour” compounds ranked by the number of positive agonist 
response observed in the data sources. All these compounds (with the exception of Medroxyprogesterone 
acetate) show a substantial antagonist activity, the reason they were considered as showing a “dual 
behaviour” in the first place. 
Name CAS Positive 
agonist  
Total 
agonist 
test 
Positive 
antagonist 
Total 
antagonist 
tests 
Medroxyprogesterone acetate 71-58-9 8 8 2 7 
Progesterone 57-83-0 6 8 9 9 
17β-Estradiol 50-28-2 5 8 6 7 
Spironolactone 52-01-7 5 8 7 7 
Cyproterone acetate 427-51-0 4 6 7 7 
Mifepristone 84371-65-3 4 6 7 7 
Table 7. Six compounds, first tagged as “inconclusive”/”dual behaviour”, with the highest number of 
agonist responses 
To make the call between Cyproterone acetate and Mifepristone (showing the same profile in the data 
sources), we let the chemistry speak by selecting the structure that would bring more diversity to the set of 
agonist. Observing the already selected agonists, only the steroid family is represented, not surprisingly. 
Mifepristone was then selected over Cyproterone acetate because the former is decorated by an additional 
aromatic ring and an interesting alkyne moiety (see Figure 3). 
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Mifepristone (CAS 84371-65-3) Cyproterone acetate (CAS 427-51-0) 
  
Figure 3. Structures of the Mifepristone and Cyproterone acetate 
 
Name CASNR Name CASNR Name CASNR 
17β-Trenbolone 10161-33-8 Testosterone 58-22-0 Medroxyprogesterone 
acetate 
71-58-9 
Stanozolol 10418-03-8 4-Androstenedione 63-05-8 Progesterone 57-83-0 
Methyldihydrotestosterone 521-11-9 Levonorgestrel 797-63-7 17β-Estradiol 50-28-2 
5α-Dihydrotestosterone 521-18-6 Dexamethasone 50-02-2 Spironolactone 52-01-7 
Methyl testosterone 58-18-4 Corticosterone 50-22-6 Mifepristone 84371-65-3 
Table 8. Proposed list of 15 agonists  
 
 
Summary 
 
 
 
 
 
Table 9. Summary table of the selection process. 
The outcome of the presented selection process is presented in Table 9 where 45 chemicals were retained 
among negatives, antagonists, agonists, dual behaviour, and inconclusive compounds. 
In term of chemical space covered, one can see in Figure 4 that the 45 selected chemicals cover well the 
initial space of 83 pre-selected compounds, thanks to the diversity-based strategy employed to select 
antagonists and negatives. 
It is obvious that the agonists cover a very restricted space of structure since only certain fine structural 
features are needed to trigger an agonist response from the AR. Antagonists cover a wider space and “dual 
behaviour” compounds lay between the two types of response. Negatives show also a satisfying diversity. 
Class Agonist Dual Antagonist Negative Inconclusive Total 
Selected 8 4 15 15 3 45 
Considered 
 
3 2 2 12 19 
Insoluble 
 
1 1 1 1 4 
Unavailable 2  1 5 7 15 
Total 10 8 19 23 23 83 
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Figure 4. PCA (first 2 PCs) calculated on the similarity profiles (Tanimoto index on the standard RDkit 
structural fingerprint) for the 83 pre-selected chemicals. Colour accounts for the behaviour class and shape 
for the selection status. 
 
In an effort to rationalize the chemical space covered by the selection, six main properties were computed 
(Figure 5). As seen on the histograms, the selection (red) represents well the space covered initially by the 
83 pre-selected chemicals (red + grey). 
In a validation study revolving around one particular receptor (AR), a substantial portion of the selection is 
centred around the activity domain (in term of properties of the binding ligands) linked to that receptor. 
Interestingly, a significant number of the selected chemicals show a profile similar to the natural binding 
ligands for the AR, testosterone (MW = 288; LogP=3.88; TPSA=37.3; HBD=1; HBA=2; rotatable bonds = 0) 
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Figure 5. Histograms for 6 physical/chemical properties for the 45 selected (red) compared to the non-
selected (grey) chemicals. 
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Information on chemicals 
In order to accurately describe the diversity space covered by the validation study, we would like to gather an identity file for each of the chemicals tested, 
including information on chemical class, properties, type of use, types of toxicities, kinetics, and potency data relevant for the AR CALUX validation. A template is 
proposed in Table 10. 
 
CASNR Name ARCALUX 
class 
Chemical 
class 
Use MW LogP ED related 
behaviour 
Other 
toxicities 
Kinetics 
(metabolism, 
clearance) 
Potency (EC50 for 
agonists, IC50 for 
antagonists, in M) 
120-47-8 Ethyl paraben Negative Paraben, 
Benzoic 
acid 
Fungicide 
Microbiocide 
Preservative 
Food additive 
(E214) 
136.1 0.77 Weak 
estrogenic 
  N/A 
13311-84-7 Flutamide Antagonist Anilide Drug (prostate 
cancer) 
276.0 3.21 Anti-androgen Hepatotoxicity Hydroxylated to 
hydroxiflutamide. 
Fast clearance 
(urine) 
3.99 10-07 (AR CALUX) 
1.84 10-06 (PALM) 
1.66 10-06 (Ecoscreen) 
7.38 10-06 (Tox21 BLA) 
4.56 10-05 (Tox21 LIC) 
10161-33-8 17β-Trenbolone Agonist Steroid Growth hormone 270.4 3.33 Androgen  HL 48/72h 
Urinary 
1.35 10-09 (Tox21 BLA) 
1.02 10-10 (Tox21 LUC) 
Table 10. Proposition of identity file to be gathered for each compounds selected for the validation study 
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Mapping of the 53 chemicals used in the validation study versus the REACH chemicals  
 
 
 
Figure 1: PCA calculated on the structural profiles (Tanimoto index) of the REACH chemicals versus AR-CALUX
®
 validation set. 
The axis and positions of the chemicals correspond to the first two principal components of the similarity matrix of the chemicals built using the RDKit (Landrum G. 
RDKit: Open-source informatics. 2015. http://www.rdkit.org) atomic pairs fingerprints. In blue: REACH chemicals; in red: AR-CALUX
®
 validation set. 
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Figure 2: Distribution of physicochemical properties of the AR-CALUX
®
 validation set versus the REACH chemicals 
In blue: REACH chemicals, in red: AR-CALUX
®
 validation set. The physicochemical predictions were carried out with ACDLabs/Perceptra.  
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5. Compilation of publicly available data on ARTA's and the AR-pathway model, for 46 coded test chemicals to be used in the AR-CALUX
®
 validation 
study 
The data sources were as follows. For the Tox21 assays and the AR-pathway computational model, the assignment of the classification is described.  
 ARTA Japan validation study 
o Compiled from OECD TG 458 
 
 ARTA Korea validation study 
o Compiled from validation report under review (2019) 
 
 Tox21 assay luc data (Run Antagonist 2 with spiking of ligand (standard response), Run Antagonist 1 with higher concentration of ligand (specificity control)). The classification 
was carried out as follows: 
o  Agonist 
 Positive: When Call of TOX21_AR_LUC_MDAKB2_Agonist is Active  
 Negative : When Call of TOX21_AR_LUC_MDAKB2_Agonist is Inactive  
 
o  Antagonist 
 Positive  
 Call of [Antagonist2, Antagonist] = [Active, Active] and Log10( ACC Antagonist) - Log10( ACC Antagonist2) is => 0.5 (exception Diethylstilbestrol and 
  p,p’-Methoxychlor with diff slightly below 0.5, both classified as P) 
 Call of [Antagonist2, Antagonist] = [Active, Inactive]  
 Negative  
 Call of [Antagonist2, Antagonist] = [Inactive, Inactive]  
 False positive  
 Call of [Antagonist2, Antagonist] = [Active, Active] and Log10( ACC Antagonist) - Log10( ACC Antagonist2) is < 0.5 (exception Diethylstilbestrol and 
  p,p’-Methoxychlor with diff slightly below 0.5, both classified as P) 
 Call of [Antagonist2, Antagonist] = [Inactive, Active] 
 no classification 
 Call of [Antagonist2, Antagonist] = [ not specified , Active  
 When Flag-Omit value is in Call 
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 Tox21 assay bla data 
o  Agonist 
 Positive : When Call of TOX21_AR_BLA_Agonist_ratio is Active  
 Negative : When Call of TOX21_AR_BLA_Agonist_ratio is Inactive  
 
o  Antagonist 
 Positive  
     Call of Antagonist_ratio = [Active] and Log10( ACC Antagonist_viability) - Log10( ACC Antagonist_ratio) is => 0.5 
 Negative  
     Call of Antagonist_ratio = [Inactive]  
 False Positive  
    Call of Antagonist_ratio = [Active] and Log10( ACC Antagonist_viability) - Log10( ACC Antagonist_ratio) is < 0.5  
  no classification 
   When Flag-Omit value is in Call 
 
 
 AR pathway model (Kleinstreuer et al, 2017; Supplemental file 4) 
 
o Agonist  
 Negative: when AUC AG < 0.1 
 Positive: AUC AG => 0.1 
o Antagonist  
 Negative: when "Tox21 Confirmation Assay Flag" is 
 NA or AUC ANT < 0.1 
 False Positive: when "Tox21 Confirmation Assay Flag" is 
 FLAG: Antagonist shift, but CI overlap, AUC ANT => 0.1 
 FLAG: Wrong direction shift (Hit/Hit), AUC ANT => 0.1 
 Positive: when "Tox21 Confirmation Assay Flag" is 
 True antagonist shift (Hit/Hit), AUC ANT => 0.1 
 True antagonist shift (No hit/Hit), AUC ANT => 0.1 
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Annex 13.4 
 
Chemical coding and distribution procedure 
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1. Sample preparation and distribution 
The chemicals to be used in the validation study were distributed to the participating laboratories as sample aliquots in 
vials prepared by EURL-ECVAM (about 300mg for test items and about 500mg for reference and control items). The 
individual weights of the aliquots were also recorded, and provided to the respective recipients for information. In 
general, the chemicals were sent as coherent sets according to the project phase (study number). 
The vials were labelled as follows: 
- Chemical name and CAS number (or identity coded) 
- Storage temperature (with inert gas, if indicated by supplier/SDS) 
- Expiry date 
- Hazard statement (H number) according to safety data sheet (SDS) 
- Recipient laboratory acronym, to ensure correct package allocation for shipment. 
Together with the aliquot weights, this information was also provided to the respective recipients as a sample list. For 
internal record keeping at EURL-ECVAM, lot numbers were also noted for all chemicals, with corresponding 
certificates of analysis (CoA) indicating material purity (available from the commercial supplier) retained on file. 
Together with printed SDS, the samples were packed for shipping in fibreboard boxes, able to withstand dropping and 
stacking. When coded items were sent, two sets of SDS were included in the package: 
- Bundled together in one sealed envelope, with all codes listed on the exterior (corresponding to the vial labels and 
marked SDS copies inside) and indicated 'for customs use only'.  
- Individually sealed in separate envelopes, each marked with respective code, and each indicated 'for emergency 
use only'.  
To preserve the integrity of the test item identity codes, the recipient was given instructions in advance to discard the 
customs set on arrival (unopened) and ensure the individual envelopes were retained (also unopened) for emergency 
reference only. 
 
2. Coding of the test items 
Random order binary letter codes were generated via Random.org string generator (on-line application) producing 676 
(26x26) different combinations (or 576, omitting O and I to avoid confusion with numerals 0 and 1). 
For the distribution of test items as unidentified chemicals, a three part code was adopted: 
- laboratory acronym (e.g., BDS for BioDetection Systems) 
- study reference (sequential study number: 1, 2, 3)  
- sample aliquot code (alphabet letter pairs). 
Thus, example codes were: BDS-2-AB, ENV-3-XY. 
The identity of the chemicals to which the codes were assigned remained confidential from the VMG and the 
statistician until the end of the experimental part of the validation study The codes corresponding to the same test item 
were disclosed to the statistician for un-biased statistical analysis of reproducibility. Once the data analysis was 
complete, the identity of the test items was released to VMG.  
  
 
147 
 
3. List of the codes 
Seq. 
# 
chemical name lab/code 
   
1 17β-Trenbolone CIT-2-CB ENV-2-VP SPT-2-WT BDS-2-SQ 
2 Stanozolol CIT-2-XF ENV-2-XN SPT-2-NM BDS-2-GG 
3 Spironolactone CIT-2-AE ENV-2-HD 
SPT-2-HX 
SPT-3-AR 
BDS-2-CG 
4 Medroxyprogesterone acetate CIT-2-NX ENV-2-ET SPT-2-KX BDS-2-LN 
5 Bisphenol A CIT-2-RD ENV-2-YA SPT-2-MZ BDS-2-CW 
6 Bicalutamide CIT-2-YY ENV-2-DF SPT-2-WS BDS-2-QX 
7 Disulfiram CIT-2-RK ENV-2-VZ SPT-2-YP BDS-2-MU 
8 Tamoxifen CIT-2-XK ENV-2-QF SPT-2-NS BDS-2-WW 
9 Atrazine CIT-2-LK ENV-2-ZR SPT-2-SH BDS-2-YN 
10 17α-Ethynyl estradiol CIT-2-GQ ENV-2-GK SPT-2-LR BDS-2-SD 
11 Sodium azide CIT-2-ZT ENV-3-AT SPT-3-AM BDS-2-XH 
12 Diethylhexyl phthalate CIT-2-DQ ENV-3-FJ SPT-3-SJ BDS-2-BU 
13 Methyldihydrotestosterone CIT-2-TJ ENV-3-UJ SPT-3-NY BDS-2-VF 
14 Vinclozolin CIT-2-NN ENV-3-GU SPT-3-RU BDS-2-AJ 
15 Prochloraz CIT-2-JB ENV-3-BH SPT-3-ZZ BDS-2-AN 
16 Fluoxymesterone CIT-2-YW ENV-3-DX SPT-3-FA BDS-2-BG 
17 17β-Estradiol CIT-2-ML ENV-3-PU SPT-3-BL BDS-2-UE 
18 Benzylbutyl phthalate CIT-2-PY ENV-3-KU SPT-3-QT BDS-2-CM 
19 Propylthiouracil CIT-2-HZ ENV-3-CK SPT-3-WZ BDS-2-NZ 
20 Hydroxyflutamide CIT-2-TF ENV-3-EH SPT-3-ZV BDS-2-MK 
21 Levonorgestrel SPT-3-RY    
22 Cyproterone acetate SPT-3-TH    
23 2-tert-Butylanthraquinone SPT-3-YC    
24 Arochlor1254 SPT-3-SB    
25 Nandrolone SPT-3-VK    
26 o,p’-DDT SPT-3-GZ    
27 Phenolphthalin SPT-3-RX    
28 2,4,5-T SPT-3-DC    
29 Methyltrienolone (R1881) SPT-3-VE    
30 Actinomycin D SPT-3-FK    
31 Diethylstilbestrol SPT-3-JA    
32 L-Thyroxine SPT-3-TM    
33 Haloperidol SPT-3-BR    
34 Norethindrone acetate SPT-3-XY    
35 Pimozide SPT-3-QM    
36 Progesterone SPT-3-JQ    
37 Linuron SPT-3-NQ    
38 Methyltestosterone SPT-3-RV    
39 2-sec-Butylphenol SPT-3-UA    
40 Corticosterone SPT-3-WJ    
41 Ketoconazole SPT-3-MG    
42 Finasteride SPT-3-FX    
43 Fulvestrant SPT-3-XR    
44 Cycloheximide SPT-3-DS    
45 Norethindrone SPT-3-VR    
46 Mifepristone SPT-3-LU    
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Annex 13.5 
 
SOP version V07 
(final version) 
 
 
Available at EURL ECVAM's  
Tracking system for alternative methods towards regulatory acceptance (TSAR) 
( https://tsar.jrc.ec.europa.eu/test-method/tm2010-07) 
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Annex 13.6 
 
Solubility data on 46 coded test items 
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 Solubility data on 46 coded test items from the 4 participating laboratories 
 
Chemical name 
Stock solution mg/ml 
 
Medium solution µg/ml 
CiToxLab ENVIGO RISE (SPT) BDS 
 
CiToxLab ENVIGO RISE (SPT) BDS 
Trenbolone 50 50 50 50 
 
5 50 15 50 
Stanozolol 50 50 5 15 
 
5 5 5 5 
Spironolactone 50 50 15 50 
 
50 50 15 50 
 Medroxyprogesterone 5 15 1.5 15 
 
5 5 1.5 15 
Bisphenol A 50 50 50 50 
 
50 50 15 50 
Bicalutamide 50 50 50 50 
 
50 50 50 50 
 Disulfiram 50 50 50 50 
 
15 15 5 15 
Tamoxifen 15 15 5 15 
 
5 15 5 15 
Atrazine 5 50 15 50 
 
5 15 15 15 
Ethynyl estradiol 50 50 15 50 
 
15 15 15 15 
Fluoxymesterone 50 5 50 50 
 
15 5 5 5 
Prochloraz 50 50 50 50 
 
50 50 50 50 
Benzylbutyl phthalate 50 50 50 50 
 
15 50 1.5 15 
 o,p'-DDT 
  
50 
    
1.5 
 
Methyldihydrotestosterone 15 5 15 15 
 
5 5 5 5 
17β-Estradiol 50 50 50 50 
 
5 15 5 15 
Hydroxyflutamide 50 50 1.5 50 
 
50 50 1.5 50 
Vinclozolin 50 50 50 50 
 
15 15 5 15 
Propylthiouracil 50 50 50 50 
 
50 50 50 50 
Diethylhexyl phthalate 50 50 15 50 
 
50 15 15 50 
Sodium azide 15 50 15 15 
 
5 15 15 15 
Linuron 
  
50 
    
15 
 
Levonorgestrel 
  
15 
    
1.5 
 
Corticosterone 
  
50 
    
50 
 
Methyltestosterone 
  
50 
    
15 
 
Progesterone 
  
50 
    
15 
 
Nandrolone 
  
50 
    
50 
 
Methyltrienolone 
  
50 
    
50 
 
Norethindrone 
  
50 
    
5 
 
Norethindrone acetate 
  
5 
    
5 
 
Cyproterone acetate 
  
50 
    
15 
 
Diethylstilbestrol 
  
50 
    
15 
 
Finasteride 
  
50 
    
50 
 
Mifepristone 
  
50 
    
5 
 
Haloperidol 
  
50 
    
5 
 
Ketoconazole 
  
15 
    
15 
 
Pimozide 
  
5 
    
5 
 
L-Thyroxine 
  
50 
    
50 
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Fulvestrant 
  
50 
    
1.5 
 
Actinomycin D 
  
5 
    
5 
 
Cycloheximide 
  
50 
    
50 
 
2,4,5-T 
  
0.15 
    
0.15 
 
2-sec-Butylphenol 
  
15 
    
15 
 
tert-Butyl anthraquinone 
  
15 
    
5 
 
Arochlor 1254 
  
50 
    
5 
 
Phenolphthalin 
  
15 
    
15 
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Annex 13.7 
 
List of additional documents filed for the study 
and available on request 
at EURL ECVAM 
 
 
 Training documents (Agenda, Planning of the training) 
 Study plans and study reports of the 4 participating laboratories 
 SOP versions V03, V04, V05 and V06, and solubility SOP 
 JRC technical report on "Technical meeting on the Implementation of the AR-CALUX® in vitro method" 
 JRC technical report on "Transfer Evaluation Report"  
 JRC technical report on "Data of study 2"  
 EURL ECVAM report GLP compliant study SR-ST57 
 Supporting data for development of the specificity control criterion R2  
 Technical issues during implementation of the AR-CALUX® method at CitoxLAB (report of BDS) 
 Quality control (Identity verification) of the cell lines used in the participating laboratories 
 Call for expression of interest "Proposal to EU-NETVAL members for participation in a multi-study 
validation trial"  
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GETTING IN TOUCH WITH THE EU 
In person 
All over the European Union there are hundreds of Europe Direct information centres. You can find the address of the centre 
nearest you at: https://europa.eu/european-union/contact_en 
On the phone or by email 
Europe Direct is a service that answers your questions about the European Union. You can contact this service: 
- by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for these calls), 
- at the following standard number: +32 22999696, or 
- by electronic mail via: https://europa.eu/european-union/contact_en 
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Online 
Information about the European Union in all the official languages of the EU is available on the Europa website at: 
https://europa.eu/european-union/index_en 
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You can download or order free and priced EU publications from EU Bookshop at: https://publications.europa.eu/en/publications. 
Multiple copies of free publications may be obtained by contacting Europe Direct or your local information centre (see 
https://europa.eu/european-union/contact_en). 
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